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 The TRIP-Br/SERTAD family of mammalian transcriptional regulators 
has recently been cloned and shown to be involved in E2F-mediated cell cycle 
progression. We report, herein, further characterization of the least understood 
member of TRIP-Br/SERTAD family, TRIP-Br2 (also known as SEI-2 or 
SERTAD2). We assessed the role of TRIP-Br2 in development, transcriptional 
regulation and cell cycle progression by inactivating the TRIP-Br2 locus in 
mouse through insertional mutagenesis and exon trapping. Ablation of TRIP-
Br2 did not lead to infertility, embryonic lethality or failure of lymphoid 
development in mice. TRIP-Br2 expression was found to be significantly 
higher in bone marrow and highly proliferative lymphohematopoietic cell 
lineages than in other tissues. Splenic T cells, normally highly proliferative in 
wild-type mice, were found to be entirely resistant to the growth-promoting 
effects of well-known T cell mitogens in TRIP-Br2-/- mice. A similar 
phenomenon was observed with another highly proliferative cell type, the 
primary murine embryonic fibroblasts (PMEFs).  Flow cytometric DNA analysis 
revealed an increase in the S phase cell population in asynchronously cycling 
TRIP-Br2-/- PMEFs, which also had a reduced proliferative rate compared to 
wild-type PMEFs. Only ~50% of quiescent serum-starved TRIP-Br2-/- cells had 
reentered the cell cycle in response to serum restimulation. Semi-quantitative 
RT-PCR and western blot analyses further revealed that key cell cycle 
regulators such as cyclin E, PCNA and CDC2 (or CDK1) were downregulated 
in TRIP-Br2-/- PMEFs.  
 Given that the ablation of TRIP-Br2 resulted in a proliferative block, we 
postulated that a gain of TRIP-Br2 function may play an important role in 
dysregulation of cell proliferation in human tumor formation and cancer. We 
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therefore validated the oncogenic potential of TRIP-Br2 in cancer 
pathogenesis. Its overexpression, which was associated with the upregulation 
of E2F-mediated transcription, transformed NIH3T3 fibroblasts and promoted 
tumor growth in athymic nude mice. We performed high throughput expression 
profiling of TRIP-Br2 in multiple human tumor tissue arrays and showed that 
TRIP-Br2 is overexpressed in many human cancers. Apart from the 
identification and validation of TRIP-Br2 overexpression as a putative novel 
mechanism underlying human tumorigenesis, such as the case of 
hepatocellular carcinoma, we have also uncovered its potential as a novel 
chemotherapeutic drug target. As a proof-of-principle, we showed that the 
siRNA knockdown of TRIP-Br2 is sufficient to inhibit cell-autonomous growth 
of HCT-116 colorectal cancer cells in vitro.  
 Since the loss-of- and gain-of-function of TRIP-Br2 are associated with 
cell proliferative arrest and tumor development respectively, we investigated 
whether spatial and/or temporal regulation of TRIP-Br2 by transcriptional 
and/or translational mechanisms may serve to control the precise execution of 
its function during cell cycle progression. We demonstrated that TRIP-Br2 
protein (not transcript) expression peaks at the G1/S boundary and 
progressively decreases through S, and G2/M phases of the cell cycle. The 
oscillatory nature of TRIP-Br2 expression in cell cycle progression was further 
shown to be tightly regulated by multiple mechanisms, including the ubiquitin-
proteasome-dependent degradation pathway and the CRM1-mediated nuclear 
export pathway. An analysis of TRIP-Br2 truncation mutants revealed that the 
acidic carboxyl-terminal region of TRIP-Br2, which includes a putative nuclear 
export signal (NES) motif, a PHD zinc finger- and/or bromodomain (PHD-
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Bromo)-interaction domain and a transcriptional activation domain (TAD), is 
required for the regulation of its protein turnover. 
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1.1 Current paradigm of the cell cycle and cancer 
1.1.1  The general schema of cell cycle progression: simplifying 
complexity 
 Cell division is characterized mainly by two consecutive processes, 
DNA replication and segregation of replicated chromosomes into two separate 
cells. It was originally divided into two stages: mitosis (M), which is the process 
of nuclear division; and interphase, the interlude between two M phases 
(Figure 1). The stages of mitosis include prophase, metaphase, anaphase and 
telophase. Although the interphase cells simply grow in size under microscopic 
examination, the complexity of interphase, which further comprises of G1, S 
and G2 phases, was not fully appreciated until much later (Norbury and Nurse, 
1992). The replication of DNA occurs at a specific time in interphase called S 
phase that is preceded by a gap called G1 during which the cell is preparing for 
DNA synthesis. S phase is in turn followed by a gap called G2 during which the 
cell prepares for mitosis. G1, S, G2 and M phases form the subdivisions of 
what is known to be the cell cycle today (Figure. 1). Cells in G1 are capable of 
entering a resting state called G0 prior to their commitment to DNA replication. 
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Figure 1. A schematic representation of the mammalian cell 
cycle. In each cell division cycle, chromosomes are replicated once (DNA 
synthesis or S phase) and segregated to create two genetically identical 
daughter cells (mitosis or M phase). These events are spaced by intervals of 
growth and reorganization (gap phases G1 and G2). Cells can stop cycling 
after division and enter a state of quiescence (G0). Commitment to traverse an 
entire cycle is made in late G1. Progress through the cycle is accomplished in 
part by the regulated activity of numerous other CDK–cyclin complexes 
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1.1.2 The control of cell cycle progression 
1.1.2.1 RB/E2F/DP-mediated transcriptional regulation of cell cycle 
progression 
 The E2F family of transcription factors integrates cellular signals and 
coordinates cell proliferation (Dyson, 1998; Nevins, 1998). Studies in recent 
years have identified E2Fs as important transcriptional regulators of the 
expression of many genes involved not only in DNA replication and cell cycle 
progression, but also of genes involved in DNA damage repair, apoptosis, cell 
differentiation and development (Bracken et al., 2004; Dimova and Dyson, 
2005). Among the E2F family members (Figure 2), E2F1-5 possess a 
transcriptional activation domain at the C-terminus and can induce 
transcription from target promoters together with dimerization partner DP1 or 
DP2 (Lam and La Thangue, 1994; Slansky and Farnham, 1996). On the 
contrary, E2F6 lacks a transcriptional activation domain and has been shown 
to compete for E2F-binding sites on promoters and to repress their activity 
(Trimarchi and Lees, 2002). In addition, the E2F family is commonly 
subdivided into activator E2Fs (E2F1-3) and repressor E2Fs (E2F4-6) based 
on the pattern of their interactions with members of the retinoblastoma tumor 
suppressor (RB) pocket-binding protein family (Chellappan et al., 1991; 
DeGregori, 2002). The RB proteins interact directly with the E2F carboxyl-
terminal transcriptional activation domain and repress E2F-dependent gene 
transactivation (Flemington et al., 1993; Helin et al., 1993). E2F1-3 can all bind 
exclusively to RB, but the other RB members such as p107 and p130 interact 
only with repressor E2Fs. Among repressor E2Fs, E2F4 uniquely interacts 
with all members of the RB family (DeGregori, 2002). Furthermore, recently-
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identified members of the extended E2F family, E2F7 and E2F8, have been 
shown to share unique structural features, including the absence of 
dimerization, RB binding, and transcriptional activation domains (Christensen 
et al., 2005; de Bruin et al., 2003; Di Stefano et al., 2003; Logan et al., 2004; 
Logan et al., 2005; Maiti et al., 2005). 
 E2F1 binds DNA as a heterodimer with DP1 or DP2 and mediates gene 
activation through a carboxyl-terminal transactivation domain (Helin et al., 
1993; Qin et al., 1992), which has been shown to interact directly with 
coactivators like TATA-binding protein and MDM2 (Hagemeier et al., 1993; 
Martin et al., 1995). In addition, many of these transcription factors have been 
shown to recruit histone acetyltransferases (HATs) and histone 
deacetyltransferases (HDACs) to differentially remodel chromatin resulting in 
n or repression. For instance, the appearance of histone 
ncluding cAMP-responsive element binding (CREB) 
n (CBP), p300, p300/CBP-associated factor (PCAF), and 
Tip60, correlates with the onset of E2F-dependent transcription (Ferreira et al., 
2001; Rayman et al., 2002; Taubert et al., 2004). Indeed, p300 and CBP 
interact with the carboxyl-terminal transactivation domain of E2F1 and serve 
as coactivators to stimulate E2F1-dependent gene activation (Morris et al., 
2000; Trouche et al., 1996). Conversely, HDAC1-3 activity has been 
implicated in the RB-mediated repression of E2F-regulated promoters in the 
G1 phase (Brehm and Kouzarides, 1999; Brehm et al., 1998; Harbour and 
Dean, 2000). In order to achieve complete cell cycle arrest in the G1 phase, it 
has been recently shown that RB recruits and requires the activity of Brg1/Brm, 
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(Dunaief et al., 1994). Brg1/Brm has also been demonstrated to be recruited 
by Prohibitin and TopB1 to repress E2F-dependent gene activation (Liu et al., 
2004; Wang et al., 2002).  Other coregulators of the RB/E2F/DP transcriptional 
pathway, such as the TRIP-Br proteins, have been recently identified and 
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Figure 2. The RB/E2F/DP network in mammals and other 
species. (A)The mammalian RB/E2F network is comprised of many different 
pocket-protein/E2F complexes. Activator E2Fs (E2F1, E2F2 and E2F3) 
interact only with RB; there are several different repressor E2Fs: E2F4 can 
interact with all three pocket proteins, E2F5 binds to p130, E2F6 binds to PcG 
proteins, and E2F6 and E2F7 do not interact with pocket proteins. The 
RB/E2F/DP pathway is evolutionary conserved. In Drosophila, the pathway is 
functionally conserved but contains fewer members, with interaction patterns 
similar to those in mammals: RBF1 binds both activator and repressor dE2F, 
and RBF2 binds to repressor dE2F only. C. elegans contains only one pocket 
protein (LIN-35), one DP (DPL-1) and two E2Fs (EFL-1 and EFL-2). (B) 
Domain structure of mammalian E2F proteins. E2F1–6 contain one DNA-
binding domain (DB) and one DP dimerization domain (DIM). Transactivation 
domains and sequences for binding to pocket proteins are present only in 
E2F1–5; the pocket-protein-binding domain is contained within the 
transactivation domain. E2F1–3 have a nuclear localization signal (NLS), while 
E2F4 and E2F5 possess nuclear export signals (NES). E2F7 lacks a 
dimerization domain and contains two DNA-binding domains [extracted from 
(Dimova and Dyson, 2005) ]. 
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1.1.2.2 Cyclin-dependent kinase (CDK)-mediated regulation 
 The transition from one cell cycle phase to another occurs in an orderly 
manner and is regulated by different cellular proteins. Key regulatory proteins 
include the cyclin-dependent kinases (CDKs), a family of serine/threonine 
protein kinases that are activated at specific points of the cell cycle. To date, 
nine CDKs have been identified and, of these, five are active during the cell 
cycle, i.e. during G1 (CDK2, CDK4, and CDK6), S (CDK2), G2 and M (CDK1) 
(Vermeulen et al., 2003). When activated, CDKs induce downstream 
processes by phosphorylating selected protein targets (Morgan, 1995; Pines, 
1995). CDK7 has been recently reported to act in combination with cyclin H as 
CDK activating kinase (CAK) (Fisher and Morgan, 1994).  CDK8, the latest 
member of the CDK family to be reported, associates with cyclin C (Rickert et 
al., 1996) and regulates transcription by phosphorylating the CDK7/cyclin H 
subunits of the general transcription initiation factor IIH (TFIIH). Following the 
phosphorylation of cyclin H in the vicinity of its functionally unique amino-
terminal (N-terminal) and carboxyl-terminal (C-terminal) α-helical domains, the 
ability of TFIIH to activate transcription and its C-terminal domain (CTD) kinase 
activity are repressed. In addition, mimicking CDK8 phosphorylation of cyclin 
H in vivo has been shown to have a dominant-negative effect on cell growth 
(Akoulitchev et al., 2000).  
 CDK protein levels remain stable during the cell cycle, in sharp contrast 
to their activating proteins, the cyclins. The oscillatory expression of most 
cyclin proteins during cell cycle progression forms the basis of their periodic 
activation of CDKs (Evans et al., 1983; Pines, 1991). As summarized in Table 
1, the activity of different cyclins is required at different phases of the cell cycle. 
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The three D-type cyclins (cyclin D1, cyclin D2, cyclin D3) bind to CDK4 and to 
CDK6; activated CDK4/6-cyclin D complexes are essential for entry in G1 
(Sherr, 1994). Cyclin E, another G1 cyclin, associates with CDK2 to regulate 
progression from G1 into S phase (Ohtsubo et al., 1995), while cyclin A binds 
to CDK2 to form an active complex that has been previously shown to be 
required for S phase progression (Figure. 3) (Girard et al., 1991; Walker and 
Maller, 1991). In late G2 and early M, cyclin A forms an active complex with 
CDK1 to promote entry into mitosis. Mitosis is further regulated by the CDK1-
cyclin B kinase complex (Arellano and Moreno, 1997; King et al., 1994). 
Sixteen cyclins have been identified thus far. Similar to CDKs, not all cyclins 
are cell cycle-related (Okamoto and Beach, 1994; Peng et al., 1998; Rickert et 
al., 1996). Cyclins A and B contain a destruction box, while cyclins D and E 
contain a PEST sequence [segments rich in proline (P), glutamic acid (E), 
serine (S), theronine (T) residues]. These protein sequences have been 
shown to be required for efficient ubiquitin-mediated cyclin proteolysis at the 





Table 1. Activation of cyclin-CDK complexes at specific points of the cell 
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 In addition to cyclin binding, CDK activity is also regulated by 
phosphorylation on conserved threonine and tyrosine residues. Full activation 
of CDK1 requires phosphorylation of threonine 161 (threonine 172 in CDK4 
and threonine 160 in CDK2), brought about by the CAK. These post-
translational modifications induce conformational changes in CDKs and 
enhance their binding of cyclins (Jeffrey et al., 1995; Paulovich and Hartwell, 
1995). The Wee1 and Myt1 kinases phosphorylate CDK1 at tyrosine-15 and/or 
threonine-14, thereby inactivating CDK1. On the other hand, 
dephosphorylation at these sites by Cdc25 phosphatase is necessary for 
activation of CDK1 and further progression through the cell cycle (Lew and 
Kornbluth, 1996). A comprehensive schematic overview of the key processes 
in cell cycle regulation is summarized in Figure 3. 
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Figure 3. A schematic overview of the key processes in cell 
cycle regulation.       : phosphorylated site. (      ) 
[extracted from (Vermeulen et al., 2003)] 
 
 CDK activity can be counteracted by cell cycle inhibitory proteins, 
known as CDK inhibitors (CKIs), which bind to CDK alone or to the CDK-cyclin 
complex and repress CDK activity. Two distinct families of CDK inhibitors, the 
INK4 family and the Cip/Kip family, have been functionally characterized 
(Table 2) (Sherr and Roberts, 1995). The INK4 family includes p15 (INK4b), 
p16 (INK4a), p18 (INK4c) and p19 (INK4d), which specifically inactivate G1 
CDKs (CDK4 and CDK6). These CKIs form stable complexes with CDK, thus 
preventing the latter’s association with cyclin D (Carnero and Hannon, 1998). 
The second family of inhibitors, the Cip/Kip family, includes p21 (Waf1, Cip1), 
p27 (Cip2) and p57 (Kip2). These inhibitors inactivate CDK-cyclin complexes 
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CDK-cyclin complexes, and to a lesser extent, CDK1-cyclin B complexes 
(Hengst and Reed, 1998). In addition, p21 inhibits DNA synthesis by binding to 
and inhibiting the proliferating cell nuclear antigen (PCNA) (Pan et al., 1995; 
Waga et al., 1997). CKIs can themselves be regulated by both internal and 
external signals. For instance, the expression of p21 is under the 
transcriptional control of the ATM/ATR/p53 transcriptional pathway that senses 
DNA damage signals. The p21 gene promoter contains a p53-binding site, 
which allows p53 to transcriptionally activate the p21 gene in response to DNA 
damage/repair signals (el-Deiry et al., 1993). The expression and activation of 
p15 and p27, on the other hand, increase in response to transforming growth 
factor β (TGF-β), thus leading to growth arrest (Hannon and Beach, 1994; 




Table 2. Cyclin dependent kinases inhibitors (CKI) bind to CDK alone or 
the CDK-cyclin complex and regulate CDK activity. p19 (ARF) is also 
encoded by the INK4a locus but has no known CKI activity [extracted from 
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 The intracellular localization of different cell cycle regulators also 
contributes to proper cell cycle progression. Cyclin B contains a nuclear 
exclusion signal and is actively exported from the nucleus until the beginning 
of prophase. The CDK inactivating kinases Wee1 and Myt1 are located in the 
nucleus and Golgi complex, respectively, and protect the cell from premature 
mitosis (Heald et al., 1993; Liu et al., 1997). The 14-3-3 group of proteins 
regulates the intracellular trafficking of different proteins. During interphase, 
the CDK-activating Cdc25 phosphatase is kept in the cytoplasm through 
interaction with 14-3-3 proteins. Sequestration of the CDK1-cyclin B complex 
in the cytoplasm following DNA damage is also mediated by 14-3-3 proteins 
(Peng et al., 1997; Yang et al., 1999). 
 
1.1.3 Substrates of CDK 
 Proteins can be targeted for phosphorylation on CDK consensus sites 
by the activated CDKs, thus resulting in changes that are physiologically 
relevant for cell cycle progression. One of the most frequently studied CDK 
substrate is the retinoblastoma tumor suppressor, RB. During early G1, RB 
becomes phosphorylated by CDK4/6-cyclin D leading to disruption of the 
complex with the histone deacetylase proteins (HDACs) and release of the 
transcription factors E2F-1 and DP-1 from transcriptional inhibition. E2F/DP 
heterodimers positively regulate the transcription of genes whose products are 
required for S phase progression, including cyclin A, cyclin E and Cdc25 
(Figure 3) (Brehm et al., 1998; Buchkovich et al., 1989; Kato et al., 1993). RB 
hyperphosphorylation is maintained by CDK2-cyclin E as the cell cycle 
progresses through the G1/S transition.  
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 During G1/S transition, the CDK2-cyclin E complex also phosphorylates 
its inhibitor, p27, thus inducing the proteasome-dependent degradation of p27 
(Hinds et al., 1992; Montagnoli et al., 1999). In addition, NPAT (nuclear protein 
mapped to the ATM locus) associates with, and is phosphorylated by, CDK2-
cyclin E. The protein level of NPAT peaks at the G1/S boundary and has been 
postulated to play a critical role in S phase entry (Zhao et al., 2000). 
Furthermore, CDK2-cyclin E phosphorylates histone H1 to facilitate 
chromosome condensation during DNA replication. Histone H1 is also a 
substrate for CDK1-cyclin B (Bradbury et al., 1974). Cyclin A-dependent 
kinases, on the other hand, regulate initiation of DNA replication by 
phosphorylation of DNA polymerase α primase (Voitenleitner et al., 1997). 
Other CDK substrates include regulators of CDK, Wee1 and Cdc25, as well as 
cytoskeletal proteins such as nuclear lamins, microtubules and vimentin, which 
are required for proper mitosis (Blangy et al., 1995; Courvalin et al., 1992; 
Heald and McKeon, 1990; Hoffmann et al., 1993). 
 
1.1.4 The restriction points and checkpoints that regulate cell cycle 
progression: an issue of quality control assurance 
 The restriction point (R) is defined as a point of no return in G1, 
following which the cell is committed to enter the cell cycle. It has been 
previously demonstrated that cells starved of serum before the restriction point 
enter a G0-like state, while cells starved after R are unaffected and continue to 
progress through mitosis (Pardee, 1974). Additional controls or checkpoints 
exist further along the cell cycle, thus ensuring an orderly sequence of events 
in the cell cycle (Hartwell and Weinert, 1989). To date, DNA damage 
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checkpoints and spindle checkpoints have been partially elucidated (Figure 3). 
In response to DNA damage, the cell cycle is arrested at checkpoints to 
provide time needed for DNA repair. DNA damage checkpoints are positioned 
before the cell enters S phase (G1-S checkpoint) or after DNA replication (G2-
M checkpoint), though it appears that DNA damage checkpoints also exist in S 
and M phases (Marchetti et al., 2002; Naiki et al., 2000). 
 At the G1/S checkpoint, cell cycle arrest induced by DNA damage is 
p53-dependent. p53 is normally maintained at a low cellular steady state level 
unless the cell is exposed to DNA damage, which leads to a rapid induction of 
p53 levels and activation of p53-dependent transcription (Levine, 1997). Some 
of the better known p53-responsive genes include p21, Mdm2 and Bax 
(Agarwal et al., 1998). Following DNA damage, the cell cycle is arrested as a 
result of p21 inhibition of CDKs, thus preventing the replication of damaged 
DNA (Figure 3) (Ko and Prives, 1996). Mdm2, on the other hand, plays an 
important role in the regulation of p53. It binds to and inhibits p53 
transcriptional activity and contributes to the proteolytic degradation of p53 by 
facilitating its ubiquitination, thereby providing a negative feedback loop (Oren, 
1999). In addition, p53 ubiquitination may also be modulated by its interaction 
with other regulatory proteins. For instance, the p19 (ARF) protein, encoded 
by the ARF-INK4 locus, binds to Mdm2 and prevents the Mdm2-mediated 
proteolysis of p53 (Zhang et al., 1998). In the case of severely damaged cells, 
cell death is induced by the activation of p53-responsive genes (e.g. Bax, Fas 
and other genes involved in oxidative stress pathways) that are involved in 
apoptotic signaling pathways (Gottlieb and Oren, 1998; Owen-Schaub et al., 
1995; Polyak et al., 1997). 
 38
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
 Prior to the activation of p53-mediated DNA repair/apoptotic pathways, 
DNA damage signals are detected by different protein kinases referred to as 
ataxia-telangiectasia-mutated (ATM), ataxia and rad3 related (ATR). These 
kinases phosphorylate and activate p53 in response to DNA damage, thus 
resulting in the arrest of the cell cycle at the G1/S checkpoint by p21 (Siliciano 
et al., 1997). DNA protein kinase (DNA-PK), a DNA double-strand break repair 
enzyme is related to ATM and ATR. It remains unknown whether DNA-PK also 
plays an important role at the G1/S checkpoint (Burma et al., 1999; Durocher 
and Jackson, 2001). 
 While the mechanisms of the S phase DNA damage checkpoint remain 
poorly understood, some studies have suggested that suppression of both the 
initiation and elongation phases of DNA replication may be a probable 
response to DNA damage (Painter, 1986; Paulovich and Hartwell, 1995). 
Furthermore, it has been demonstrated that the ATM-mediated 
phosphorylation of Nijmegen breakage syndrome 1 (NBS1) is required for the 
induction of S phase arrest at the S phase checkpoint (Lim et al., 2000). 
 When DNA damage occurs during the G2 phase, cells have been 
shown to initiate a cell cycle arrest in p53-dependent and p53-independent 
manners. The entry into mitosis is prevented by maintaining CDK1 in its 
inactive form through inhibitory phosphorylation or by sequestration of 
components of the CDK1-cyclin B complex outside the nucleus. This is 
achieved by the protein kinases Chk1 and Chk2, which are activated during 
DNA damage in an ATM-dependent manner, which in turn phosphorylate 
Cdc25. Phosphorylation of Cdc25 leads to the inhibition of its own activity and 
promotes its binding to 14-3-3 proteins, thus sequestering Cdc25 outside the 
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nucleus and preventing it from activating CDK1-cyclin B and mitotic entry 
(Sanchez et al., 1997; Zeng et al., 1998). Besides the induction of inhibitory 
modifications on CDKs by phosphorylation, p53 has been implicated in the 
regulation of the G2/M checkpoint. A DNA damage-dependent surge of p53 
expression at the G2/M checkpoint has been shown to result in increased 
transcription of p21 and of 14-3-3 sigma (14-3-3σ). Increased binding of cyclin 
B to 14-3-3σ actively excludes it from the nucleus. In addition, p53 mediates 
the dissociation of CDK1-cyclin B1 complexes by induction of Gadd45, a 
growth arrest and DNA damage inducible gene (Hermeking et al., 1997; Taylor 
and Stark, 2001). 
 Last but not least, cells rely on the spindle checkpoint to detect 
improper alignment of chromosomes on the mitotic spindle such that the cell 
cycle can be arrested at metaphase when necessary. Originally identified in 
budding yeast, several mammalian spindle checkpoint-associated proteins 
have recently been identified and characterized. Mitotic arrest deficient (Mad) 
and budding uninhibited by benomyl (Bub) proteins are activated when defects 
in microtubule attachment occur. This leads to the inhibition of the Cdc20 
subunit of the anaphase-promoting complex (APC), thus resulting in the arrest 
of metaphase-anaphase transition (Amon, 1999; Fang et al., 1998). 
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1.1.5 Dysregulation of the cell cycle in human cancer 
 In cancer, fundamental alterations in the genetic control of cell division 
that result in an unrestrained cell proliferation have been demonstrated. 
Mutations mainly occur in two classes of genes: protooncogenes and tumor 
suppressor genes. In normal cells, the products of protooncogenes act at 
different levels along the pathways that stimulate cell proliferation. Mutated 
versions of protooncogenes or oncogenes can promote tumor growth. 
Inactivation of tumor suppressor genes like RB and p53 results in dysfunction 
of proteins that normally inhibit cell cycle progression. Cell cycle dysregulation 
associated with cancer occurs through mutation of proteins that are critical at 
different levels of the cell cycle. Other mutations that led to aberrant 
expression of genes encoding CDK, cyclins, CDK-activating enzymes, CKI, 
CDK substrates, and checkpoint proteins have also been reported in human 
cancers (McDonald and El-Deiry, 2000; Sherr, 1996). 
 
1.1.5.1 Role of altered cyclin-dependent kinase (CDK) expression and/or 
function in human cancer 
 CDK4 overexpression, which occurs as a result of gene amplification, 
has been identified in breast cancers, melanoma, gliomas, glioblastomas 
multiforme, sarcomas and meningiomas (An et al., 1999; He et al., 1995; 
Khatib et al., 1993; Schmidt et al., 1994; Simon et al., 2002; Wei et al., 1999). 
Mutations in CDK4 and CDK6 genes that led to a loss in CKI binding have 
also been identified (Easton et al., 1998). In addition, CDK1 and CDK2 have 
both been reported to be overexpressed in a subset of colon adenomas and in 
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focal carcinomas of adenomatous tissue (Kim et al., 1999; Yamamoto et al., 
1998). 
 
1.1.5.2 Role of altered cyclin expression and/or function in human cancer 
 Cyclin D serves as a growth sensor and provides a link between 
mitogenic stimuli and the cell cycle. Cyclin D1 binds to CDK4 and CDK6 in 
early G1. The improper formation of cyclin D1 complexes with CDK4/6 or 
dysregulated hyperactivation of these complexes could act equivalently to RB 
loss to render a cell insensitive to the need for mitogenic signaling. Molecular 
analyses of human cancers fully support this notion. For instance, 
amplification or rearrangement of the CYCLIN D1 gene that is located on 
chromosome 11q13, as well overexpression of cyclin D1 protein has been 
described in a wide spectrum of human cancers such as squamous cell 
carcinomas of the head and neck, the esophagus, the tongue and larynx, 
carcinomas of the uterine cervix, astrocytomas, non-small-cell lung cancers, 
soft tissue sarcomas and others (Cheung et al., 2001; Fujii et al., 2001; 
Lammie et al., 1991; Reissmann et al., 1999; Rodrigo et al., 2000; Vielba et al., 
2003). The best documented of these is the frequent involvement of cyclin D1 
in pathogenesis of human breast cancer. Approximately 15–20% of human 
mammary carcinomas exhibit amplification of the CYCLIN D1 gene (Buckley 
et al., 1993; Dickson et al., 1995; Lammie et al., 1991), while cyclin D1 protein 
is overexpressed in over 50% of human breast cancers (Bartkova et al., 1994; 
Gillett et al., 1994; Gillett et al., 1996; McIntosh et al., 1995). Cyclin D1 
overexpression is seen at the earliest stages of breast cancer progression 
such as ductal carcinoma in situ (DCIS), but not in premalignant lesions (such 
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as atypical ductal hyperplasia). Hence, overexpression of cyclin D1 can serve 
as a marker of malignant transformation of mammary epithelial cells (Weinstat-
Saslow et al., 1995). Once cyclin D1 overexpression occurs in nascent tumor 
cells, it is maintained at the same level throughout breast cancer progression 
from DCIS to invasive carcinoma and is preserved even in metastatic lesions 
(Bartkova et al., 1994; Gillett et al., 1996). CYCLIN D2 and CYCLIN D3 genes 
are also amplified and the encoded proteins overexpressed in many human 
cancers. Dysregulated expression of cyclin D2 is involved in B-cell lymphocytic 
leukemias and lymphoplasmacytic lymphomas (Delmer et al., 1995), chronic 
lymphocytic leukemias (Motokura and Arnold, 1993), as well as in testicular 
and ovarian germ cell tumors, while cyclin D3 overexpression in seen in 
glioblastomas, renal cell carcinomas, pancreatic adenocarcinomas and 
several B-cell malignancies such as diffuse large B-cell lymphomas or multiple 
myelomas (Buschges et al., 1999; Filipits et al., 2002; Hedberg et al., 2002; Ito 
et al., 2001; Shaughnessy et al., 2001). 
 In addition, other cyclin gene family members such as CYCLIN E and 
CYCLIN A have been found to be aberrantly expressed in multiple human 
cancer malignancies. For instance, CYCLIN E is either amplified and/or 
overexpressed in some cases of breast and colon cancer, and in acute 
lymphoblastic and acute myeloid leukaemias (Hunter and Pines, 1994; 
Keyomarsi et al., 1995; Leach et al., 1993; Loda et al., 1997; Scuderi et al., 
1996). While both CYCLIN A and CYCLIN E have been shown to be 
overexpressed in lung carcinoma, elevated expression of CYCLIN A but not 
CYCLIN E is correlated with shorter survival (Dobashi et al., 1998). 
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1.1.5.3 Role of altered Cdc25 expression and/or function in human 
cancer  
 The activation of CDKs is regulated through dephosphorylation by 
members of the Cdc25 phosphatase family. Cdc25A, Cdc25B and Cdc25C 
have been shown to play important roles at the G1/S phase transition, S phase 
and entry into mitosis, respectively. Dysregulation or overexpression of Cdc25 
led to an unscheduled activation of CDK-cyclins and has been found to be 
associated with tumor formation. Cdc25A and Cdc25B, in particular, have 
been demonstrated to be potential human oncogenes (Nilsson and Hoffmann, 
2000). For instance, Cdc25B has been shown to be overexpressed in 32% of 
primary breast cancers. The induction of Cdc25A and Cdc25B gene activation 
has been found to be mediated by c-myc, another oncogene that is frequently 
mutated in human cancers (Galaktionov et al., 1996). Raf, a kinase 
downstream of the frequently mutated ras oncogene, has been shown to be 
able to bind, activate and dysregulate Cdc25 protein during oncogenesis 
(Galaktionov et al., 1995). 
 
1.1.5.4 Role of altered CDK inhibitor (CKI) expression and/or function in 
human cancer  
 The inhibitory activity of CKIs results in growth suppression through 
activation of RB, a key tumor suppressor that has been found to be mutated in 
about 3% of the cancers occurring in children under the age of 15 years old 
(Knudson, 1971). The p16 gene has been shown to be altered in a high 
percentage of human tumors; its inactivation has been linked to a variety of 
negative regulatory events including deletion, point mutations and 
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hypermethylation (Kamb, 1998). Cells with altered p16 typically present a 
phenotype of unrestrained cell cycle progression through G1. Being a specific 
inhibitor of CDK-cyclin D, p16 acts to prevent the phosphorylation of RB and to 
maintain cell cycle arrest in G1 phase (Table 2). Since RB, p16 and CDK-cyclin 
D are functionally interconnected, perturbations in any of these cell cycle 
regulators are likely to have similar consequences. Moreover, alterations of at 
least one of these regulators have been found in nearly all human cancers 
(Bates et al., 1994; Gronbaek et al., 1998; Jiang et al., 1993; Okamoto et al., 
1994; Parry et al., 1995). Deletions of p16 have been reported in 
approximately 50% of gliomas and mesotheliomas, 40–60% of 
nasopharyngeal, pancreatic and bilary tract tumors and 20–30% of acute 
lymphoblastic leukaemias (Hall and Peters, 1996).  
 The p16 gene product is encoded by the ARF-INK4 locus. Besides p16, 
this locus also encodes p19 (ARF) through translation of an alternative reading 
frame. The p19 transcript acts independently of p16 in regulating p53 stability. 
Large deletions of the ARF-INK4 locus could also affect the p19 gene, 
resulting in mutated p19 and in dysregulation of p53. The gene encoding p15, 
another CKI, is located close to the p16 gene on chromosome 9 and has also 
been shown to be frequently simultaneously deleted (Harper and Elledge, 
1996).  
 The loss of p27 expression has been reported in a number of human 
tumor types (lung, breast, and bladder) and has been correlated with poor 
prognosis and tumor aggressiveness. It has been shown in colorectal 
carcinomas that increased proteasome-dependent proteolysis, rather than 
gene deletion, is responsible for p27 downregulation (King et al., 1996; 
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Pagano, 1997). A variety of alterations has also been found in p18 and p21 in 
breast tumor and leukaemia, respectively (Esposito et al., 1997; Lapointe et al., 
1996; Loda et al., 1997; Shi et al., 1996; Tan et al., 1997). p21 has been 
implicated in tumorigenesis through its regulation by the p53 tumor suppressor 
protein. Regulation of p21 in response to DNA damage is abolished following 
the inactivation of p53 (Deng et al., 1995). 
 
1.1.5.5 Role of altered checkpoint protein expression and/or function in 
human cancer  
 Mutations of checkpoint proteins are frequent in all types of cancer. The 
tumor suppressor protein p53 is a sequence-specific DNA-binding protein that 
is able to induce either cell cycle arrest or apoptosis at various cell cycle 
checkpoints. The p53 tumor suppressor gene was first discovered in SV40 
transformed cells by the finding that its gene product p53 was tightly bound to 
the SV40 large T oncoprotein. To date, the p53 gene is known to be the most 
frequently mutated gene in human cancers (Miller & Koeffler 1993; Greenblatt 
et al. 1994). Point and missense mutations lead to conformational changes 
and inactivation of p53 (Nataraj et al., 1995). Furthermore, its interactions with 
viral oncoproteins, including SV40 T antigen, HPV E6 and adenovirus E1B-
55K, may lead to alteration or abrogation of p53 function (Crook and Vousden, 
1994; van den Heuvel et al., 1990). In general, tumors that retain wildtype p53 
have a better prognosis and are more responsive to our current regimes of 
cancer therapy (Lowe et al., 1994). Overexpression of p53 by gene 
amplification or by dysregulation of Mdm2, the negative regulator of p53, has 
been reported in breast carcinoma, sarcoma, glioma, leukaemia and 
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lymphoma. These represent alternative mechanisms to p53 mutation for 
evading p53-mediated growth control (Bueso-Ramos et al., 1995; Bueso-
Ramos et al., 1996; Moller et al., 1999). 
 
1.1.5.6 Dysregulation of the RB/E2F/DP transcription pathway in cancer 
cell cycle 
 RB, the most important member of the pocket protein family, is 
frequently mutated in human retinoblastoma, osteosarcomas and lung cancers 
(Hall and Peters, 1996; Knudson, 1971). Deletion or missense mutations may 
result in truncated, non-functional RB or in a complete loss of RB, while 
interactions of RB with certain tumor viral oncoproteins, such as human 
papillomaviruses (HPV) E7, adenovirus E1A and simian virus 40 (SV40) large 
(T),  lead to its inactivation (Gage et al., 1990; Hu et al., 2005). Loss of RB 
function is associated with unrestrained cell cycle progression and has been 
found to be common in acute lymphoblastic leukaemia (Horsthemke, 1992; 
Tsai et al., 1996).  
 Interestingly, the other pocket protein family members such as p107 
and p130 have not been linked with tumor-promoting mutations. Similarly, 
tumor-associated mutations of the E2F family of transcription factors have not 
been described (Bartek et al., 1996). Although homozygous deletion of E2F1 
in the mouse led to increased tumor formation in several tissues (Yamasaki et 
al., 1996), a link between E2F1 and human cancer has not been established. 
Likewise, mutations or alteration that would lead to loss of expression or 
dysregulated expression of other E2F proteins have not been clearly 
established in human tumors. Thus, even though E2F3 appears to play a 
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particularly important role in the control of cellular proliferation (Humbert et al., 
2000; Leone et al., 1998) and E2F4 appears to play a widespread role in 
determining cellular differentiation (Rempel et al., 2000), direct alteration of 
these genes does not appear to contribute significantly to the development of 
human cancer. Alterations in the E2F4 gene involving changes in the 
trinucleotide repeat element have been observed, but there is no evidence as 
yet that these alterations have an impact on E2F4 function or that they 
contribute to a cancer phenotype. There are numerous potential explanations 
for the apparent lack of direct alterations of E2F genes in cancer. Perhaps the 
most likely reason is the overlap in function within the family, as well as the 
potential disruptive role of dysregulated expression, which might not have 
allowed for a cancer phenotype to be observed. The current paradigm of the 
role of RB/E2F/DP transcription pathway in promoting normal cell cycle 
progression and representative tumor types known to be associated with 
dysregulation of various components of this regulatory pathway are 
summarized in Figure 4. 
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Figure 4. Current molecular model for RB/E2F function. (A) Pocket 
protein (PP)/E2F4 or pocket-protein/E2F5 complexes are present at cell cycle-
regulated promoters in G0 and early G1 cells and function to repress 
transcription. Upon mitogenic stimulation in G1, CDKs phosphorylate pocket 
proteins and disrupt pocket protein/E2F interactions. In late G1 and early S 
phase, activator E2Fs (E2F1–3) bind to cell cycle-regulated promoters and 
activate transcription. Cell cycle exit and differentiation signals block this 
transition. (B) The RB pathway in human tumors. Human tumors often contain 
alterations such as point mutations, deletions, amplifications or promoter 
methylation in components of the RB pathway. These alterations can be either 
inactivating or activating. Most frequently, they occur in upstream regulators of 
RB. Examples of the types of human cancer where such alterations occur are 
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1.2 TRIP-Br: a novel family of PHD zinc finger- and bromodomain-
interacting proteins that regulate E2F-dependent transcription and cell 
cycle progression. 
  
1.2.1 General background of the TRIP-Br family  
 The TRIP-Br/SERTAD (henceforth referred to as TRIP-Br) family of 
novel mammalian transcriptional regulators have been identified and 
characterized by our group and others independently (Abdullah et al., 2001; 
Bennetts et al., 2006; Calgaro et al., 2002; Cho et al., 2000; Darwish et al., 
2007; Gupta et al., 2003; Hayashi et al., 2006; Hsu et al., 2001; Lai et al., 2007; 
Li et al., 2004; Li et al., 2005; Sim et al., 2006; Sim et al., 2004; Sugimoto et al., 
1999; Tang et al., 2005; Tang et al., 2002; Watanabe-Fukunaga et al., 2005). 
They include the TRIP-Br1/p34SEI-1/SERTAD1/SEI-1 (henceforth referred to as 
TRIP-Br1), TRIP-Br2/SERTAD2/SEI-2 (henceforth referred to as TRIP-Br2), 
TRIP-Br3/HEPP/CDCA4/SEI-3 (henceforth referred to as TRIP-Br3), RBT1 
(Replication Protein A Binding Transactivator 1)/SERTAD3 (henceforth 
referred to as RBT1) and the recently-identified SERTAD4 (Bennetts et al., 
2006). In addition, the TRIP-Br homolog in Drosophila, TARANIS (TARA), was 
identified in a screen for functional partners of the homeotic loci and was 
shown to represent a novel member of the trithorax group (trxG) of regulatory 
proteins (Calgaro et al., 2002).  
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1.2.2 Genomic organization of the TRIP-Br genes 
 The TRIP-Br family shares a similar but unusual genomic structure. As 
shown in Figure 5, all members have intronless coding regions but also 
contain a spliceable intron in their 5’ untranslated regions (UTR). In addition, 
the splice acceptor site is always found within 7bp of the ATG start codon 
(Darwish et al., 2007).  TARA, the Drosophila homolog of mammalian TRIP-Br 
genes, also contains one intron in its 5’UTR (Calgaro et al., 2002). It remains 
unknown whether the TRIP-Br family is regulated by post-transcriptional 
modifications such as alternative splicing. 
 
 
Figure 5. Genomic organization of TRIP-Br genes. The hTRIP-
Br1/hSERTAD1 and hRBT1/hSERTAD3 genes are located in tandem on 
chromosome 19q13.1-13.2 in close proximity to the human hAKT2 gene that 
encodes a serine/threonine protein kinase. All genes containing a SERTA 
domain have an intron in their 5’ UTR close to the translational start site (ATG). 
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1.2.3 Structural and functional homology of TRIP-Br proteins 
 Members of the TRIP-Br family possess four evolutionary conserved 
regions including a putative cyclin A-binding motif (containing a putative 
conserved nuclear localization signal, KRK) at the amino terminus, a novel 
SERTA (SEI-1, RBT1 and TARA) domain, a PHD zinc finger- and/or 
bromodomain-interacting domain and a gene transactivation domain at the 
acidic carboxyl-terminus (Figures 6A and 6B) (Calgaro et al., 2002).  While the 
function of the SERTA domain remains to be elucidated, studies have shown 
that this motif of TRIP-Br1 binds to cyclin-dependent kinase 4 (CDK4) and 
facilitates the assembly and activation of CDK4-cyclin D complexes (Sugimoto 
et al., 1999). Proteins containing this domain has been implicated in cell cycle 
control, chromatin remodeling and gene regulation (Cho et al., 2000). Recent 
evidence also suggests that CDK4-cyclin D and the TRIP-Br proteins may 
activate and act synergistically with CDK2-cyclin E, resulting in cell cycle 
progression (Gomez Lahoz et al., 1999; Lundberg and Weinberg, 1998).  It 
remains an open question as to whether CDK4 binding is mediated by the 
SERTA domain in other TRIP-Br family members.  
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Figure 6. Homology of the TRIP-Br family. (A) The sequences of the 
conserved portions of TARA-β are shown aligned with homologous motifs from 
the related human TRIP-Br proteins, human transcription factor E2F-1, as well 
as predicted human (Hs) and Drosophila (Dm) proteins. Numbers flanking the 
amino acid sequences indicate positions in the complete protein sequences. 
Shown on a solid or shaded background are amino acids that are identical or 
conserved, respectively, among TARA proteins. The following amino acids 
were treated as conserved: R/K/H; S/T; E/D/Q/N; A/G/P; and I/L/V/M/C/F/Y/W. 
For the cyclin A-binding homology motif the equivalent region of E2F-1 is 
shown below. For the SERTA motif homologous regions from the predicted 
proteins HsdJ667H12.2.1 and DmCG2865 [without discernible cyclin A-
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are shown below with consensus positions displayed further below. In these 
positions, conserved or identical amino acids were found in at least six of the 
seven aligned sequences. Note that only four positions were identical in all 
nine SERTA motifs compared (marked by an asterisk). The percentage of 
amino acid identity with respect to the TARA-α/-β SERTA motif is indicated on 
the right. The GenBank accession numbers are hsY127/TRIP-Br2 (BAA09476); 
HsSEI-1/TRIP-Br1 (AAF08349); HsRBT1 (AAF05761); HsHEPP/TRIP-
Br3/CDCA4 (AAK31075); HsdJ667H12.2.1 (CAB81635); DmCG2865 
(AAF45770); and HsE2F-1 (Q01094). (B) Comparison of the motif structure of 
TARA-α/-β and human TRIP-Br proteins. For each alignment the overlying box 
refers to the corresponding motif in A. Note the equivalent order of the four 
conserved motifs in TARA and the mammalian TRIP-Br proteins. The minimal 
region of TRIP-Br1 required for interaction with CDK4 is indicated by brackets 
(aa 44–161) [extracted from (Calgaro et al., 2002)]. 
 
1.2.4 Coactivator function of TRIP-Br proteins 
 We have previously shown another unique role that the TRIP-Br 
proteins play in the regulation of cell cycle progression. TRIP-Br1 and TRIP-
Br2 functionally interact directly with DP-1 and activate the E2F1/DP1 
transcriptional complex to mediate cell cycle progression (Hsu et al., 2001). 
The heterodimeric E2F/DP complex has been shown to play a central role at 
the G1/S transition by stimulating the transcriptional activity of specific E2-
responsive promoters (Trimarchi and Lees, 2002). Recently, another TRIP-Br 
family member, RBT1, has also been shown to stimulate E2F-dependent 
transcription by acting as a transcriptional coactivator (Darwish et al., 2007; 
Watanabe-Fukunaga et al., 2005). We and others have further demonstrated 
that the carboxyl-terminal transactivation domain (TAD) of TRIP-Br1, TRIP-Br2 
and RBT1 is required for the stimulation of E2F-mediated transcription 
(Darwish et al., 2007; Hsu et al., 2001; Watanabe-Fukunaga et al., 2005).  In 
addition, the Drosophila homolog of TRIP-Br proteins, TARA, has been shown 
to modify expression of the homeotic loci, presumably by binding and 
activating bromodomain-containing trxG proteins leading to the imposition of 
 54
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
an active chromatin state (Calgaro et al., 2002; Dingwall et al., 1995).  TRIP-
Br1 and RBT1 have been further shown to be localized in tandem within a 
19q13 amplicon frequently found in human tumors, consistent with their 
putative role as oncogenes that promote tumor growth. Indeed, cytogenetic 
studies have revealed a gain of chromosomal region 19q13.1-13.2 in more 
than 30% of ovarian carcinomas (Sham et al., 2002; Thompson et al., 1996) 
as well as a variety of other tumors including pancreatic carcinomas (Hoglund 
et al., 1998) and lung cancers (Ried et al., 1994). Among these ovarian cancer 
patients, 19q amplification appears to be an early event and persists 
throughout the later stages of oncogenesis. Tang and others have reported 
the identification of overlapping minimal 19q amplification regions that contain 
a number of genes including AKT2 and TRIP-Br1 and RBT1 (Darwish et al., 
2007; Tang et al., 2002). AKT2, a member of a subfamily of protein 
serine/threonine kinases, has been shown to be a putative oncogene at the 
19q13 amplicon (Cheng et al., 1992). Although TRIP-Br1 has been further 
demonstrated to be amplified and overexpressed in several ovarian cancer 
cell lines as well as in ovarian carcinomas (R. Akhand and S.I. Hsu, 
unpublished data) (Tang et al., 2002), the association of RBT1 amplification to 
human cancers remains elusive. As a proof-of-principle that at least a subset 
of the TRIP-Br gene family consists of novel protooncogenes that play 
important roles in cellular proliferation and human cancer, the knockdown of 
TRIP-Br1 or RBT1 in cultured cell lines has been shown to reduce cell growth 
and colony formation (Darwish et al., 2007; Sim et al., 2006; Tang et al., 2005).  
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 As shown in Figure 7, TRIP-Br proteins have also been proposed to 
function in the coordination of the cell cycle through the “integration” of signals 
provided by PHD zinc finger- and/or bromodomain-containing transcription 
factors such as CBP/p300, KRIP-1, TIF1α and SP140 (Hirose et al., 2003; Hsu 
et al., 2001), which may confer both positive and negative coregulatory 
activities on the E2F/DP transcription complex. CBP is an essential 
transcriptional coactivator, which functions as a histone acetyltransferase 
(HAT) and has been implicated in the regulation of diverse cellular processes 
like gene transcriptional activation, cell differentiation and cell cycle regulation 
at the G1/S transition. Antagonism of the TRIP-Br integrator function elicits 
anti-proliferative effects through the transcriptional downregulation of a subset 
of E2F-responsive genes in vivo, and induces aberrant cyclin E accumulation, 
leading to Geminin dysregulation and caspase-3-independent cellular sub-
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Figure 7. TRIP-Br proteins play a dual function in the regulation 
of cell cycle progression during late G1 and the G1/S transition. 
In the absence of mitogenic stimulation, the CDK4-cyclin D complex is 
inhibited by p16INK4a (step 1). However, upon mitogenic stimulation, the serum-
induced TRIP-Br1 protein forms a quaternary complex with CDK4-cyclin D-
p16INK4a that interferes with the inhibitory effect of p16INK4a on the kinase 
activity of CDK4-cyclin D complex to which it remains bound (step 2). This 
active quaternary complex contributes to both CDK2-cyclin E activation and 
the generation of hypophosphorylated RB (step 3). The hypophosphorylated 
RB bound to otherwise-transcriptionally inactive E2F-1/DP-1 complexes 
serves as a target for hyperphosphorylation by functionally activated CDK2-
cyclin E (step 4), resulting in the dissociation of RB and release of cells from 
the late G1 checkpoint. Upon RB dissociation, TRIP-Br proteins are recruited 
to E2F-1/DP-1 complexes assembled on E2F-responsive promoters through 
physical association with DP-1 (step 5), resulting in the assembly of an E2F-
1/DP-1/TRIP-Br ternary complex. PHD zinc finger- and/or bromodomain-
containing proteins such as p300/CBP and KRIP-1, present in differing 
amounts and possessing different binding affinities are envisioned to compete 
for binding to TRIP-Br proteins and confer positive (+) and/or negative (-) 
regulatory signals to E2F-1/DP-1 transcription complexes assembled on E2F-
responsive promoters. An ‘integrated’ transcriptional read-out is achieved by 
effects on the basal transcription machinery [extracted from (Hsu et al., 2001)]. 
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 Furthermore, TRIP-Br proteins have been implicated in the regulation of 
the DNA damage response. To date, TRIP-Br1, TRIP-Br2 and TRIP-Br3 have 
all been shown to function with the ING family of proteins in a synergistic 
manner to stimulate the transactivation function of p53, although direct protein-
protein interactions have not been observed by co-immunoprecipitation 
studies (Watanabe-Fukunaga et al., 2005).  
 
1.2.5 Corepressor function of TRIP-Br proteins 
 Apart from their role as coactivators in the stimulation of E2F-
dependent transcription, the corepressor function of TRIP-Br proteins has also 
been described. Overexpression of TRIP-Br1 has been found to suppress 
CREB-mediated transcription and this suppression could be overcome by 
ectopic overexpression of CBP (Hirose et al., 2003). 
 In addition, TRIP-Br3 has been recently identified as a novel E2F-
responsive gene and as a repressor of E2F-dependent transcriptional 
activation (Hayashi et al., 2006). Analysis of TRIP-Br3 promoter constructs 
showed that an E2F-responsive sequence in the vicinity of the transcription 
initiation site is necessary for the E2F1-4-induced activation of TRIP-Br3 gene 
activation. Chromatin immunoprecipitation analysis further validated the 
binding of E2F1 and E2F4 to an E2F-responsive sequence of the human 
TRIP-Br3 promoter. Like all 3 other TRIP-Br family members, the TAD of 
TRIP-Br3 has been mapped to the carboxyl-terminal acidic region. However, 
this transactivation function of TRIP-Br3 is inhibited by E2F1-4 and DP2, but 
not by E2F5-8. Inhibition of TRIP-Br3 transactivation activity by E2F1 was 
partially reversed by RB overexpression. Conversely, TRIP-Br3 suppressed 
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E2F1-3 induced reporter activity in a dose-dependent manner. Interestingly, 
the loss of the acidic carboxyl-terminus of TRIP-Br3 led to a failure to suppress 
E2F1-regulated gene promoter activity. These findings suggest that TRIP-Br3 
functions as a corepressor on E2F-responsive promoters and that such 
suppression of promoter activity might be mediated by its acidic carboxyl-
terminus. Coupled with our understanding that TRIP-Br3 stimulates p53-
induced gene transactivation through its association with ING family proteins, 
TRIP-Br3 serves as a unique molecular switch to repress E2F-induced gene 
transactivation while simultaneously serving to activate p53-dependent 
pathways in response to DNA damage events (Figure 8). Indeed, the siRNA-
mediated knockdown of TRIP-Br3 expression in cancer cells has been shown 
to result in upregulation of cell growth rates and DNA synthesis (Hayashi et al., 
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Figure 8. Proposed model for the function of TRIP-
Br3/HEPP/CDCA4 in the regulation of E2F1 and p53 
transcriptional activity. A subset of TRIP-Br genes, which include TRIP-
Br1, TRIP-Br2, and TRIP-Br3/HEPP/CDCA4, are transcriptionally induced by 
E2F1. TRIP-Br1 and TRIP-Br2 are recruited to the E2F1-loaded E2F-
responsive promoters through physical association with E2F1/DP1. TRIP-
Br3/HEPP/CDCA4 associates with ING family proteins or the coactivators 
p300 and CBP to regulate p53-induced transactivation. E2F1 can mediate 
both cell proliferation and p53-dependent/independent apoptosis. TRIP-
Br3/HEPP/CDCA4 represses primarily E2F1-induced transactivation. However, 
in certain contexts it promotes p53-induced transactivation. This differential 
regulation by TRIP-Br3/HEPP/CDCA4 probably occurs through a mechanism 
that involves transactivation of E2F1/DP1 by p300/CBP, HDAC, or Brg1/Brm 
within the established E2F/RB framework. Positive (+) and negative (-) signals 
refer to transregulatory properties mediated by the TRIP-Br3/HEPP/CDCA4 
protein on E2F1- and p53-responsive promoters [extracted from (Hayashi et 
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1.2.6 Other interactors of TRIP-Br proteins 
 Apart from CDK4, CBP/p300, KRIP-1, TIF1α and SP140, TRIP-Br 
proteins have also been shown to interact with human papilloma virus E6 
oncoprotein (HPV E6), PCAF, STAF65γ and CRM1/Exportin-1 (Gupta et al., 
2003; Lai et al., 2007).   HPV E6, PCAF and STAF65γ have all been reported 
to enhance the transcriptional activities of TRIP-Br1 and/or TRIP-Br2, while 
the subcellular distribution of TRIP-Br proteins was linked to their association 
with CRM1/Exportin-1 nuclear export machinery (Gupta et al., 2003; Lai et al., 
2007). Furthermore, TRIP-Br1 was found to heterodimerize with TRIP-Br2; but 
the significance of such interaction remains elusive (S.I. Hsu, unpublished 
data). With the exception of CDK4 and CBP/p300 (Hirose et al., 2003; 
Sugimoto et al., 1999), the interacting domains in TRIP-Br proteins to these 
various protein interactors have yet to be elucidated.   
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1.3 Specific aims of this study 
 While most of the other TRIP-Br family members have recently been 
extensively characterized and shown to be involved in a broad spectrum of 
cellular processes such as E2F-mediated cell cycle progression, p53-
dependent stress response and cancer pathogenesis (Abdullah et al., 2001; 
Calgaro et al., 2002; Cho et al., 2000; Gupta et al., 2003; Hayashi et al., 2006; 
Hsu et al., 2001; Li et al., 2004; Li et al., 2005; Sim et al., 2004; Sugimoto et 
al., 1999; Tang et al., 2005; Tang et al., 2002; Watanabe-Fukunaga et al., 
2005), the physiological role of TRIP-Br2 in eukaryotic cells remains poorly 
understood and its direct link to cancer pathogenesis has not been established.  
  
1.3.1 Specific Aim 1:  To unravel the physiologic role(s) of TRIP-Br2 in 
cell cycle regulation by characterizing the phenotype of a TRIP-Br2 
knockout mouse model.  
 In collaboration with Lexicon Genetics (USA), we assessed the role of 
TRIP-Br2 in development, transcriptional regulation and cell cycle progression 
by inactivating the TRIP-Br2 locus in mouse through insertional mutagenesis 
and exon trapping (Zambrowicz et al., 1998). We investigated whether 
ablation of TRIP-Br2 would lead to infertility and embryonic lethality in mice. 
As the lymphoid system consists of numerous cell types with high turnover, we 
envisaged that the loss of TRIP-Br2 would also lead to a failure of lymphoid 
development in mice. We isolated high proliferative cell types, such as 
spleonocytes and primary murine embryonic fibroblasts (PMEFs), from these 
animals and focused our phenotypic characterization on cellular proliferative 
potential, colony-forming potential as well as changes in the kinetics of cell 
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cycle progression of these primary cells. In addition, we performed mRNA and 
protein expression profiling on the PMEFs to further determine the effect of 
TRIP-Br2 ablation in these fibroblasts.  
 
1.3.2 Specific Aim 2:  To validate the oncogenic potential of TRIP-Br2 in 
cancer pathogenesis by stable overexpression of TRIP-Br2 in NIH3T3 
mouse fibroblasts and high-throughput immunoscreens of human tumor 
tissue microarray to identify TRIP-Br2 overexpression 
 We validated the oncogenic potential of TRIP-Br2 in cancer 
pathogenesis by stably overexpressing TRIP-Br2 in NIH3T3 mouse fibroblasts. 
In addition, we investigated the cellular proliferative-, colony-forming- as well 
as tumor inducing-potentials of these TRIP-Br2-overexpressing mouse 
fibroblasts. We also performed mRNA and protein expression profiling to 
further characterize these TRIP-Br2-overexpressing cells. We conducted high 
throughput expression profiling of TRIP-Br2 in multiple human tumor tissue 
arrays and studied the prognostic value of TRIP-Br2 in cancer pathogenesis. 
To determine whether TRIP-Br2 could serve as a novel transcription-based 
chemotherapeutic drug target, siRNA-mediated knockdown of TRIP-Br2 was 
performed in serum-deprived HCT-116 colorectal cancer cells in vitro.  
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1.3.3 Specific Aim 3:  To elucidate the regulatory mechanism(s) that 
govern the protein turnover of TRIP-Br2 to confer tight regulation of 
TRIP-Br2 function during cell cycle progression 
 As the oscillatory nature of other TRIP-Br proteins during cell cycle 
progression has been reported (Darwish et al., 2007; Hayashi et al., 2006; Hsu 
et al., 2001; Sugimoto et al., 1999), we investigated whether temporal 
regulation of TRIP-Br2 by transcriptional and/or translational mechanisms 
exists and if such regulation could serve to tightly control the execution of its 
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2.1 Methods & Material 
2.1.1 Generation and characterization of rabbit anti-TRIP-Br2 polyclonal 
antibody 
 The primary amino acid sequence of human TRIP-Br2 (hTRIP-Br2, 
GenBankTM accession no. NP055570) was obtained from NCBI PubMed 
(http://www.ncbi.nlm.nih.gov/sites/entrez). It was analyzed by the Abie Pro 3.0-
Peptide Antibody Design software (freely available from 
http://www.changbioscience.com/abie/abie.html) that employs the 
performance of Hopp-Woods and Kyte-Doolittle hydropathy plots to identify 
putative antigenic epitopes of human TRIP-Br2. The N-terminal sequence of 
hTRIP-Br2 (aa1-14) was selected for peptide synthesis and antibody 
production due to its abundance of surface residues, higher hydrophilicity, high 
antigenicity (Figure 9) and relatively low homology with the other TRIP-Br 
family members (data not shown). Peptide synthesis and rabbit anti-TRIP-Br2 
polyclonal antibody production were performed in collaboration with Genemed 
Synthesis Inc. (San Antonio, TX). Briefly, 5 mg of N-terminal cysteine-tagged 
hTRIP-Br2 peptides (C-MLGKGGKRKFDEHE) were synthesized and 
conjugated to Keyhole Limpet Hemocyanin (KLH) to increase immunogencity 
of these peptides. The KLH-conjugated hTRIP-Br2 peptides were used as the 
immunogen to immunize New Zealand White rabbits. The amount of 
immunogen used for each immunization was 0.5 mg/per rabbit/per injection. 
The immunogen was diluted to one ml with sterile saline and combined with 
one ml of the appropriate adjuvant. The antigen and adjuvant were mixed 
thoroughly to form a stable emulsion and injected subcutaneously to provide 
enhanced immune response from the sustained presence of the immunogen. 
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Complete Freund's Adjuvant (CFA) was used for the initial injection, followed 
by the use of Incomplete Freund's Adjuvant (IFA) for all subsequent injections. 
The generation of rabbit TRIP-Br2 polyclonal antibody was performed at 
Genemed Synthesis Inc. with the following schedule: Day 1: an initial bleed of 
25 ml of blood from each rabbit (yield 10 ml pre-immune serum) and 1st 
immunization with antigen in CFA; Day 20: 2nd immunization with antigen in 
IFA; Day 40: 3rd immunization with antigen in IFA; Day 50: test bleed of 10 ml 
of blood for ELISA screen (internal quality control only, data not shown); Day 
60: 4th immunization with antigen in IFA; Day 70: Final total bleed of 50 ml of 
blood from each rabbit.  Blood collected from the central ear artery with a 19 
gauge needle was allowed to clot and retract at 37°C overnight. The clotted 
blood was then refrigerated for 24 hours before the serum was decanted and 
clarified by centrifugation at 2500 rpm for 20 minutes. All rabbit serum samples 
were stored at -80°C. Serum processed from the final bleed at Day 70 was 
diluted in 4% fat-free skim milk (1:4000) and used as primary antibody in 
western blot and immunocytochemical analyses. 
 To test the specificity of rabbit anti-hTRIP-Br2 antibody, peptide 
competition assay was performed. Briefly, 2 µl of rabbit anti-hTRIP-Br2 serum 
(Lot no. G4195; ~1 mg/ml of IgG) was blocked with 200-fold excess of hTRIP-
Br2 peptides (100 µg/µl), i.e. 4 µl, and topped up with 94 µl of PBS to make up 
a final reaction volume of 100 µl. The antibody-peptide mixture was incubated 
at room temperature for 1 h with gentle shaking prior to centrifugation at 4oC at 
10,000 rpm to pellet the immune complexes.  The pellet was resuspended in 8 
ml of 4% fat-free skim milk (in PBS-Tween) and used for Western blot 
analyses. Cell lysates from NIH3T3 mouse fibroblasts and WI38 human 
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primary fibroblasts were prepared and proteins were resolved by denaturing 
SDS-PAGE prior to transfer on PVDF membrane and Western blot analyses 
using pre-immunized rabbit serum, hTRIP-Br2 peptide-blocked G4195 (hTRIP-
Br2-specific) rabbit serum and G4195 (hTRIP-Br2-specific) rabbit immune 
serum. In addition, lysates from GAL4DBD and GAL4DBD-hTRIP-Br2 
transfected HEK293 cells were prepared and proteins were resolved by 
denaturing SDS-PAGE prior to transfer on PVDF membrane and Western blot 
analyses using G4195 (hTRIP-Br2-specific) rabbit immune serum. β-tubulin 
was used as a loading control. All cell lines were cultured in DMEM 
supplemented with 10% FBS and maintained at 37oC in a 5% CO2 
environment. The use of GAL4DBD and GAL4DBD-hTRIP-Br2 expression 
plasmids have been previously described (Hsu et al., 2001). 
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Figure 9. Antigenicity of human TRIP-Br2. Primary amino acid 
sequence of human TRIP-Br2 (hTRIP-Br2, GenBankTM accession no. 
NP055570) was obtained from NCBI PubMed and analyzed by the Abie Pro 
3.0: Peptide Antibody Design software, in which Hopp-Woods and Kyte-
Doolittle hydropathy plots were performed to determine antigenicity of hTRIP-
Br2. The sequence of aa1-14 (in capital letters and highlighted by cyan color) 
at the N-terminus of hTRIP-Br2 was selected for peptide synthesis and 
antibody production due to its abundance of surface residues, higher 
hydrophilicity, high antigenicity and relatively low homology with the other 
TRIP-Br family members. aa15-56, a region of low hydrophilicity, was depicted 
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2.1.2 Generation of TRIP-Br2+/- heterozygous founder mice 
 TRIP-Br2+/- founder mice were created in collaboration with Lexicon 
Genetics (The Woodlands, Tx). The mTRIP-Br2+/- locus  was disrupted by 
gene trapping, using random insertional mutagenesis with the retroviral gene 
trap vector VICTR48 as previously described (Zambrowicz et al., 1998). Briefly, 
VICTR48 was generated by cloning a sequence acquisition component and a 
mutagenic component into the pGen sup-expression vector, followed by 
packaging in GP+E86 cells. The acquisition component consisted of 
phosphoglycerate kinase 1 promoter (PGK) fused to the Bruton's tyrosine 
kinase (BTK) gene, followed by a synthetic consensus splice donor sequence 
(PGK-BTK-SD), while the mutagenic component consisted of a splice acceptor 
sequence that was followed by a neomycin selection marker and a poly A tail 
(SA-neo-pA). Mouse embryonic stem cells (derived from the 129SvEvBrd 
strain) were retrovirally infected with VICTR48 and clonally selected. The 
presence of only one gene copy of the mutational insertion was verified and 
the sequence of the trapped gene was obtained for each clone by 3’ rapid 
amplification of cDNA ends (RACE). mTRIP-Br2 nucleotide sequence 
(GenBankTM accession no. BC014726) was obtained from NCBI PubMed and 
used to screen the Lexicon OmniBank® library database of disrupted genes 
(http://www.lexgen.com). Clone OST98734, in which only one gene copy of 
the retroviral trap insertion was found in intron 2 of the mTRIP-Br2 locus 
(preceding the single coding exon of mTRIP-Br2), was selected and inserted 
into blastocysts (C57BL/6J albino) prior to implantation into female C57BL/6J 
albino mice to generate F1 chimeric heterozygous TRIP-Br2+/- founder animals. 
These progeny were then intercrossed to generate F2 wildtype, heterozygous, 
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and homozygous mutant progeny. For generation of a congenic strain of 
TRIP-Br2 ablated mice, F1 chimeric heterozygous mutant progeny were 
mated with C57BL/6J mice (The Jackson Laboratory, Bar Harbor, Maine) and 
their descendants were backcrossed 10 generations with C57BL/6J mice. 
Phenotypic analyses were performed on TRIP-Br2 ablated mice in these 2 
genetic backgrounds. The targeted disruption was validated by PCR 
genotyping, semi-quantitative RT-PCR and Western blot analysis. The 
targeted disruption of the TRIP-Br2 locus in mouse is illustrated in Figure 10.  
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Figure 10. Targeted disruption of the TRIP-Br2 locus in mouse. 
The TRIP-Br2+/- locus in mouse chromosome 11 was disrupted by gene 
trapping, using random insertional mutagenesis with the retroviral targeting 
construct VICTR48 as previously described (Zambrowicz et al., 1998). 
VICTR48 was generated by cloning a sequence acquisition component and a 
mutagenic component into the pGen sup-expression vector, followed by 
packaging in GP+E86 cells. The acquisition component consisted of 
phosphoglycerate kinase 1 promoter (PGK) fused to the Bruton's tyrosine 
kinase (BTK) gene, followed by a synthetic consensus splice donor sequence 
(PGK-BTK-SD), while the mutagenic component consisted of a splice acceptor 
sequence that was followed by a neomycin selection marker and a poly-A tail 
(SA-neo-pA). Disruption of the TRIP-Br2 locus in mice was achieved by the 
insertion of VICTR48 into intron 2 thereby abrogating transcription of the 
coding region of mTRIP-Br2.   A: Lexicon250InsF forward primer; LTR2: 
Lexicon250LTR2 forward primer; B: Lexicon250InsR reverse primer; 5’UTR: 5’ 
untranslated region; CE: coding exon.  
A B
CE 5’UTR 5’UTR Wildtype allele  
Mutated allele 
  LTR SA      ΝΕΟ   pA PGK     BTK  SD  LTR  
B LTR2 
5’UTR 5’UTR CE 
  LTR SA      ΝΕΟ   pA PGK     BTK   SD LTR  Retroviral trap 
Mouse genomic DNA 
(chromosome 11) 
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2.1.3 PCR genotyping  
 To validate the presence of the retroviral trap upstream of the mTRIP-
Br2 coding sequence in adult mice, tail biopsies were performed and samples 
were lysed in Tail Lysis Buffer (50 mM Tris-HCl, pH7.5; 50 mM EDTA, pH8.0, 
100 mM NaCl, 5 mM DTT, 0.05 mM spermidine, 1% sarkosyl, filter sterilized) 
and proteinase K at 65oC for 3 hours. The genomic DNA obtained was used in 
a multiplex PCR genotyping reaction. This multiplex PCR genotyping was 
performed by 2 sets of primer pairs: (1) a 5’ primer that annealed to the 
retroviral C-terminal LTR2 (Lexicon250LTR2) and a 3’ primer that annealed to 
mouse chromosome 11 downstream of the intronic insertion site 
(Lexicon250InsR), and (2) a 5’ primer that annealed to mouse chromosome 11 
upstream of the intronic insertion site (Lexicon250InsF) and Lexicon250InsR. 
PCR was performed as follows: 30 cycles of denaturation (94oC, 30 seconds), 
annealing (56oC, 2 minutes) and extension (72oC, 30 seconds) with a 2-minute 
initial denaturation step at 94oC and a 3-minute terminal polishing step at 72oC. 
Amplified PCR products were separated in 2% agarose gels and visualized by 
staining with ethidium bromide. All primer sequences used for PCR genotyping 
are listed in Table 3C. 
 
2.1.4 Histological examination of mouse tissues 
 8-week old wildtype and mutant mice (n=6, each group) were sacrificed 
and tissues removed from these animals were trimmed and housed in marked 
cassettes prior to fixation in 10% neutral buffered formalin at room 
temperature for 24 h. The tissue cassettes were then immersed in 70% 
ethanol for 24 h, followed by tissue dehydration and paraffin-embedding using 
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an automated tissue processor (Leica Microsystems, Heerbrugg, Switzerland). 
The paraffin-embedded tissues were made into blocks and cut into 4 µm 
sections by a microtope (Leica Microsystems, Heerbrugg, Switzerland).  
These tissue sections were stained with hematoxylin and eosin (H&E, Sigma-
Aldrich, St. Louis, MO), followed by light microscopic examination of tissue 
histopathology by 3 independent animal research pathologists in a double-
blinded manner. 
  
2.1.5 Preparation of single cell suspension from mouse tissues  
 Thymus, spleen and lymph nodes (superficial cervical, axillary, brachial, 
mesenteric and inguinal) from TRIP-Br2+/+, TRIP-Br2+/- and TRIP-Br2-/- mice 
were isolated and single cell suspensions were prepared from these soft 
tissues by mechanical shearing through 70 micron disposable filters (BD 
Biosciences, San Jose, CA). Spleen cell suspensions were centrifuged (1500 
rpm, 8 minutes) at 4oC and cell pellets were resuspended in 5 ml of ACK Red 
Blood Cell Lysis Buffer (BioWhittaker, Walkersville, MD) prior to incubation at 
room temperature for 5 minutes with occasional shaking. 30 ml of sterile PBS 
was added to quench the reaction. All cell suspensions were centrifuged (1500 
rpm, 8 minutes) at 4oC and cell pellets were resuspended in 1 ml of sterile 
PBS prior to cell count determination. They were centrifuged again (1500 rpm, 
8 minutes) at 4oC and resuspended in appropriate buffers/media for further 
manipulations. 
 74
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
2.1.6 Preparation of anti-CD3/anti-CD28 pre-coated 96-well plates 
 1 µg/ml of anti-CD3 (145-2C11, eBioscience Inc., San Diego, CA) and 
0.5 µg/ml of anti-CD28 (11-0289, eBioscience Inc.) was prepared in sterile 
PBS and 50 µl of mixed antibody solution was dispensed in each well of a 96-
well flat-bottom microtiter plate. For the control unstimulated wells, 50 µL of 
sterile PBS was dispensed. The plate was then sealed with Parafilm and 
incubated at 37oC for 2 h. The antibody solution was subsequently removed 
from the plate with a multichannel pipettor, followed by three washes with PBS 
and storage in PBS at 4oC until use.  
 
2.1.7 In vitro T cell proliferation assays  
 In vitro T cell proliferation assays have been previously described 
(Marinova et al., 2007). Briefly, 1X106 spleen cells per 200 µl RPMI 1640 
medium supplemented with L-glutamine (0.2 mM), sodium pyruvate (1 mM), 
nonessential amino acids (0.01 mM), penicillin (100 U/ml), streptomycin (100 
mg/m), 10% FBS and 4 µg/ml Concavalin A (Con A; Sigma, St. Louis, MO) 
were cultured in 96-well flat-bottom microtiter plates and maintained at 37oC 
for 48 h in a 5% CO2 environment. Cells that were not exposed to Con A 
stimulation was used as a negative control. In addition, 1X106 spleen cells per 
200 µl of RPMI 1640 medium supplemented with L-glutamine (0.2 mM), 
sodium pyruvate (1 mM), nonessential amino acids (0.01 mM), penicillin (100 
U/ml), streptomycin (100 mg/ml) and 10% FBS were cultured in anti-CD3/anti-
CD28 pre-coated 96-well flat-bottom microtiter plates and maintained at 37oC 
for 48 h in a 5% CO2 environment. Proliferation of splenic T cells in response 
to these specific mitogenic stimulations was analyzed by MTT assays in 
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accordance with the manufacturer’s instructions (Roche Applied Science, 
Indianapolis, IN). All assays were performed in triplicates on cell preparations 
derived from at least 3 independent groups of mice. A Student’s t-test was 
performed to analyze the data collected.  
 
2.1.8 Flow cytometric lymphoid cell analysis  
 Cells prepared from mouse lymphoid tissues were divided into three 
groups and 1x106/ml of cells from each group were stained for 20 minutes at 
4oC in the dark with the antibodies listed in Table 3A. Cells were washed three 
times with PBS and resuspended in Flow Cytometry Staining Buffer (00-4222, 
eBioscience Inc.) prior to analysis using a LSRII flow cytometer (BD 
Biosciences). Intracellular staining with anti-FoxP3-PE (12-5773, eBioscience 
Inc.) was performed on cells from Group C (see Table 3A). Briefly, primary 
antibody-stained cells were fixed and permeabilized with 
Fixation/Permeabilization Buffer (1:1 ratio) (00-8222, 00-8333, eBioscience 
Inc.) in the dark for 30 minutes at 4oC. These cells were centrifuged (1500 rpm, 
8 minutes) at 4oC and washed twice with 1X Permeabilization Buffer prior to 
intracellular staining with anti-FoxP3-PE in the dark for 30 minutes at 4oC. 
Cells were washed three times with 1X Permeabilization Buffer and 
resuspended in Flow Cytometry Staining Buffer (00-4222, eBioscience Inc.) 
prior to analysis using a LSRII flow cytometer. The analysis was performed on 
pilot-scale, using cell preparations described in Section 2.1.5. 
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 Group A  
(Thymus, spleen, LN)
Group B  Group C  
(Spleen, LN) (Thymus, LN)
 
Fluorophore Antibody 
FITC anti-CD4 anti-CD4 anti-CD4 
PE Anti-CD62L anti-B220 - 
PercP/ 
PE-Cy5 
anti-CD8 anti-CD8 - 
APC Anti-CD44 anti-CD11c anti-CD25 
Intracellular staining 
with anti-FoxP3-PE 
- - + 
 
Table 3A. Fluorophore-conjugated antibodies used in flow cytometric 
lymphoid cell analysis. Lymphoid cells isolated from 8-week old TRIP-Br2+/+, 
TRIP-Br2+/- and TRIP-Br2-/- mice were divided into three groups and stained 
with the above-mentioned antibodies in various combinations. These cells 
were fixed and analyzed by flow cytometry. Intracellular staining with anti-
FoxP3-PE was performed on cells from Group C. 
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2.1.9 In silico TRIP-Br2 gene expression profiling  
 The GNF SymAtlas ver. 1.2.4 (Novartis, 
http://symatlas.gnf.org/SymAtlas/) human and mouse microarrays database 
was interrogated to determine the in silico gene expression profiling of TRIP-
Br2 across all tissues. The NCBI symbol SERTAD2 was used in the query of 
the GNF SymAtlas database. The median (med) was calculated based on 
expression of TRIP-Br2 across all human tissues; medX3: 3-fold more than 
the median; medX10: 10-fold more than the median. In silico TRIP-Br2 
expression, (χ), across all tissues was scored via the following scheme: +: 
(χ)≤median; ++: median<(χ)≤medX3; +++: medX3<(χ)≤medX10; ++++: 
medX10<(χ). 
 
2.1.10 Establishment of PMEF cell lines  
 PMEFs were isolated from E15.5 mouse embryos. Briefly, pregnant 
mice were sacrificed when embryos were ~15.5 days post-copulation (dpc). 
The uterus was dissected out and transferred to a 100 mm Petri dish 
containing sterile PBS. The embryos were dissected away from the uterus and 
all membranes before being transferred into a new dish containing sterile PBS. 
They were decapitated and all internal organs (liver, heart, kidney, lung, and 
intestine) were removed. The carcasses were washed in a 50 ml Falcon tube 
in 50 ml sterile PBS at least twice to remove as much blood as possible, 
before being minced into small pieces by a pair of surgical scissors. Ten ml of 
trypsin/EDTA was added to the minced carcasses and they were further 
dislodged into fine cell suspension by repeated pipetting before being 
incubated at 37oC for 15 minutes.  The cell suspension was then transferred 
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into a 50 ml Falcon tube with the subsequent addition of 40 ml DMEM 
supplemented with 10% FBS. The cells were centrifuged at 300 x g for 5 
minutes and the supernatant was discarded. The cell pellet was resuspended 
with 25 ml DMEM supplemented with 10% FBS and plated onto a 175 cm2 
Falcon tissue culture flask for maintenance at 37oC in a 5% CO2 environment. 
Confluent cell cultures were trypsinized and kept frozen at -20oC for 3 h before 
a short-term storage at -80oC or a long-term storage in liquid nitrogen (in 5% 
DMSO, 50 mM sucrose, 95% FBS).  
 
2.1.11 Semi-quantitative RT-PCR analysis  
 Total RNA was isolated from mouse tissues and PMEFs using the 
TRIZOL® Reagent (Life Technologies Inc., Gaithersburg, MD) according to the 
manufacturer’s instructions. Total RNA (3 µg) was reverse transcribed using 
the ABI High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instructions. Polymerase Chain Reactions 
(PCR) were performed on 1 µl cDNA samples in the presence of 10 mM 
deoxyribonucleotide triphosphates (dNTPs) and 10 µM of specific primer pairs 
in a total reaction volume of 20 µl. PCR was performed as follows: 20 cycles of 
denaturation (94oC, 30 seconds), annealing (51oC, 30 seconds) and extension 
(72oC, 1 minute) with a 2-minute initial denaturation step at 94oC and a 3-
minute terminal polishing step at 72oC. Amplified PCR products were 
separated in 2% agarose gels and visualized by staining with ethidium 
bromide. The primer sequences used for RT-PCR are listed in Tables 3B and 
3C. 
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Species Orientation Primer sequence (5’→3’) 
































































HA - Reverse AGC GTAATCTGGAACATCGTATGGGTA 











Table 3B. Sequences of gene-specific primers used in semi-quantitative 
RT-PCR. Nucleotide sequences were obtained from NCBI 
PubMed/GenBankTM and used as templates for the design of gene-specific 
primers using DNAstarTM software (continues in next page). 
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Species Orientation Primer sequence (5’→3’) 
Semi-qRT-PCR and Real-time qRT-PCR 

































Lexicon250InsF Mouse Forward CCGACTGAGAAGAAGCCACTAAACCACAC 
Lexicon 
250LTR2 
Mouse Forward AAATGGCGTTACTTAAGCTAGCTTGC 






TRIP-Br2-HA Human Reverse TCAAGCGTAATCTGGAACATCGTAT-
GGGTAGCCGGACCCAACAAGCACC 
T7 - Forward TAA TAC GAC TCA CTA TAG GG 
HA - Reverse Refer to Table 3B 
 
 
Table 3C. Sequences of gene-specific primers used in PCR. Nucleotide 
sequences were obtained from NCBI PubMed/GenBankTM and used as 
templates for the design of gene-specific primers using DNAstarTM software. 
These primers were used in semi-quantitative RT-PCR, real-time quantitative 
RT-PCR, PCR genotyping or molecular cloning.    
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2.1.12 Denaturing SDS-PAGE and western blot analyses 
 Proteins from cell lysates were resolved using standard denaturing 
polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (Hsu 
et al., 2001). Rabbit anti-TRIP-Br2 (G4195) polyclonal antibody and mouse 
anti-TRIP-Br1 monoclonal antibody (Zang et al., 2007) were used in Western 
blot and/or immunocytochemical analyses. All other antibodies used in 
Western blot analyses were purchased from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA). They include anti-p53 (sc-126), anti-caspase 3 (sc-7148), 
anti-cyclin D1 (sc-718), anti-cyclin E (sc-481), anti-PCNA (sc-7907), anti-CDC2 
(sc-747), anti-CDK2 (sc-163) and β-tubulin (sc-5274). 
 
2.1.13 Serum deprivation, bromodeoxyuridine (BrdU) labeling and flow 
cytometric DNA content analysis 
 PMEFs were cultured in 96 well-plates (for BrdU incorporation assays) 
or 100 mm culture dishes (for flow cytometry assays) in DMEM supplemented 
with 0.2% FBS and were maintained for 72 h at 37oC in a 5% CO2 environment. 
To release cells from growth quiescence, they were subsequently maintained 
in DMEM supplemented with 10% FBS for 22 h at 37oC in a 5% CO2 
environment prior to BrdU incorporation and flow cytometric DNA content 
analyses. For colony formation assays, cells were restimulated with 10% FBS 
for 48 h. BrdU incorporation was monitored using a cell 
proliferation/colorimetric ELISA assay according to the manufacturer’s 
instructions (Boehringer Mannheim, Mannheim, Germany). Flow cytometry 
was performed using a FACScan flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ) at a wavelength of 488 nm. 
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2.1.14 Colony formation assay 
 1X104 cells were grown in 6-well plates and maintained in DMEM 
supplemented with 10% FBS up to 14 days at 37oC in a 5% CO2 environment. 
Routine change of medium was performed in 3-day intervals. Cells were fixed 
with 100% methanol and stained with 0.4% Giemsa stain as previously 
described (Zang et al., 2007).  For colony quantitation, the intracellular Giemsa 
stain was eluted with 1% SDS and quantitated using a SpectraMax M5 
spectrophotometer (Molecular Devices, Sunnyvale, CA) at a wavelength of 
595 nm. 
 
2.1.15 Nuclear condensation assay  
 Nuclear condensation in apoptotic cells was assayed as previously 
described (Dasari et al., 2006). Briefly, PMEFs and control NIH3T3 fibroblasts 
were grown to 60% confluence on coverslips, washed three times with PBS, 
fixed in prechilled 4% paraformaldehyde for 20 minutes, and permeabilized in 
0.1% Triton-X for 10 minutes. Cells were then incubated with RNase A (10 
µg/ml in PBS) for 10 minutes and subsequently mounted with 
DAPI/VectorShield® (Vector Laboratories Inc., Burlingame, CA), before being 
examined and photographed using a Nikon Eclipse E1000 fluorescence 
microscope (Nikon, Japan). NIH3T3 fibroblasts without and with hydrogen 
peroxide (H2O2, 250 µM, 1 h) treatment were used as negative and positive 
controls. Induction of apoptosis in cells by H2O2 treatment has been previously 
described (Yu et al., 2002).  Total apoptotic nuclei, which were characterized 
by condensation of chromatin into multiple dense masses, were counted from 
10 randomly chosen fields in three independent experiments. % apoptotic 
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nuclei = (total apoptotic nuclei counted in 10 fields/total no. of nuclei counted in 
10 fields) X 100. 
 
2.1.16 Determination of cell number and viability 
 Following serum deprivation, cells were washed twice with PBS, 
harvested by trypsinization and resuspended in 1 ml PBS. 10 µl of cell 
suspension was taken from each sample and enumerated electronically or 
manually. For electronic total cell counts, 10 µl of cell suspension was diluted 
in 20 ml of isoton® II buffer (Coulter®) and cell number was estimated using 
an electronic Coulter® counter. For manual counting of viable cells, 10 µl of 
cell suspension from each sample was mixed with equal volume of trypan blue 
stain (Sigma, 0.4% in PBS). The number of dye-excluding viable cells was 
enumerated manually using a hemocytometer. 
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2.2 Results 
2.2.1 Generation and characterization of rabbit anti-TRIP-Br2 polyclonal 
antibody 
 To facilitate the characterization of a novel TRIP-Br2 knockout mouse 
model, we generated rabbit anti-TRIP-Br2 polyclonal antibody from short 
hTRIP-Br2 peptides. Briefly, the primary amino acid sequence of human TRIP-
Br2 (hTRIP-Br2) was analyzed by the Abie Pro 3.0-Peptide Antibody Design 
software, in which Hopp-Woods and Kyte-Doolittle hydropathy plots were 
performed to determine antigenicity of hTRIP-Br2. The amino-terminal 
sequence of hTRIP-Br2 (N-terminal, aa1-14), which was highly conserved in 
widely diverse species as revealed by the Blast analysis (data not shown), 
was selected for peptide synthesis and antibody production due to its 
abundance of surface residues, higher hydrophilicity, high antigenicity (Figure 
9) and relatively low homology with the other TRIP-Br family members (data 
not shown). These N-terminal hTRIP-Br2 peptides were cysteine-tagged (C-
MLGKGGKRKFDEHE), synthesized and conjugated to Keyhole Limpet 
Hemocyanin (KLH) to increase immunogenicity of these peptides. These KLH-
conjugated hTRIP-Br2 peptides were subsequently used as the immunogen to 
immunize New Zealand White rabbits. Serum processed from the final bleed 
of immunized rabbits was diluted in 4% fat-free skim milk (1:4000) and used 
as a primary antibody in Western blot analyses.  
 As shown in Figure 11 (left panel), the anti-hTRIP-Br2 polyclonal 
antibodies in G4195 rabbit serum recognized both endogenous hTRIP-Br2 
and exogenously-expressed GAL4DBD-hTRIP-Br2 in HEK293 cells as protein 
molecules of ~42-45 kDa (doublet) and ~60 kDa, respectively. The exogenous 
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GAL4DBD-tagged proteins were shown to be properly expressed in HEK293 
cells (Figure 11, right panel). 
 
 
Figure 11. Endogenously- and exogenously-expressed hTRIP-
Br2 in HEK293 cells were detected by anti-hTRIP-Br2 
polyclonal antibodies in G4195 rabbit serum. Left panel: 
Endogenous hTRIP-Br2 was detected to be a doublet of 42 and 45 kDa 
protein molecules, while the molecular weight of exogenous GAL4DBD-
hTRIP-Br2 was determined to be approximately 60 kDa. β-tubulin was used as 
a loading control. Right panel: The exogenous GAL4DBD proteins were 
properly expressed in HEK293 cells.  WB: Western Blot (with the appropriate 
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 To test the specificity as well as cross-reactivity of these rabbit anti-
hTRIP-Br2 antibodies to other species, peptide competition assays was 
performed. Briefly, anti-hTRIP-Br2 polyclonal antibodies in G4195 rabbit 
serum were blocked with excess amounts of N-terminal hTRIP-Br2 synthetic 
peptides before their use in Western blot analyses. These N-terminal hTRIP-
Br2 synthetic peptides were previously used to immunize rabbits and served 
as a target for anti-hTRIP-Br2 polyclonal antibody recognition. Pre-immunized 
serum from the same animal that was subjected to immunization with hTRIP-
Br2 peptides was used as a negative control. As shown in Figure 12, the anti-
hTRIP-Br2 polyclonal antibodies in G4195 rabbit immune serum showed 
specificity for their targets, while pre-incubation with N-terminal hTRIP-Br2 
peptides completely blocked detection of hTRIP-Br2. Pre-immune rabbit 
serum control did not detect any protein molecules from the cell lysates. In 
addition, the anti-hTRIP-Br2 polyclonal antibodies in G4195 rabbit immune 
serum exhibited cross-reactivity in recognizing TRIP-Br2 from other species as 
it detected endogenous mTRIP-Br2 and hTRIP-Br2 in NIH3T3 mouse 
fibroblasts and WI38 human primary fibroblasts, respectively. In contrast to the 
doublet observed for hTRIP-Br2, mTRIP-Br2 was shown to be expressed as a 
single protein molecule of ~45kDa. It remains unknown whether such a 
difference in molecular size of TRIP-Br2 in different species reflects the 
existence of transcriptional, post-transcriptional and/or post-translational 
regulation.   
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Figure 12. Peptide competition assay reveals specificity and 
cross-reactivity of rabbit anti-hTRIP-Br2 polyclonal antibodies 
to their protein targets in mouse and human cell lysates. 
Endogenous hTRIP-Br2 was detected as a doublet of ~42 and ~45 kDa 
proteins, while the molecule weight of endogenous mTRIP-Br2 was 
determined to be approximately 45 kDa. Interactions of rabbit anti-hTRIP-Br2 
polyclonal antibodies with their protein targets in mouse and human were 
abrogated when blocked by incubation with excess N-terminal hTRIP-Br2 
peptides. β-tubulin was used as a loading control. 
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2.2.2 Inactivation of the TRIP-Br2 locus in mice 
 To assess the role of TRIP-Br2 in mammalian development, gene 
transcriptional regulation and cell cycle progression, we collaborated with 
Lexicon Genetics to generate a TRIP-Br2 knock-out mouse model. Briefly,  the 
mouse TRIP-Br2 locus was disrupted by gene trapping employing random 
insertional mutagenesis by the retroviral targeting construct VICTR48, as 
previously described (Zambrowicz et al., 1998).  The mouse TRIP-Br2 locus 
was found to share similar genomic organization found in all human and 
Drosophila TRIP-Br genes (Calgaro et al., 2002; Darwish et al., 2007). Instead 
of having only one spliceable intron in its 5’ untranslated region (UTR) 
immediately followed by a coding exon, TRIP-Br2 has two such introns. 
Embryonic stem cell clone OST98734, in which only one copy of the retroviral 
trap insertion was found in intron 2 of the mouse TRIP-Br2 locus (preceding 
the single coding exon of TRIP-Br2 on mouse chromosome 11), was selected 
and inserted into blastocysts (C57BL/6J albino) prior to implantation into 
female C57BL/6J albino mice to generate F1 chimeric heterozygous TRIP-
Br2+/- founder animals. F1 mTRIP-Br2+/- males and females were then 
interbred to produce F2 litters. Genotyping by genomic polymerase chain 
reactions (PCR, Figure 13 upper panel) demonstrated that TRIP-Br2 
nullizygous mutants (TRIP-Br2-/-), heterozygous mutants (TRIP-Br2+/-) and 
wildtype animals were viable and phenotypically indistinguishable at the gross 
anatomic level.  The F1 TRIP-Br2+/- male-female interbreeds produced F2 
litters at the normal Mendelian ratio of 1:2:1 and all F2 TRIP-Br2 ablated mice 
were fertile. The absence of TRIP-Br2 gene expression in TRIP-Br2-/- mice 
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was further validated by semi-quantitative reverse transcription-multiplex PCR 
(RT-PCR, Figure 13 lower panel).  
  TRIP-Br2-/- male and female mice examined at 8 weeks of age showed 
no gross anatomical or overt histological abnormalities (Figures 32-38, 
Appendices). Furthermore, TRIP-Br2 protein expression appears to be 
dispensable in the development of the lymphoid system of mice, as the levels 
of T cells, B cells and dendritic cells (DC) remained constant in the wildtype 
and nullizygous mutant mice (Figures 39-49, Appendices). Collectively, these 
data suggested that although TRIP-Br2 expression is present in mouse during 
embryonic development and throughout adulthood, TRIP-Br2 either does not 
play a role during development or adulthood or that its function(s) in TRIP- 
Br2-/- animals can be compensated by other members of the TRIP-Br family. 
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Figure 13. Validation of TRIP-Br2 ablation in mice. Upper panel: All 
progeny were genotyped by a multiplex genomic PCR, in which 
Lexicon250InsF (A), Lexicon250LTR2 (LTR2) and Lexicon250InsR (B) primers 
were used to detect the wildtype allele (350 bp) and/or the mutant allele (250 
bp). PCR primer positions are indicated in Figure 9. Lower panel: Total RNA 
samples harvested from tissues of TRIP-Br2 wildtype and nullizygous mutant 
mice were analyzed by a multiplex semi-quantitative RT-PCR approach. Total 
RNA harvested from mouse ES cells served as a positive control and β-Actin 
was used as a loading control. RT (+): reverse transcription with addition of 
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2.2.3 TRIP-Br2, a novel proliferation marker, is highly expressed in 
lymphohematopoietic cell lineages 
 As global ablation of TRIP-Br2 did not lead to reduced fertility, 
embryonic lethality or failure of lymphoid development in mice, we envisage 
that TRIP-Br2 may have tissue-specific roles that are important in post-
development of an organism that are not revealed by a global gene ablation 
approach. In order to investigate the tissue-specific biological significance 
TRIP-Br2 in human and mouse, we performed in silico gene expression 
profiling of TRIP-Br2 using a comprehensive web-based human and mouse 
microarrays database, GNF SymAtlas v 1.2.4 (Novartis, 
http://symatlas.gnf.org/SymAtlas/). As compared to other human tissues/cell 
types, TRIP-Br2 is highly expressed in the bone marrow, the thymus, the tonsil 
and the smooth muscle. It is also highly expressed in lymphohematopoietic 
cell lineages, particularly in BDCA4+ dendritic cells, CD34+ cells (bone 
marrow hematopoietic stem cells), CD71+ early erythroid cells, B lymphoblasts, 
CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ NK cells and CD33+ 
myeloid cells (Table 4). Similar in silico gene expression profiling of TRIP-Br2 
in mouse was observed (data not show).  
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Table 4. TRIP-Br2 expression profiling in human tissues by interrogation 
of the Novartis GNF SymAtlas v1.2.4 microarray database. The median 
(med) was calculated based on expression of TRIP-Br2 across all human 
tissues; medX3: 3-fold more than the median; medX10: 10-fold more than the 
median. In silico TRIP-Br2 expression, (χ), across all human tissues was 
scored via the following scheme: +: (χ)≤median; ++: median<(χ)≤medX3; +++: 
medX3<(χ)≤med*10; ++++: med*10<(χ). TRIP-Br2 is found to be highly 
expressed in human tissues such as bone marrow, thymus, tonsil and smooth 
muscle. TRIP-Br2 is also highly expressed in the highly proliferative 
lymphohematopoietic cell lineages. *denotes high TRIP-Br2 expression in 
these cells and tissues. 
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2.2.4 Ablation of TRIP-Br2 in splenic T cells and primary embryonic 
fibroblasts of mice leads to reduced cell proliferative potential 
associated with aberrant cell cycle reentry and defective DNA synthesis
  
Given that TRIP-Br2 is preferentially expressed in the highly 
proliferative lymphohematopoietic cell lineages of human and mouse, we 
postulated that TRIP-Br2 plays an important role in cellular proliferation in a 
tissue-specific manner. We isolated splenocytes from 8-week old TRIP-Br2+/+ 
and TRIP-Br2-/- adult mice and exposed them to T cell-specific mitogens such 
as Con A or anti-CD3/anti-CD28. The in vitro T cell proliferation assays 
revealed that splenic T cells of TRIP-Br2-/- adult mice were completely 
resistant to the effect of Con A and significantly less responsive to the 
mitogenic effect of anti-CD3/anti-CD28 (Figure 14 upper and lower panels).  
 A similar phenomenon was observed in another highly proliferative 
murine cell type, the primary murine embryonic fibroblasts (PMEFs). We 
derived PMEFs from mTRIP-Br2-/- embryos (dpc 15.5) and validated the 
targeted disruption of the TRIP-Br2 locus in these PMEFs by Western blot 
analyses using a rabbit anti-TRIP-Br2 polyclonal antibody (Figure 15A). 
Analysis of in vitro cultured TRIP-Br2 ablated PMEFs revealed that these cells 
have a reduced proliferation rate, which was characterized by defective DNA 
synthesis, as compared to their wildtype counterparts (Figure 15B). Similarly, 
prolonged culture of TRIP-Br2 ablated cells over 14 days showed that the 
cellular proliferation rate was reduced, as they formed fewer colonies 
compared to their wildtype counterparts (Figure 15C). Such a reduction in the 
proliferative rate of TRIP-Br2 ablated PMEFs was not a result of an increase in 
apoptosis as revealed by nuclear condensation and flow cytometric DNA 
content analyses. Nuclear condensation was observed in apoptotic mouse 
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NIH3T3 fibroblasts that were treated with 250 µM hydrogen peroxide (H2O2). 
On the other hand, well-defined nuclear bodies were observed in most mouse 
NIH3T3 fibroblasts that were not treated with H2O2, and in both TRIP-Br2 
wildtype and mutant PMEFs (Figure 16A). Furthermore, Western blot analyses 
showed no increase in key apoptotic markers such as p53 and caspase 3 in 
the TRIP-Br2-/- PMEFs (Figure 16B). Flow cytometric DNA content analysis 
further demonstrated that a sub-G1 apoptotic cell population was not present in 
TRIP-Br2 wildtype and mutant PMEFs, but that an unusual buildup of S phase 
cell population in TRIP-Br2-/- PMEFs was evident (Figure 16C). Collectively, 
these data suggest that the delay in cell cycle progression of TRIP-Br2-/- 
PMEFs was most likely due, at least in part, to defects in DNA synthesis and 
not increased apoptosis.  
 As TRIP-Br1 and TRIP-Br2 have been previously shown to stimulate 
E2F-mediated transcription (Hsu et al., 2001) and were both demonstrated to 
be serum-inducible (Sim et al., 2006), we next analyze the ability of TRIP-Br2 
ablated PMEFs to reenter the cell cycle from the quiescent G0 state. Cells 
were plated at a lower density (2X104 cells in 6-well plates) to avoid effects of 
contact inhibition, before their exit into G0 phase by serum deprivation for 72 h. 
They were stimulated to reenter the cell cycle by addition of 10% FBS to the 
culture media. Total viable cell count was performed 48 h after 10% FBS 
addition. As shown in Figure 17A, TRIP-Br2 ablated PMEFs appeared to be 
capable of cell cycle reentry but fewer daughter cells were produced after an 
estimated 2 rounds of cell division, as compared to their wildtype counterparts. 
All PMEFs were equally sensitive to 72 hours of serum deprivation, which 
resulted in loss of ~25% of the total cell plating densities.  
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 To investigate whether such reduction in new TRIP-Br2-/- daughter cells 
was due to dysregulated cell cycle progression, we further analyzed the 
PMEFs within one division cycle by BrdU incorporation and flow cytometric 
DNA content analyses. PMEFs were serum deprived for 72 h and then 
exposed to 10% FBS for 22 h. Flow cytometric DNA content analyses 
revealed that more than 75% of the wildtype PMEFs had reentered and 
progressed through the cell cycle after serum restimulation. In contrast, more 
than 40% of TRIP-Br2 ablated PMEFs were observed to be trapped in the 
G0/G1 phase of the cell cycle, presumably due to inefficient cell cycle entry in 
response to serum restimulation (Figure 17B). Furthermore, there was less 
DNA synthesis in these serum restimulated mutant cells (Figure 17C). 
Although such a reduction in DNA synthesis in TRIP-Br2 ablated PMEFs may 
simply be a reflection of a reduced ability of quiescent TRIP-Br2 ablated 
PMEFs to reenter the cell cycle upon serum stimulation, we envisage that 
inefficient cell cycle reentry is further compounded by a block at the G1/S 
transition or a specific reduction in DNA synthesis during S phase and that the 
above defects are not mutually exclusive, consistent with our earlier 
demonstration that continually cycling TRIP-Br2 ablated PMEFs are defective 
in DNA synthesis as assessed by BrdU incorporation.   
 To further dissect the cause of dysregulated cell cycle progression in 
TRIP-Br2 ablated PMEFs, gene expression profiles of known key regulators of 
DNA synthesis during the G1/S transition and S phase were studied by semi-
quantitative RT-PCR and Western blot analyses. Given that TRIP-Br2 
stimulates E2F-mediated transcription (Hsu et al., 2001); we focused on the 
effect of TRIP-Br2 ablation on E2F-responsive cell cycle regulators. We found 
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that a subset of E2F-responsive cell cycle regulators, such as cyclin E, PCNA 
and CDC2, were down-regulated in TRIP-Br2 ablated PMEFs (Figure 18 
upper panel), although the expression of the majority of E2F-responsive genes 
remained constant (data not shown). For instance, the downregulation of 
cyclin E, a key cell cycle regulator that governs the G1/S phase transition, was 
found to be dose-dependent in TRIP-Br2 ablated PMEFs (Figure 18 upper and 
lower panel).  
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resistant to Con A- or anti-CD3/anti-CD28-stimulated 
proliferation. Splenocytes were isolated from 8-week old TRIP-Br2+/+ and 
TRIP-Br2-/- adult mice and exposed to T cell-specific mitogenic stimulants such 
as Con A (4 µg/ml) or anti-CD3/anti-CD28 (1/0.5 µg/ml) for 72 h. Control cells 
were not exposed to the T cell-specific mitogenic stimulants. Cell proliferation 
was analyzed by MTT assay. All assays were performed in triplicates in at 
least three independent groups of mice. A Student’s t-test analysis was 
performed; *indicates p-value <0.001 for the comparison of TRIP-Br2+/+ and 
TRIP-Br2-/- cells.  
Figure 14. Splenic T cells of TRIP-Br2-/- adult mice were 
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Figure 15A. Validation of TRIP-Br2 ablation in PMEFs. Anti-hTRIP-
Br2 polyclonal antibodies in G4195 rabbit immune serum detected 
endogenous TRIP-Br2 in TRIP-Br2+/+ but not TRIP-Br2-/- PMEFs. Interactions 
of rabbit anti-hTRIP-Br2 polyclonal antibodies with their protein targets were 
abrogated by pre-incubation with excess N-terminal hTRIP-Br2 peptides. Pre-
immune rabbit serum served as a negative control and β-tubulin was used as 
a loading control. 
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Figure 15B. Reduced DNA synthesis in continually cycling 
TRIP-Br2 nullizygous mutant PMEFs. BrdU incorporation in DNA of 
asynchronously cycling PMEFs was quantitated by colorimetric ELISA assays. 
All assays were performed in triplicates in at least three independent 
experiments. A Student’s t-test analysis was performed; *indicates p-value 
<0.01 for the comparison of TRIP-Br2+/+ and TRIP-Br2+/- cells; **indicates p-
value <0.01 for the comparison of TRIP-Br2+/+ and TRIP-Br2-/- cells. 
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Figure 15C. Reduced colony forming potential of continually 
cycling TRIP-Br2 nullizygous mutant PMEFs. 1X104 cells were 
maintained in DMEM supplemented with 10% FBS for 14 days at 37oC in a 5% 
CO2 environment. Cells were fixed with 100% methanol and stained with 0.4% 
Giemsa stain as previously described (Zang et al., 2007).  For colony 
quantitation, the intracellular Giemsa stain was eluted with 1% SDS and OD 
was quantitated using a SpectraMax M5 spectrophotometer (Molecular 
Devices, Sunnyvale, CA) at a wavelength of 595 nm. All assays were 
performed in triplicates in at least three independent experiments. A Student’s 
t-test analysis was performed; *indicates p-value <0.05 for the comparison of 
TRIP-Br2+/+ and TRIP-Br2+/- cells; **indicates p-value <0.01 for the comparison 
of TRIP-Br2+/+ and TRIP-Br2-/- cells.  
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Figure 16A. The reduction in proliferative potential of TRIP-Br2 
mutant PMEFs is not a result of increased apoptosis. Apoptosis 
was induced in mouse NIH3T3 fibroblasts by treatment with 250 µM hydrogen 
peroxide (H2O2); this treatment also served as a positive control for DAPI 
staining. Apoptotic cells were characterized by chromatin condensation into 
dense masses. Defined nuclear bodies were observed in most negative 
control mouse NIH3T3 fibroblasts that were not treated with H2O2 and all 
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Figure 16B. Key apoptotic markers were not dysregulated in 
TRIP-Br2 nullizygous mutant PMEFs. Western blot analyses of PMEF 
cell lysates demonstrated that key apoptotic markers such as p53 and 
caspase 3 were not significantly increased in TRIP-Br2 nullizygous mutant 
PMEFs. β-tubulin was used as a loading control. 
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Figure 16C. Accumulation of S phase cell population in 
asynchronously cycling TRIP-Br2 nullizygous mutant PMEFs. 
Flow cytometric DNA content analysis revealed that cell populations of TRIP-
Br2 nullizygous mutant PMEFs in G0/G1 and G2/M phases were significantly 
lower than that of their wildtype counterparts, while their S phase cell 
population was shown to be significantly higher. The percentage of cells in any 
particular phase of the cell cycle was calculated as a percentage relative to the 
total cell count. The analysis was performed in triplicates and repeated at least 
two independent times. A Student’s t-test analysis was performed. *indicates 
p-value <0.01. 
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Figure 17A. Reduced cell cycle reentry potential of TRIP-Br2 
nullizygous mutant PMEFs following their release from serum 
deprivation. 2X104 cells (in 6-well plates) were maintained in DMEM 
supplemented with 0.2% FBS for 72 h at 37oC in a 5% CO2 environment and 
subsequently maintained in DMEM supplemented with 0.2% FBS for 48 h at 
37oC in a 5% CO2 environment. Viable cell count analysis revealed that TRIP-
Br2 nullizygous mutant PMEFs were capable of cell cycle reentry but fewer 
daughter cells were produced following their release from serum deprivation. 
The analysis was performed in triplicates and repeated at least two 
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Figure 17B. Accumulation of G0/G1 phase cell population in 
serum restimulated TRIP-Br2 nullizygous mutant PMEFs. Flow 
cytometric DNA content analysis revealed that although cell populations of 
synchronously cycling-TRIP-Br2 nullizygous mutant PMEFs in S and G2/M 
phases were significantly smaller than that of their wildtype counterparts 
following a timed-release (22 h) from serum deprivation, their G0/G1 phase cell 
population was shown to be significantly higher. Flow cytometric DNA content 
analysis also showed that all serum-deprived PMEFs were arrested in the 
G0/G1 phase of cell cycle. The percentage of cells in any particular phase of 
the cell cycle was calculated as a percentage relative to the total cell count. 
The analysis was performed in triplicates and repeated at least two 
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Figure 17C. Reduced DNA synthesis in serum restimulated 
TRIP-Br2 nullizygous mutant PMEFs. BrdU incorporation analysis 
revealed that although TRIP-Br2 nullizygous mutant PMEFs were capable of 
cell cycle reentry following a timed-release (22 h) from serum deprivation, their 
DNA synthesis rate was found to be significantly lower than their wildtype 
counterparts. No DNA synthesis activity was detected in all serum-deprived 
PMEFs. The analysis was performed in triplicates and repeated at least two 
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Figure 18. A subset of E2F-responsive genes, including CYCLIN 
E, was downregulated in TRIP-Br2 mutant PMEFs. Upper panel: A 
subset of E2F-responsive genes, such as CYCLIN E (CCNE), PCNA and 
CDC2, were downregulated in TRIP-Br2 nullizygous mutant PMEFs, as 
demonstrated by semi-quantitative RT-PCR (Upper left panel) and Western 
blot (Upper right panel) analyses. Non-E2F-responsive genes, such as 
CYCLIN D1 (CCND1) and CDK2, were included as negative/loading controls. 
Lower panel: Semi-quantitative RT-PCR analyses further demonstrated that 
CYCLIN E expression was downregulated in TRIP-Br2 mutant PMEFs in a 
dose-dependent manner. β-Actin was used as a loading control. 
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2.3 Discussion 
 The TRIP-Br proteins represent a novel family of mammalian 
transcriptional regulators that have been proposed to recruit PHD zinc finger- 
and/or bromodomain-containing transcription factors such as p300/CBP to 
E2F/DP transcriptional complexes in order to regulate E2F-mediated gene 
transcription and cell cycle progression (Hsu et al., 2001). To assess the role 
of TRIP-Br2 in mammalian development, transcriptional regulation and cell 
cycle progression, we collaborated with Lexicon Genetics to generate a TRIP-
Br2 knock-out mouse model. Briefly, the mouse TRIP-Br2+/- locus was 
disrupted by gene trapping to achieve random insertional mutagenesis using 
the retroviral gene trap targeting construct VICTR48 as previously described 
(Zambrowicz et al., 1998). We generated rabbit anti-hTRIP-Br2 polyclonal 
antibodies and validated the targeted disruption of TRIP-Br2+/- locus in the 
founder mice and their progeny. Ablation of TRIP-Br2 in mice did not lead to 
infertility, embryonic lethality or failure of lymphoid development, suggesting 
that TRIP-Br2 function may be redundant in mouse during development and 
adulthood and that its function may be compensated for by other members of 
the TRIP-Br family to maintain normal development and a normal gross 
anatomic phenotype. We envisaged that TRIP-Br2 may still have tissue-
specific roles that are important in post-development, but such functional roles 
in TRIP-Br2 ablated mice may only be observed at the molecular level. 
 Given that TRIP-Br2 is preferentially expressed in the highly 
proliferative lymphohematopoietic cell lineages of human and mouse, we 
postulated that TRIP-Br2 may play an important role in cellular proliferation in 
a tissue-specific manner. We demonstrated that splenic T cells, which were 
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isolated from TRIP-Br2-/- adult mice, were clearly resistant to Con A- or anti-
CD3/anti-CD28-stimulated proliferation. Furthermore, TRIP-Br2 ablation in 
another highly proliferative cell type, the PMEFs, led to a reduced cell 
proliferative potential, which is associated with inefficient cell cycle reentry and 
a defect in DNA synthesis. We further showed that these associated defects 
were not mutually exclusive when TRIP-Br2 ablated cells were forced to exit 
cell the cycle upon serum deprivation and to reenter upon serum restimulation. 
As we have earlier demonstrated, continually cycling-TRIP-Br2 ablated 
PMEFs are defective in new DNA synthesis.   
 As TRIP-Br2 has been previously shown to stimulate E2F-mediated 
transcription (Hsu et al., 2001), we studied the effect of TRIP-Br2 ablation on 
E2F-responsive cell cycle regulators. We found that a subset of E2F-
responsive cell cycle regulators, such as cyclin E, PCNA and CDC2, were 
down-regulated in a dose-dependent manner in TRIP-Br2 ablated PMEFs. 
Interestingly, Geng and coworkers have recently demonstrated that cyclin E 
deficient fibroblasts were unable to reenter the cell cycle from the quiescent G0 
state (Geng et al., 2003). Cyclin E has also been shown to be indispensable 
for the control of initiation of DNA replication (Arata et al., 2000), centrosome 
duplication (Hinchcliffe et al., 1999; Okuda et al., 2000), histone biosynthesis 
(Ma et al., 2000; Zhao et al., 2000) and cell cycle progression (Hoffmann et al., 
1994; Sheaff et al., 1997). While PCNA is important for DNA replication in 
eukaryotic cells (Zhang et al., 2000), an active cyclin B-CDC2 kinase complex 
is essential for phosphorylation of key protein substrates for proper execution 
of cellular mitosis (Riabowol et al., 1989). More recently, the cyclin E-CDC2 
kinase complex has been shown to regulate the G1/S transition (Aleem et al., 
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2005). Collectively, our data suggest that TRIP-Br2 is required for the 
expression of a subset of cell cycle regulators that whose gene transcriptional 
activity is controlled by the RB/E2F/DP pathway. Ablation of TRIP-Br2 in cells 
may lead to the dysregulation of some of these key cell cycle regulators, thus 
resulting in a block in serum restimulated cell cycle reentry and at the G1/S 
transition, and defective DNA synthesis. 
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TRIP-Br2 is a novel protooncogene that is 
aberrantly overexpressed in human cancers 
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3.1 Materials and Methods 
3.1.1 Construction of C-terminal HA-tagged hTRIP-Br2 expression 
plasmid 
 The nucleotide sequence of human TRIP-Br2 (hTRIP-Br2) was 
obtained from NCBI PubMed (GenBankTM accession no. BC101639) and used 
as the template for design of hTRIP-Br2-specific primers using DNAstarTM 
software. These primers were modified to include the following features: a 
kozak sequence that precedes the 5’ end of the forward primers and an HA-
tag coding sequence that follows the 3’ end of hTRIP-Br2 reverse primers 
(Table 3C). Polymerase Chain Reactions (PCR) were performed on 1 µl cDNA 
samples, from WI38 human primary lung fibroblasts, in the presence of 10 mM 
deoxyribonucleotide triphosphates (dNTPs) and 10 µM of the above-
mentioned primer pair in a total reaction volume of 20 µl. PCR was performed 
as follows: 30 cycles of denaturation (94oC, 30 seconds), annealing (56oC, 30 
seconds) and extension (72oC, 90 seconds) with a 2-minute initial denaturation 
step at 94oC and a 3-minute terminal polishing step at 72oC.  The amplicon 
was purified by QIAquick Gel Extraction kit (Qiagen Inc., Valencia, CA) and 
cloned into pCR2.1®-TOPO® using the TOPO TA cloning® kit (Invitrogen, 
Carlsbad, CA) , in accordance with the manufacturers’ instructions. The 
resultant plasmid was digested with Eco RI prior to ligation of the released 
insert into the same site in the pcDNA3.1 expression vector (Invitrogen, 
Carlsbad, CA). The resultant plasmid, pcDNA3.1-hTRIP-Br2-HA, was then 
transformed into Escherichia coli DH5α® hosts [genotype: φ80dlacZΔM15, 
recA1, endA1, gyrA96, thi-1, hsdR17 (rk-, mk+), supE44, relA1, deoR, 
Δ(lacZYA-argF) U169] (Promega Biosciences Inc., San Luis Obispo, CA) and 
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positive clones were selected by ampicillin (50 μg/ml). Positive plasmid clones 
were further verified by Bam HI digestion, T7/HA-specific PCR as well as 
direct sequencing analysis of PCR products. Amplified PCR products and 
restriction enzyme-digested DNA samples were separated on 0.7% and 1% 
agarose gels respectively, and visualized by staining with ethidium bromide. 
The map of pcDNA3.1-hTRIP-Br2-HA expression plasmid is illustrated in 
Figure 19. 
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Figure 19. Map of pcDNA3.1-hTRIP-Br2-HA expression plasmid. 
The hTRIP-Br2-HA amplicon was ligated into the Eco RI restriction site of the 
pcDNA3.1 expression plasmid. The hTRIP-Br2 open reading frame is depicted 
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3.1.2 Cell culture and reagents 
 NIH3T3 mouse primary fibroblasts, WI38 human primary lung 
fibroblasts, U2OS human osteosarcoma cells, PC3 human prostate 
adenocarcinoma cells, 769-P human renal adenocarcinoma cells, HCT-116 
human colorectal carcinoma cells, HepG2 human hepatocellular carcinoma 
cells, MCF-7 human breast carcinoma cells and A549 human lung carcinoma 
epithelial cells were purchased from American Type Culture Collection 
(Manassas, VA). All cell lines were cultured in DMEM supplemented with 10% 
FBS, and maintained at 37oC in a 5% CO2 environment. Rabbit anti-TRIP-Br2 
polyclonal antibodies were generated as described in Section 2.1.1 and used 
in Western blot, immunocytochemical and immunohistochemical analyses. All 
other antibodies used in Western blot analyses were purchased from Santa 
Cruz Biotechnology Inc (Santa Cruz, CA). They include anti-HA (sc-805), anti-
cyclin E (sc-481), anti-PSer780Rb (sc-12901-R) and anti-β-tubulin (sc-5274). 
The use of expression plasmids pcDNA3.1 (Invitrogen, Carlsbad, CA) and 
pcDNA3.1-TRIP-Br1-HA have been previously described (Hsu et al., 2001). 
 
3.1.3 Generation of cells stably expressing TRIP-Br2 
 NIH3T3 mouse fibroblasts were transfected with the empty vector 
pcDNA3.1 as a control or with the expression vectors pcDNA3.1-TRIP-Br1-HA 
or pcDNA3.1-TRIP-Br2-HA using FuGENE 6 Transfection Reagent (Roche 
Diagnostics Co., Mannheim, Germany) in accordance with the manufacturer’s 
instructions. Stable clones were selected using Geneticin (Invitrogen Life 
Technologies, Carlsbad, CA) at a concentration of 750 µg/ml. Expression 
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levels of the carboxyl terminal HA-tagged TRIP-Br1 and TRIP-Br2 in each 
respective clone were determined by Western blot analysis. 
 
3.1.4 Serum deprivation, Bromodeoxyuridine (BrdU) labeling and flow 
cytometric DNA content analysis 
 NIH3T3vector-only, NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts were 
cultured in 96-well plates (for BrdU) or 100 mm culture dishes (for flow 
cytometry) in DMEM supplemented with 0.2% FBS and were maintained for 
72 h at 37oC in a 5% CO2 environment. BrdU incorporation was monitored 
using a cell proliferation/colorimetric ELISA assay according to the 
manufacturer’s instructions (Boehringer Mannheim, Mannheim, Germany). 
Flow cytometry was performed using a FACScan flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ) at a wavelength of 488 nm. 
 
3.1.5 Soft agar colony formation and tumor induction assays 
 Soft agar assays were used to assess anchorage-independent growth 
of NIH3T3 cells as previously described (Radkov et al., 2000). For tumor 
induction assays, athymic nude mice (nu/nu) purchased from Charles River 
Laboratories, Inc. (Wilmington, MA) were kept under SPF conditions and used 
under protocol #06-231, which was approved by the Harvard Institutional 
Animal Care and Use Committee (IACUC) and the Harvard Committee on 
Microbiological Safety (COMS). 5X106 NIH3T3vector-only or NIH3T3TRIP-Br2-HA 
fibroblasts were injected subcutaneously into 6-week-old athymic nude mice 
(n=4 for each group). On day 13 post-injection, the mice were examined for 
tumor formation. Tumor dimensions were measured every 2 days from day 13 
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until day 25 post-injection, at the end of which time both groups were 
sacrificed and all tumors were harvested for histological, immunohistochemical 
and Western blot analyses. The experiment was repeated by injection of new 
NIH3T3vector-only or NIH3T3TRIP-Br2-HA clones into new groups of 6-week-old 
athymic nude mice (n=4). The penetrance of tumor induction from 
subcutaneous injection of NIH3T3vector-only or NIH3T3TRIP-Br2-HA into these 
athymic nude mice was 0% and 100%, respectively. Tumor ellipsoid volume 
was estimated using the formulae previously described (Tomayko and 
Reynolds, 1989). 
 
3.1.6 Semi-quantitative and real-time quantitative RT-PCR analyses  
 Total RNA from serum-deprived NIH3T3vector-only, NIH3T3TRIP-Br1-HA and 
NIH3T3TRIP-Br2-HA cells was isolated and analyzed by semi-quantitative RT-PCR 
as described in Section 2.1.11, respectively. For real-time quantitative RT-
PCR analysis, total RNAs and cDNAs of WI38, A549, U2OS, 769-P, HCT-116 
and MCF-7 cells were prepared as described in Section 2.1.11. The cDNAs 
were added to iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) 
with the respective primer pairs followed by quantitative PCR measurements 
using a iQ5 real-time thermal cycler (Bio-Rad Laboratories, Hercules, CA), in 
accordance with the manufacturer’s instructions. The fold increase in TRIP-Br 
transcript expression of all cancer cell lines was calculated relative to that of 
WI38 primary cells, which was set arbitrarily to 1.0. Amplified PCR products 
were separated on 2% agarose gels and visualized by staining with ethidium 
bromide. The primer sequences used for RT-PCR are listed in Tables 3B and 
3C. 
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3.1.7 Subcellular fractionation, denaturing SDS-PAGE and Western 
blotting  
 Subcellular fractionation of the cells was performed using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce Biotechnology Inc., 
Rockford, IL) according to the manufacturer’s instructions. Proteins from 
whole-cell lysates were resolved using standard denaturing polyacrylamide gel 
electrophoresis as described previously (Hsu et al., 2001). 
 
3.1.8 Tissue microarray (TMA) construction, immunohistochemistry and 
immunocytochemistry  
 Multiple TMA slides were obtained from the Department of Pathology 
TMA Program at the National University of Singapore, in compliance with 
Institutional Review Board approval (IRB 05-017). These tumor tissue arrays 
were constructed as previously described (Salto-Tellez et al., 2004; Salto-
Tellez et al., 2007; Salto-Tellez et al., 2006; Zhang et al., 2003) and 
represented samples from the following human tumor types that occur in a 
broad range of organs: prostate carcinoma, squamous cell lung carcinoma, 
lung adenocarcinoma, breast carcinoma, gastrointestinal stromal tumor, 
ovarian cystadenocarcinoma, colorectal carcinoma, basal cell carcinoma, 
renal cell carcinoma, osteosarcoma, hepatocellular carcinoma. Antigens were 
retrieved from the tissues using a microwave histoprocessor (Milestone, 
Shelton, CT) and DAKO pH 6.0 citrate buffer (DAKO, Via Real Carpinteria, 
CA). Immunohistochemical staining was performed on paraffin-embedded 
tissue sections using the DAKO Envision kit (DAKO) and the rabbit anti-TRIP-
Br2 antibody or its pre-immune serum control at a concentration of 1:300. 
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Staining was visualized using a Leica DM LB2 microscope and TRIP-Br2 
expression in the human tissue arrays was scored independently by three 
research pathologists in a double-blinded manner. For immunocytochemistry, 
cells were grown to 80% confluence on coverslips, washed three times with 
PBS, fixed in prechilled 4% paraformaldehyde for 20 minutes, and 
permeabilized in 0.1% Triton-X for 10 minutes. Primary immunostaining with 
rabbit anti-TRIP-Br2 antibody (1:4000) was performed at room temperature for 
1 h. Pre-immune rabbit serum was used as a negative control for the primary 
immunostaining of cells. Secondary immunostaining with goat anti-rabbit-FITC 
antibodies was performed at room temperature for 1 h, following 3 washes 
with PBS at the end of primary immunostaining. Cellular DNA was 
subsequently counterstained with DAPI. Staining was visualized and 
photographed using a Nikon Eclipse E1000 fluorescence microscope. 
 
3.1.9 RNA interference of TRIP-Br2 expression  
 5X104 HCT-116 human colorectal cells were plated in 12-well plates 
and transfected with Cy3-labeled oligomer, scrambled siRNA (negative control) 
or three different TRIP-Br2-specific siRNAs at the dose of 4 pmol or 40 pmol 
(in 1 ml of DMEM supplemented with 10% FBS) respectively (TriFECTaTM kit, 
IDT, Coralville, IA) using LipofactamineTM Transfection Reagent (Invitrogen, 
Carlsbad, CA), in accordance with the manufacturer’s instructions. Twenty-
four hours post-transfection, these cells were cultured in serum-free DMEM 
and maintained at 37oC in a 5% CO2 environment for 72 h. HCT-116 cells that 
were not subjected to transfection reagent treatment were included as controls. 
Cells in colony forming assays were stained with 0.4% Giemsa stain as 
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previously described (Zang et al., 2007). The dye in these cells was 
subsequently eluted with 1% SDS and quantitated using a spectrophotometer 
at a wavelength of 595 nm. A standard curve was plotted using OD readings 
taken from dye-eluted HCT-116 cells that were plated at pre-determined cell 
densities. 
 
3.1.10 Statistical analysis  
 Survival curves for various patient cohorts were estimated according to 
the method of Kaplan and Meier, and curves were compared using the 
generalized Wilcoxon's test. The log-rank test was used to assess the strength 
of association between survival time and single variables corresponding to 
factors thought to be prognostic for survival. 
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3.2 Results 
3.2.1 TRIP-Br2 overexpression transforms murine fibroblasts by 
upregulation of E2F/DP-mediated transcription 
 As we have shown earlier that TRIP-Br2 is expressed in the highly 
proliferative lymphohematopoietic cell lineages, we postulated that TRIP-Br2 
plays an important role in cellular proliferation and/or tumor progression. This 
is supported in part by our previous observation that ablation of TRIP-Br2 
resulted in cellular proliferation arrest, which was associated with 
downregulation of a subset of E2F-responsive genes such as CYCLIN E. To 
validate the protooncogenic role of TRIP-Br2 in cell cycle regulation and 
tumorigenesis, we stably overexpressed C-terminal HA-tagged-TRIP-Br2 in 
NIH3T3 diploid fibroblasts (NIH3T3TRIP-Br2-HA; Figure 20A). We demonstrated 
that overexpression of TRIP-Br2-HA enabled these NIH3T3 fibroblasts to 
proliferate under low serum concentrations, possibly through enhancing DNA 
synthesis (Figure 20B). Flow cytometric DNA analysis revealed significantly 
higher proportions of NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts in the 
S phase of cell cycle as compared to the NIH3T3vector-only control, despite 
serum deprivation (Figure 20C, upper panel). Data from the flow cytometric 
DNA analysis  was represented in a single bar graph the mean values derived 
from combining FACS data from each comparison group of clones (V, R1, R2), 
which showed differences that were statistically significant.  This was done to 
simplify and minimize the number or statistical comparisons.  When results are 
plotted for each independent clone, we observed a dose-dependent effect in 
which the differences observed are increasingly greater in proportion to the 
level of TRIP-Br1 and TRIP-Br2 overexpression (Figure 20C, lower panel). 
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Although TRIP-Br1 overexpression has been recently shown to transform 
NIH3T3 fibroblasts (Tang et al., 2005), the underlying molecular mechanism of 
cellular transformation by TRIP-Br1 remains elusive. Thus, we also stably 
overexpressed C-terminal HA-tagged-TRIP-Br1 in NIH3T3 fibroblasts 
(NIH3T3TRIP-Br1-HA) and investigated the mechanism(s) by which TRIP-Br1 and 
TRIP-Br2 facilitate cellular transformation. 
 As TRIP-Br proteins have been shown to regulate E2F/DP-mediated 
transcriptional activities (Hsu et al., 2001), we screened these serum-deprived 
NIH3T3 fibroblasts for a panel of E2F-responsive cell cycle regulators that 
govern cell cycle progression. Elevated mRNA transcript levels of a subset of 
these E2F-responsive cell cycle regulators, such as CYCLIN E (CCNE), 
CYCLIN A2 (CCNA2), CDC6 and DHFR, were found in serum-deprived 
fibroblasts that stably overexpress TRIP-Br proteins (Figure 20D, upper panel). 
 As TRIP-Br1 has previously been found to associate with the cyclin D-
CDK4 kinase complex and render it resistant to the inhibitory effect of p16INK4a 
(Sugimoto et al., 1999), we hypothesized that TRIP-Br2 might work through a 
similar mechanism to enable serum-deprived cells to overcome cell cycle 
checkpoint restriction in the late G1 phase of cell cycle. Serum deprivation 
normally renders cells quiescent through key checkpoint proteins like p16INK4a 
that inactivate CDK4 kinases. As a result, RB is kept under-phosphorylated 
and functions to associate with and to maintain E2F-1/DP-1 complexes in a 
transcriptionally silent form (Sherr, 2000). Notably, in serum-deprived NIH3T3 
cells that stably overexpress TRIP-Br1 or TRIP-Br2, we observed active 
phosphorylation of RB at serine residue 780, a key site that is specifically 
phosphorylated by the cyclin D-CDK4 kinase complex before the release of 
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RB from the E2F/DP transcriptional machinery.  We also observed a 
concomitant increase in cyclin E expression (Figure 20D, lower panel). These 
data demonstrate that overexpression of TRIP-Br2 enabled the cells to 
overcome RB-dependent repression of E2F-mediated transcription. 
Furthermore, in corroboration with our previous observation that cyclin E was 
downregulated following ablation of TRIP-Br1 or TRIP-Br2 (Sim et al., 2006) 
(Section 2.2.4), we demonstrated that cyclin E was upregulated following 
overexpression of TRIP-Br1 or TRIP-Br2. Thus, our data suggest that CYCLIN 
E is a TRIP-Br-coregulated gene. 
 124
Jit Kong, CHEONG  Medicine, NUS 
















Figure 20A:  Generation of NIH3T3 fibroblasts that stably 
overexpress TRIP-Br1-HA or TRIP-Br2-HA. NIH3T3 fibroblasts were 
transfected with pCDNA3.1 vector (NIH3T3vector-only), pCDNA3.1-TRIP-Br1-HA 
(NIH3T3TRIP-Br1-HA) or pCDNA3.1-TRIP-Br2-HA (NIH3T3TRIP-Br2-HA), selected by 
G418, and analyzed by immunoblotting using an anti-HA antibody. Data was 
obtained from three independent experiments that were performed in 
triplicates.  V: Vector-only clones, R1: TRIP-Br1-HA-overexpressing clones, 
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Figure 20B: Increased DNA synthesis observed in various 
serum-deprived TRIP-Br-overexpressing NIH3T3 clones. 
NIH3T3vector-only, NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts were 
cultured in 96-well plates in DMEM supplemented with 0.2% FBS and were 
maintained for 72 h at 37oC in a 5% CO2 environment. BrdU incorporation was 
monitored using a cell proliferation/colorimetric ELISA assay. The fold 
increase in BrdU incorporation of all clones was calculated relative to that of 
V16, which was set arbitrarily to 1.0. V: Vector-only clones, R1: TRIP-Br1-HA-
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Figure 20C: Increased S phase cells observed in various serum-
deprived TRIP-Br-overexpressing NIH3T3 clones. Upper panel: 
Upon serum deprivation, S phase cell counts were significantly higher in the 
TRIP-Br-overexpressing NIH3T3 clones than the vector-only control. The 
results shown in each bar represent the combined mean ± SD for all V clones 
(-16, -17, -19), R1 clones (-19 and -20) and R2 clones (-4, 14, 43), 
respectively, and incorporate data from 3 independent experiments performed 
in triplicate. A Student’s t-test was performed; *indicates p-value <0.05 for the 
comparison of NIH3T3vector-only and NIH3T3TRIP-Br1-HA cells; **indicates p-value 
<0.05 for the comparison of NIH3T3vector-only and NIH3T3TRIP-Br2-HA cells. Lower 
panel: TRIP-Br1-HA- and TRIP-Br2-HA-overexpressing clones exhibit a dose-
dependent ability to traverse cell cycle checkpoints under low serum 
conditions. The results shown represent the mean ± SD for each independent 
R1 (-19 and -20) and R2 clone (-4, 14, 43), compared to all V clones combined 
(-16, -17, -19), and incorporate data from 3 independent experiments 
performed in triplicate. A Student’s t-test was performed; *indicates p-value 
<0.001; **indicates p-value <0.01 for the comparison of NIH3T3vector-only and 
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Figure 20D. TRIP-Br2-HA-overexpressing-NIH3T3 fibroblasts 
proliferate in the absence of mitogenic stimulation as a result 
of dysregulation of the RB/E2F/DP1 transcriptional pathway. 
Upper panel: Semi-quantitative RT-PCR analysis revealed up-regulation of 
CYCLIN E (CCNE), CYCLIN A2 (CCNA2), CDC6 and DHFR in serum-
deprived NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts. TS: Thymidylate 
synthase; 18srRNA was used as a loading control. Lower panel: Western blot 
analysis showed an increase in phosphorylation of RB at the serine residue 
780 in serum-deprived NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts. 
Increased cyclin E was also observed when these cells were immunostained 
with anti-cyclin E antibodies (M20). β-tubulin was used as a loading control. V: 
Vector-only clones, R1: TRIP-Br1-HA-overexpressing clones, R2: TRIP-Br2-
HA-overexpressing clones. 
Western blot (0.2% FBS, 72 h) 
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3.2.2 TRIP-Br2 overexpression confers anchorage-independent growth in 
soft agar and promotes tumor growth in athymic nude mice 
 We next evaluated the oncogenic potential of TRIP-Br2 by assessing 
anchorage-independent growth of these NIH3T3TRIP-Br2-HA fibroblasts in soft 
agar (Figure 21A). As many as 17.7% of the seeded NIH3T3TRIP-Br2-HA 
fibroblasts formed colonies at 4 weeks post-plating, while NIH3T3vector-only were 
incapable of anchorage-independent growth in soft agar. PC3 cells and 
NIH3T3TRIP-Br1-HA fibroblasts were used as positive controls in this assay.  
 We then tested the NIH3T3TRIP-Br2-HA fibroblasts in an in vivo tumor 
formation assay to validate the tumorigenic potential of TRIP-Br2. One 
inoculum (5X106 cells) of either NIH3T3vector-only or NIH3T3TRIP-Br2-HA fibroblasts 
(from one representative clone each) was injected subcutaneously into the 
lower flanks of athymic nude mice (n=4). This experiment was repeated at 
least twice by subcutaneous injection of a different clone of either NIH3T3vector-
only or NIH3T3TRIP-Br2-HA fibroblasts into other groups of four athymic nude mice. 
Data from two mice from a representative experiment are shown in Figure 21B 
(Upper panel). All sites injected with NIH3T3TRIP-Br2-HA fibroblasts developed a 
tumor, which was typically ~0.7 cm3 (Figure 21B Lower panel, data derived 
from one tumor induction assay, n=4) at day 25 post-injection. Tumors derived 
from NIH3T3TRIP-Br2-HA fibroblasts were histologically fibrosarcomas (Figure 
21C). Western blot analyses of tumor extracts as well as HA-immunostaining 
of paraffin-embedded tumor sections indicated the presence of the transgene 
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Figure 21A. Overexpression of TRIP-Br2-HA confers anchorage-
independent growth on soft agar. Anchorage-independent growth of 
NIH3T3vector-only, NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA was assessed by 
colony formation in soft agar. Colonies were counted using a dissecting 
microscope and colony formation was calculated as (no. of colonies formed/no. 
of cells plated in a 6-well plate) X100%. PC3 cells were used as a positive 
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Figure 21B. Overexpression of TRIP-Br2-HA induces tumors in 
nude mice (nu/nu). Upper panel: Results of a representative experiment in 
which NIH3T3TRIP-Br2-HA and NIH3T3vector-only fibroblasts were subcutaneously 
injected into the left and right flanks of nude mice, respectively. Lower panel: 
Average tumor ellipsoid volume over 25 days post-subcutaneous injection was 
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Figure 21C. Histological examination of TRIP-Br2-HA 
overexpression-induced tumors excised from nude mice (nu/nu). 





Figure 21D. Biochemical and immunohistochemical 
examinations of TRIP-Br2-HA overexpression-induced tumors 
excised from nude mice (nu/nu). Western blot and 
immunohistochemical analyses of excised tumors showed expression of TRIP-
Br2-HA. Immunopositive staining for TRIP-Br2-HA is represented by the brown 
color against the hematoxylin (blue) counterstain. β-tubulin was used as a 
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3.2.3 TRIP-Br2 is overexpressed in many human cancer cell lines and 
tumors 
 Given that overexpression of TRIP-Br2 transformed NIH3T3 fibroblasts, 
we envisaged that expression of TRIP-Br2 may be dysregulated and 
contribute to oncogenesis in human cancer. We screened normal and cancer 
cell lines for TRIP-Br2 expression using rabbit anti-TRIP-Br2 polyclonal 
antibodies and found that TRIP-Br2 was overexpressed in the cancer cell lines 
U2OS (osteosarcoma), PC3 (prostate adenocarcinoma), 769-P (renal cell 
adenocarcinoma), HCT-116 (colorectal carcinoma), HepG2 (hepatocellular 
carcinoma) and MCF-7 cells (breast adenocarcinoma), but not in WI38 primary 
cript levels of 
the TRIP-Br family of transcriptional coregulators did not significantly differ 
between primary cells and cancer cells (Figure 22A lower panel); the 
mechanism of overexpression of TRIP-Br2 in human cancers may exist at the 
post-translational level and involve dysregulation of protein turnover rather 
than dysregulation of gene transcription. 
 We next sought to identify the cellular role(s) of TRIP-Br2 by 
investigating its localization in WI38 and U2OS cells. Using rabbit anti-TRIP-
Br2 polyclonal antibodies, we first demonstrated by immunocytochemistry that 
TRIP-Br2 was predominantly localized to the nuclei of WI38 and U2OS cells 
(Figure 22B), with little cytoplasmic staining. This is in agreement with a recent 
observation made by Lai and coworkers (Lai et al., 2007). As compared to 
WI38 cells, TRIP-Br2 was clearly overexpressed in the nuclei of U2OS cells. 
Our data from subcellular fractionation analysis is consistent with this 
observation. We further showed that TRIP-Br2 was overexpressed and 
lung fibroblasts (Figure 22A Upper panel). Notably, as the trans
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predominantly localized to the nuclear fractions of other human cancer cell 
lines, such as PC3, 769-P, HCT-116 and HepG2 (Figure 22C), suggesting that 
TRIP-Br2 expression and localization might be dysregulated in these cancer 
cells. Our data corroborates some previously-reported functions of TRIP-Br2 
(Hsu et al., 2001) and supports our hypothesis that TRIP-Br2 is a novel 
cellular proliferation marker.  
 In order to address a protooncogenic role for TRIP-Br2 in human 
cancers, we assessed the immunohistochemical expression of TRIP-Br2, by 
comparing normal and cancer tissue sections, on microarrays that were 
constructed from patient specimens of 10 different human cancer 
malignancies. Tissue microarray (TMA) is a high-throughput method for the 
analysis of large numbers of formalin-fixed, paraffin-embedded (FFPE) 
materials associated with minimum cost and effort (Kononen et al., 1998). We 
found that TRIP-Br2 was overexpressed in prostate carcinoma (50.8%), 
squamous cell lung carcinoma (100%), lung adenocarcinoma (48.7%), ovarian 
cystadenocarcinoma (73.1%), colorectal carcinoma (64.9%), renal cell 
carcinoma (50%), osteosarcoma (100%) and hepatocellular carcinoma 
(72.4%). However, the frequency of TRIP-Br2 overexpression was lower in 
breast carcinoma (25%), basal cell carcinoma (16.7%) and gastrointestinal 
stromal tumor (15.6%). We also observed minor variations of TRIP-Br2 
overexpression between different subtypes of ovarian carcinoma such as 
serous, mucinous and endometroid ovarian cystadenocarcinoma (data not 
shown). A representative TRIP-Br2-immunostained tumor specimen from each 
of the 10 tumor tissues examined by TMA is shown in Figure 22D, and the 
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frequency of TRIP-Br2 upregulation in these cancer malignancies is 
summarized in Table 5. 
 In addition, we found that the expression pattern of TRIP-Br2 in these 
multiple human tumors in vivo matched that in cultured cells originally derived 
from these tumors. For instance, in both osteosarcoma tissues and U2OS 
cells, TRIP-Br2 was overexpressed and localized to the nucleus. No nuclear 
presence and little/no cytoplasmic presence of TRIP-Br2 were observed in 
normal prostate, lung, breast, gastric, ovary, colon, skin or kidney sections 
(also available in a TMA format, data not shown). These data demonstrate that 
TRIP-Br2 is highly expressed in tumors, but not in the corresponding normal 
tissues and suggests that TRIP-Br2 expression and localization might be 
dysregulated in tumors. Interestingly, we have also observed overexpression 
of TRIP-Br2 in the cytoplasm of a small subset of these tumor specimens 
(data not shown), thus suggesting that TRIP-Br2 may perform novel functions 
in the cytoplasm and/or intracellular organelles to support oncogenesis in 
these tumor subsets. 
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Figure 22A. TRIP-Br2 is aberrantly expressed in many human 
cancer cell lines. (A) Upper panel: Western blot analysis revealed 
overexpression of TRIP-Br2 in the human cancer cell lines U2OS 
(osteosarcoma), PC3 (prostate adenocarcinoma), 769-P (renal 
adenocarcinoma), HCT-116 (colorectal carcinoma), HepG2 (hepatocellular 
carcinoma) and MCF-7 (breast carcinoma), as compared to normal WI38 
primary fibroblasts. β-tubulin was used as a loading control. Lower panel: 
Transcript levels of TRIP-Br gene family members were not significantly 
different in primary cells versus cancer cells, as demonstrated by real time 
PCR analysis. The baseline gene expression level represented by WI38 cells 
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Figure 22B. TRIP-Br2 is a nuclear factor that is overexpressed 
in cancer cells. Immunocytochemical analysis showed that TRIP-Br2 is 
found predominantly in both the nuclei of WI38 human primary fibroblasts and 
U2OS human osteosarcoma cells. TRIP-Br2 is clearly overexpressed in the 









Figure 22C. TRIP-Br2 is overexpressed and preferentially 
localized to the nuclei in cancer cells. Subcellular fractionation 
analysis further confirmed that TRIP-Br2/SERTAD2 is overexpressed and 
preferentially localized to the nuclei of U2OS, PC3, 769-P, HCT-116 and 
HepG2 cells. Lamin B and GAPDH were used as loading controls for nuclear 
fractions (N) and cytoplasmic fractions (C) respectively. 
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Figure 22D. TRIP-Br2 is aberrantly expressed in many human 
tumors. Multiple human tumor tissue arrays (includes normal and cancer 
sections at tumor margins) were immunostained with rabbit anti-TRIP-Br2 
polyclonal antibodies. 1: Prostate carcinoma; 2: Squamous cell lung 
carcinoma; 3: Breast carcinoma; 4: Gastrointestinal stromal tumors, GIST; 5: 
Renal cell carcinoma; 6: Ovarian carcinoma; 7: Colon carcinoma; 8: Basal cell 
carcinoma; 9: Hepatocellular carcinoma; 10: Osteosarcoma. The small insert 
represents 400X magnification of the tissue in each window (shown at 100X 
magnification). A scale is included in the small insert of window #1 (for all 
400X magnified tissue specimens). Immunopositive staining for hTRIP-Br2 is 
represented by the brown color against the hematoxylin (blue) counterstain.   
Jit Kong, CHEONG  Medicine, NUS 







Table 5. Frequency of TRIP-Br2 overexpression in 10 different cancer 
malignancies. TRIP-Br2 was found to be overexpressed in many human 
cancers, including prostate carcinoma, squamous cell lung carcinoma, lung 
adenocarcinoma, ovarian cystadenocarcinoma, colorectal carcinoma, renal 
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3.2.4 TRIP-Br2 overexpression is associated with poor prognosis in HCC 
 The effect of the presence or absence of TRIP-Br2 overexpression on 
the survival of hepatocellular carcinoma (HCC) patients was investigated to 
determine whether TRIP-Br2 overexpression is associated with poor prognosis. 
A patient cohort (n=12) with full survival data was divided into two groups, 
survival of less than or equal to one year (n=8) and survival for more than one 
year (n=4). These two groups were subsequently scored against the presence 
or absence of TRIP-Br2 overexpression in the corresponding tumor tissue 
biopsies represented on the TMA.  As shown in Table 6, six of eight HCC 
patients with TRIP-Br2 overexpression were found to have survived for less 
than or equal to one year, while three of four HCC patients with no TRIP-Br2 
overexpression were found to have survived for more than one year. A 
survival analysis using the Kaplan Meier log rank test was performed, which 
showed that the mean survival of patients exhibiting TRIP-Br2 overexpression 
(9 months) was found to be significantly lower than the survival of HCC 
patients without evidence of TRIP-Br2 overexpression (16 months) (p=0.0452) 
(Figure 23). This information is not only significant from a statistical viewpoint, 




Jit Kong, CHEONG  Medicine, NUS 





















Table 6. Hepatocellular carcinoma (HCC) patient survival in the presence 
or absence of TRIP-Br2 overexpression. A patient cohort (n=12) with full 
survival data was divided into two groups, survival of less than or equal to one 
year (n=8) and survival for more than one year (n=4). These two groups were 
subsequently scored against the presence or absence of TRIP-Br2 
overexpression in the corresponding tumor tissue biopsies represented on the 
TMA.  
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Figure 23. TRIP-Br2 overexpression is associated with poor 
prognosis in HCC. Survival analysis was performed and the mean survival 
of patients with TRIP-Br2 overexpression (9 months) was found to be 
significantly lower than that of HCC patients without TRIP-Br2 overexpression 
(16 months). The p-value of this survival analysis was determined to be 
0.0452 using the Kaplan Meier log rank test. 
 
(months) 
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3.2.5 RNA interference of TRIP-Br2 expression inhibits cell-autonomous 
growth of HCT-116 human colorectal cancer cells 
 In order to validate the potential of TRIP-Br2 as a novel transcription-
based chemotherapeutic target for human cancers, we performed TRIP-Br2-
specific siRNA knockdown of TRIP-Br2 expression in HCT-116 colorectal 
cancer cells. Cy3-labeled oligomer transfection control (Cy3-O), scrambled 
siRNA non-specific control (Scr) or TRIP-Br2-specific siRNAs (DS1, DS2 or 
DS3) were transiently transfected into HCT-116 cells, respectively, at a low 
dose of 4 picomoles (pmol) or a high dose of 40 pmol (in one ml of DMEM 
supplemented with 10% FBS). Twenty-four hours post-transfection, these cells 
were serum-deprived for 72 h to investigate the role of TRIP-Br2 in cell-
autonomous growth of HCT-116 cells. As shown in Figure 24A (left and center 
panels), specific knockdown of TRIP-Br2 expression in HCT-116 cells (12-well 
plate) was only achieved by TRIP-Br2-specific siRNAs, DS1 and DS2, at the 
higher dose of 40 pmol. The presence of Cy3-labeled oligomer in these 
transfected HCT-116 cells was observed even after 72 h post-serum 
deprivation, suggesting that the siRNA oligomers might be present in 
transfected HCT-116 cells for longer than 72 h. In general, the Cy3-labeled 
oligomers persisted in the cells for more than 96 hours post-transfection. 
These oligomers were present in significantly higher amounts in HCT-116 cells 
that were transfected at the dose of 40 pmol, compared to the lower dose of 4 
pmol (Figure 24A, right panel).  Colony forming assays (Figure 24B upper 
panel) and cell count analyses (Figure 24B lower panel) further showed that 
siRNA knockdown of TRIP-Br2 expression inhibited the cell-autonomous 
growth of serum-deprived HCT-116 cells. 
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Figure 24A. siRNA knockdown of TRIP-Br2 expression in HCT-
116 colorectal cancer cells. 4 pmol or 40 pmol of Cy3-labeled oligomer 
control (Cy3-O), scrambled siRNA (Scr) and TRIP-Br2-specific siRNAs (DS1, 
DS2 or DS3) were transiently transfected into HCT-116 cells respectively. Left 
panel: The specificity of TRIP-Br2 siRNAs was assessed by semi-quantitative 
RT-PCR (20 cycles). TRIP-Br2 gene expression remained constant in HCT-
116 cells that were exposed to Scr siRNA or TRIP-Br2 siRNA (4pmol). At the 
dose of 40 pmol, siRNAs DS1and DS2 specifically knocked down the gene 
expression of TRIP-Br2 in HCT-116 cells, but not transcript levels of other 
members of the TRIP-Br family. 18srRNA was used as a loading control. 
Center panel: Knockdown of TRIP-Br2 expression in HCT-116 cells (12-well 
plate) was achieved by TRIP-Br2-specific siRNAs, DS1 and DS2, at the dose 
of 40 pmol. β-tubulin was used as a loading control. “Not transfected” (NT) 
samples were used as negative controls.Right panel: Cy3-labeled oligomer 
persisted in the cells for more than 96 hours post-transfection. Three 
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Figure 24B. siRNA knockdown of TRIP-Br2 expression inhibits 
cell-autonomous growth of HCT-116 colorectal cancer cells. 
Colony forming assays (upper panel) and cell count analyses (lower panel) 
showed that siRNA knockdown of TRIP-Br2 expression (DS-1 or DS-2 at the 
dose of 40 pmole) inhibited the cell-autonomous growth of serum-deprived 
HCT-116 cells. The dashed line indicates the initial cell density plated. “Not 
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3.3 Discussion 
 We have earlier reported that ablation of TRIP-Br1 or TRIP-Br2 
expression suppresses serum-inducible CYCLIN E expression. The deficiency 
of either TRIP-Br1 or TRIP-Br2 resulted in a proliferative block, indicating that 
these proteins may have interdependent but not superimposable roles in the 
regulation of serum-inducible cell cycle progression (Sim et al., 2006) (Section 
2.2.4). Although amplification of TRIP-Br1 is commonly detected in ovarian 
cancers (Tang et al., 2002) and overexpression of TRIP-Br1 has been shown 
to induce tumors in nude mice (Tang et al., 2005), the role of the closely 
related family member, TRIP-Br2, in cell cycle regulation and tumor 
progression has not been elucidated. 
 With an increasing number of mRNA expression profiling studies 
employing microarrays showing a positive correlation between TRIP-Br2 
overexpression and cellular proliferation (Albertini et al., 2006; Gentile et al., 
2003; Klener et al., 2006; Kuchinskaya et al., 2005; Soo et al., 2006; Turk et 
al., 2006), we postulated that TRIP-Br2 plays an important protooncogenic role 
in cell cycle regulation and tumor progression. To validate its function(s) in 
growth and proliferation, we stably overexpressed TRIP-Br2 in NIH3T3 diploid 
fibroblasts and demonstrated that TRIP-Br2 overexpression transformed these 
murine fibroblasts, rendering them capable of proliferation under low serum 
concentrations and of anchorage-independent growth in soft agar. We also 
demonstrated that overexpression of TRIP-Br2 induced tumors in athymic 
nude mice (nu/nu). Transformed cellular phenotypes were associated with 
dysregulation of the RB/E2F/DP-transcriptional pathway through an increase 
in CDK4-mediated RB phosphorylation and with upregulation of a subset of 
 146
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
key E2F-responsive genes, such as CYCLIN E, CDC6, DHFR and CYCLIN A2. 
These data demonstrate that TRIP-Br2 overexpression was sufficient to 
overcome RB-dependent repression of E2F-mediated transcription. 
Furthermore, we have shown in our knockdown/knockout and overexpression 
studies that CYCLIN E is indeed a TRIP-Br-coregulated gene. Ongoing 
microarray studies will help us to identify other candidate TRIP-Br-coregulated 
genes and to establish the mechanism by which TRIP-Br proteins promote 
growth and tumor progression. 
 As overexpression of TRIP-Br2 resulted in the transformation of 
NIH3T3 fibroblasts, we hypothesized that TRIP-Br2 expression is dysregulated 
in human cancer. We found TRIP-Br2 to be overexpressed in many cancer 
cell lines and observed its localization to the nuclei of these cells. In contrast to 
the microarray studies that were previously performed by others, we observed 
that the transcript levels of the TRIP-Br family of transcriptional coregulators 
did not significantly differ between primary cells and cancer cells. Thus, the 
mechanism of overexpression of TRIP-Br2 in human cancers may exist at the 
post-translational level and involve dysregulation of protein turnover rather 
than dysregulation of gene transcription. We subsequently showed that TRIP-
Br2 was also overexpressed in many human cancers, including prostate 
carcinoma, squamous cell lung carcinoma, lung adenocarcinoma, ovarian 
cystadenocarcinoma, colorectal carcinoma, renal cell carcinoma, 
osteosarcoma and hepatocellular carcinoma. Collectively, our data suggest 
that TRIP-Br2 is a bona-fide protooncogene and that its overexpression is 
associated with poor prognosis in human cancers such as hepatocellular 
carcinoma. We further validated the potential of TRIP-Br2 as a novel 
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transcription-based chemotherapeutic target for human cancers by 
demonstrating that siRNA knockdown of TRIP-Br2 inhibited cell-autonomous 
growth of serum-deprived HCT-116 colorectal cancer cells. We have also 
recently demonstrated that antagonism of the TRIP-Br integrator function by 
synthetic decoy peptides, which compete with TRIP‑Br for binding to PHD zinc 
finger‑  and/or bromodomain‑containing proteins, arrests proliferation and 
induces caspase‑3‑ independent sub‑diploidization in cancer cells in vitro 
(Zang et al., 2007). 
 In summary, we have identified TRIP-Br2 as a novel protooncogene 
that is aberrantly overexpressed in human cancers. By making use of a 
comprehensive and high-throughput tissue array technology, we were able to 
advance rapidly from experimental validation of the protooncogenic role of 
TRIP-Br2 to uncovering its value in translational medicine for the treatment of 
a wide variety of human cancers. 
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4.1 Materials and Methods 
4.1.1 Cell culture, DNA transfection and reagents  
 The human osteosarcoma cell line U2OS and the African Green 
Monkey SV40-transfected kidney fibroblast cell line COS-7 were purchased 
from American Type Culture Collection (Manassas, VA). NIH3T3 mouse 
fibroblasts, which stably overexpress TRIP-Br1-HA and TRIP-Br2-HA 
respectively, were generated as described in Section 3.1.3. All cell lines were 
cultured in DMEM supplemented with 10% FBS and maintained at 37oC in a 
5% CO2 environment. COS-7 cells were transfected with expression plasmids 
using LipofactamineTM Transfection Reagent (Invitrogen, Carlsbad, CA), in 
accordance with the manufacturer’s instructions. The use of expression 
plasmids, which include pMT123-HA-Ub (kind gift from Dr. Dirk Bohmann, 
University of Rochester Medical Center), pcDNA3.1-TRIP-Br2-HA (refer to 
Figure 19), pBXG1N, pBXG1N-hTRIP-Br2 (aa1-314), pBXG1N-hTRIP-Br2 
(aa72-314), pBXG1N-hTRIP-Br2 (aa1-179) and pBXG1N-hTRIP-Br2 (aa235-
311), has been previously described (Hsu et al., 2001; Treier et al., 1994). 
Hydroxyurea (HU) (H8627, Sigma-Aldrich Inc, St. Louis, MO) was stored at -
20oC as a 1 M stock solution in deionized water. Cycloheximide (CHX) (C4859, 
Sigma-Aldrich Inc, St. Louis, MO) was purchased as a 0.2 µm-filtered 100 
mg/ml stock solution in DMSO. MG132 (C2211, Sigma-Aldrich Inc, St. Louis, 
MO) was stored at -20oC as a 25 mM stock solution in DMSO. Leptomycin B 
(LMB) (L2913, Sigma-Aldrich Inc, St. Louis, MO) was stored at -20oC as a 1 
mg/ml stock solution in ethanol. Fresh working dilutions of HU, CHX, MG132 
and LMB were made-on-demand. 
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4.1.2 Cell synchronization and flow cytometric DNA content analysis 
 U2OS cells and COS-7 cells were grown to 50% confluence on 100 mm 
culture dishes 24 h prior to incubation with 10 mM HU for an additional 24 h to 
synchronize them at the G1/S boundary [modified from (Liu and Erikson, 
2002)]. Cells were released from G1/S block and harvested at the indicated 
time points for flow cytometric DNA content, semi-quantitative RT-PCR and 
Western blot analyses. Flow cytometry was performed using a FACScan flow 
cytometer (Becton Dickinson, Franklin Lakes, NJ) at a wavelength of 488 nm. 
 
4.1.3 Semi-quantitative RT-PCR  
 Total RNA was isolated from cells was isolated and analyzed by semi-
quantitative RT-PCR as described in Section 2.1.11. Amplified PCR products 
were separated on 2% agarose gels and visualized by staining with ethidium 
bromide. The primer sequences used for RT-PCR are listed in Tables 3B and 
3C. 
 
4.1.4 Protein degradation and 26S proteasome inhibition assays 
 Cycloheximide (CHX) chase assay for the analysis of protein 
degradation was performed as previously described (Gardner et al., 1998). 
Briefly, cells (untransfected and transfected) were exposed to CHX (20 µg/ml) 
over a time course. To achieve 26S proteasome inhibition, cells were exposed 
to ALLN (50 µM) or MG132 (25 µM) over a time course. Whole cell lysates 
were prepared from the drug-treated cells at the indicated time points for semi-
quantitative RT-PCR and Western blot analyses. 
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4.1.5 Immunoprecipitation and immunocytochemistry  
 Transfected cells were washed twice with PBS and cell lysates were 
prepared by resuspension of cells with gentle rocking in ice-cold modified 
RIPA buffer (50 mM Tris-HCl, pH7.4; 1% NP-40; 0.25% Na-deoxycholate; 150 
mM NaCl; 1 mM EDTA; 1 mM PMSF; Aprotinin, Leupeptin, Pepstatin: 1 µg/ ml 
each). The cell lysates were pre-cleared with protein A/G agarose beads (sc-
2003, Santa Cruz Biotechnology Inc, Santa Cruz, CA) for 30 minutes prior to 
centrifugation at 14,000 x g (4oC, 15 minutes). The supernatants were then 
incubated overnight with pre-conjugated anti-HA-protein A/G agarose beads 
(sc-7392AC, Santa Cruz Biotechnology Inc, Santa Cruz, CA) or anti-
GAL4DBD-protein A/G agarose beads (sc-510AC, Santa Cruz Biotechnology 
Inc, Santa Cruz, CA). These agarose beads were precipitated with 
centrifugation at 1000 x g (4oC, 5 minutes) and washed five times with ice-cold 
modified RIPA buffer. They were then resuspended in 60 µl of 2X Western blot 
sample loading buffer and boiled for 5 minutes prior to denaturing SDS-PAGE 
and Western blot analysis. To analyze the subcellular localization of 
endogenous TRIP-Br2, cells were grown to 80% confluence on coverslips, 
washed three times with PBS, fixed in prechilled 4% paraformaldehyde for 20 
minutes, and permeabilized in 0.1% Triton-X for 10 minutes. Primary 
immunostaining with rabbit anti-TRIP-Br2 antibody (G4195, 1:4000) was 
performed at room temperature for 1 h. To analyze the subcellular localization 
of GAL4DBD-hTRIP-Br2 and its derivatives, cells were grown to 50% 
confluence on coverslips and transfected as described in Section 4.1.1. After 
48 hours, transfected cells were washed three times with PBS, fixed in 
prechilled 4% paraformaldehyde for 20 minutes, and permeabilized in 0.1% 
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Triton-X for 10 minutes. Primary immunostaining with mouse anti-GAL4DBD 
antibody (1:300) was performed at room temperature for 1 h. Secondary 
immunostaining with goat anti-rabbit-Cy3 or goat anti-mouse-Cy3 antibodies 
was performed at room temperature for 1 h, following 3 washes with PBS at 
the end of primary immunostaining. Cellular DNA was subsequently 
counterstained with DAPI. Staining was visualized and photographed using a 
Nikon Eclipse E1000 fluorescence microscope. 
 
4.1.6 NES motif prediction analysis and nuclear export inhibition assay  
 Nuclear export signal (NES) motif prediction was achieved by in silico 
interrogation of the TRIP-Br2 primary amino acid sequence with a web-based 
NES motif predictor, NetNES 1.1 (http://www.cbs.dtu.dk/services/NetNES/). To 
inhibit CRM1-mediated nuclear export, cells were treated with 10 ng/ml of 
Leptomycin B (LMB) for 2 h as previously described (Lai et al., 2007) prior to 
immunocytochemical or denaturing SDS-PAGE/Western blot analyses. 
 
4.1.7 Subcellular fractionation, denaturing SDS-PAGE and Western 
blotting  
 Subcellular fractionation of cells was described in Section 3.1.7. 
Proteins from whole cell lysates were resolved using standard denaturing 
polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (Hsu 
et al., 2001). Rabbit anti-TRIP-Br2 (G4195) polyclonal antibodies (Section 
2.1.1) and mouse anti-TRIP-Br1 monoclonal antibodies, which were generated 
as previously described (Zang et al., 2007), were used in Western blot and/or 
immunocytochemical analyses. All other antibodies used in Western blot 
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analyses were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, 
CA). They include anti-HA (sc-805), anti-cyclin D1 (sc-718), anti-cyclin A (sc-
596), anti-CDK2 (sc-163), anti-PSer780Rb (sc-12901-R), anti-HA (sc-805 and 
sc-7392), anti-GAL4DBD (sc-510), anti-lamin B (sc-6217), anti-GAPDH (sc-
59540) and β-tubulin (sc-5274). 
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4.2 Results 
4.2.1 TRIP-Br2 expression is differentially regulated during cell cycle 
progression 
 Members of the TRIP-Br family of mammalian transcription coregulators 
have been shown to play key roles in regulating cell cycle progression. Our 
group and others have previously demonstrated that some members of this 
novel family of protooncogenes and/or tumor suppressors, such as TRIP-Br1, 
RBT1 and TRIP-Br3, are themselves tightly controlled during cell cycle 
progression via a yet-to-be elucidated set of regulatory processes (Darwish et 
al., 2007; Hayashi et al., 2006; Hsu et al., 2001). Earlier we showed that the 
loss-of- and gain-of-function of the poorly-studied TRIP-Br2 protein leads to 
cell proliferation arrest and tumor progression, respectively. We, herein, seek 
to investigate whether temporal regulation of TRIP-Br2 involving transcriptional 
and/or translational mechanisms may serve to control the precise execution of 
its function(s) during cell cycle progression.  
 To study whether TRIP-Br2 is regulated spatially and/or temporally 
during cell cycle progression, we synchronized human osteosarcoma U2OS 
cells at the G1/S boundary by exposure to 10 mM hydroxyurea (HU) for 24 
hours, before reversing the drug treatment. We found that the transcript level 
of TRIP-Br2, as well as TRIP-Br1, remained constant in all phases of the cell 
cycle (Figure 25A).  Notably, U2OS cells do not exit the cell cycle (i.e. did not 
enter the quiescent G0 state) under HU treatment in the present study, unlike 
what is typically observed upon serum deprivation-induced synchronization of 
primary cells. Serum-inducibility of TRIP-Br1 and TRIP-Br2 has been 
previously reported by our group and others (Sim et al., 2006; Sugimoto et al., 
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1999). The data presented below reflects the gene expression status of TRIP-
Br1 and TRIP-Br2 in continually cycling cells unless otherwise indicated.  
 Similar to TRIP-Br1, we observed that TRIP-Br2 was differentially 
regulated post-translationally during cell cycle progression of continually 
cycling cells (Figure 25B). Both TRIP-Br1 and TRIP-Br2 levels accumulate at 
the G1/S boundary and decrease progressively through S phase until the G2/M 
phase of the cell cycle is reached. The oscillatory nature of TRIP-Br2 during 
cell cycle progression was also observed in African Green Monkey SV40-
transfected kidney fibroblast COS-7 cells (Figure 25C). The temporal 
accumulation of TRIP-Br2 at the G1/S boundary and its persistence through 
the S phase parallels the previously described pathway of E2F-mediated gene 
transcriptional regulation during cell cycle progression and cancer 
pathogenesis. In contrast to cyclin A, a known proliferation marker that is 
rapidly degraded when cells progress out of S phase, residual expression of 
TRIP-Br2 was observed in the G2/M and early G1 phases of the cell cycle in 
continually cycling cells. This suggests that TRIP-Br2 may play a novel role 
during these phases of the cell cycle, such as cell division in the G2/M phase, 
and mitogen-sensing and participation in a positive autoregulatory loop that is 
responsible for its own accumulation at the G1/S boundary in the early G1 
phase. 
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Figures 25A-B. TRIP-Br2 is differentially expressed during the 
cell cycle in U2OS cells. Human osteosarcoma U2OS cells were 
synchronized at the G1/S boundary by treatment with 10 mM hydroxyurea (HU) 
for 24 h, before the drug treatment was reversed. Cells were harvested at the 
indicated time points after the drug effect was reversed and synchronization 
was validated by flow cytometric DNA content analysis. (A) Neither TRIP-Br1 
nor TRIP-Br2 transcript levels changed as continually-cycling cells progressed 
from the G1 phase of one cell cycle to the next. (B) Similar to TRIP-Br1, TRIP-
Br2 was differentially regulated post-translationally during cell cycle 
progression of continually cycling cells. Both TRIP-Br1 and TRIP-Br2 
accumulated at the G1/S boundary and decreased progressively during S 
phase progression to the G2/M phase of the cell cycle. Cyclin A and P-
Ser780Rb were used as a positive control, β-tubulin served as a loading 
control for Western blot analyses, and β–Actin was used as a loading control 
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Figure 25C. TRIP-Br2 is differentially expressed during the cell 
cycle in COS-7 cells. African Green Monkey SV40-transfected kidney 
fibroblast COS-7 cells were synchronized at the G1/S boundary by treatment 
with 10 mM hydroxyurea (HU) for 24 h, before the drug treatment was 
reversed. Cells were harvested at the indicated time points after the drug 
effect was reversed and synchronization was validated by flow cytometric DNA 
content analysis. TRIP-Br2 was differentially regulated post-translationally 
during cell cycle progression of continually cycling COS-7 cells. It accumulated 
at the G1/S boundary and decreased progressively during S phase 
progression to the G2/M phase of the cell cycle. Cyclin A was used as a 
positive control, the non-cell cycle-regulated cyclin dependent kinase 2 (CDK2) 
was used as a negative control and β–tubulin was used as a loading control 
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4.2.2 C-terminal HA-tagged TRIP-Br2 is susceptible to rapid turnover 
 Since the transcript level of TRIP-Br2 did not vary across the different 
phases of cell cycle in continually cycling cells, a post-translational regulatory 
mechanism may serve to limit the function of TRIP-Br2 in the G2/M and early 
G1 phases of cell cycle by controlling the turnover rate of TRIP-Br2.  We first 
performed cycloheximide chase analysis to examine the half-lives of 
endogenously-expressed TRIP-Br2 and exogenously-expressed amino-
terminal (N-terminal) GAL4DBD-tagged TRIP-Br2 in COS-7 cells. 
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms 
by interfering with the peptidyl transferase activity of the 60S ribosome, 
thereby blocking translation elongation. Both endogenously-expressed TRIP-
Br2 and exogenously-expressed N-terminal GAL4DBD-tagged TRIP-Br2 
exhibited similar half-lives of approximately two hours (Figure 26A). However, 
when we performed cycloheximide chase analysis on C-terminal HA-tagged 
TRIP-Br2 in COS-7 cells, we observed that its half-life was significantly 
reduced to less than 30 minutes (Figure 26B). Compared with known short-
lived cell cycle regulatory proteins like cyclin D that has a half-life of ~1 hour, 
we found that the C-terminal HA-tagged TRIP-Br2 was rapidly turned over, 
with its half-life estimated to be about 20 minutes (Figure 26C). It is unlikely 
that such control over the protein turnover of C-terminal HA-tagged TRIP-Br2 
reflects a transcriptional mechanism, as its exogenous expression in 
transiently-transfected COS-7 cells was driven by a strong and constitutively 
active CMV promoter. As shown in Figure 26D, we demonstrated that the 
transcript level of C-terminal HA-tagged TRIP-Br2 did not vary across the time 
intervals of the cycloheximide chase analysis. These data suggest that the 
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introduction of epitope-tagged sequences to TRIP-Br2 at the C-terminus may 
have exposed encrypted degradation signals of TRIP-Br2 through changes in 
its native protein conformation. Interestingly, the function of C-terminal HA-
tagged TRIP-Br2 was apparently not affected by its intrinsic instability, as we 
have shown earlier that its overexpression transformed murine fibroblasts and 
promoted tumor growth in athymic nude mice. We reasoned that the 
overexpression of any functional forms of TRIP-Br2 above normal physiologic 
levels, including the less stable TRIP-Br2-HA epitope-tagged protein that 
retains gene transactivation function, is sufficient to promote tumorigenesis. 
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Figure 26A-D. Rapid turnover of C-terminal HA-tagged TRIP-Br2. 
(A) Following de novo protein synthesis inhibition by treatment with CHX (20 
µg/ml) in COS-7 cells, the endogenously-expressed TRIP-Br2 and 
exogenously-expressed N-terminal GAL4DBD-tagged TRIP-Br2 steadily 
degraded over time. (B) C-terminal HA-tagged TRIP-Br2 (TRIP-Br2-HA) 
degraded more rapidly over time. (C) The half-life of TRIP-Br2-HA was as 
short as 20 minutes. (D) TRIP-Br2-HA mRNA levels remained constant over 
the time course of CHX treatment. β–tubulin was used as a loading control in 
Western blot analyses, while β–Actin was used as a loading control in RT-PCR 
analyses. 
(A)       (C) 
      (D) 
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4.2.3 Degradation of TRIP-Br2 through the 26S proteasome-dependent 
pathway 
 Protein turnover in eukaryotic cells is governed by multiple proteolytic 
systems, including the lysosomal proteases, calpains, the ATP-ubiquitin-
proteasome-dependent pathway, and an ATP-independent non-lysosomal 
process (Barrett, 1992). Since the ubiquitin-proteasome-dependent pathway is 
known to be involved in regulating the turnover of key regulators of the cell-
cycle machinery such as cyclins and cyclin-dependent kinase inhibitors 
(Barinaga, 1995; Glotzer et al., 1991), we investigated whether TRIP-Br2 
protein levels are regulated by this mechanism. This protein proteolytic 
pathway is uniquely characterized by the addition by conjugation of ubiquitin to 
target substrates resulting in the formation of a polyubiquitin chain on these 
substrates that earmarks them for recognition by the 26S proteasome complex 
(Hochstrasser, 1995; Jentsch and Schlenker, 1995). As the process from 
recognition to degradation of polyubiquitinated substrates by the 26S 
proteasome complex occurs rapidly, these species are usually transient and 
are rarely detected.  
 To determine whether the 26S proteasome complex is involved in the 
regulation of TRIP-Br2 protein turnover, we treated TRIP-Br2-HA transfected 
COS-7 cells with known 26S proteasome inhibitors MG132 (25 µM, 2 h) or 
ALLN (50 µM, 2 h). As shown in Figure 27A, either MG132 or ALLN was 
sufficient to cause accumulation of TRIP-Br2-HA in COS-7 cells (compare 
treatment lanes 2 and 3 to control lanes 4 and 5). To investigate whether the 
26S proteasome complex plays an active role in maintaining the steady-state 
level of TRIP-Br2-HA under normal physiological conditions, we treated TRIP-
 162
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
Br2-HA transfected COS-7 cells with a combination of cycloheximide (20 µg/ 
ml) and MG132 (Figure 27A, lane 1). We have earlier shown that TRIP-Br2-
HA is a short-lived protein and has a half-life of ~20 minutes in a 
cycloheximide chase analysis. The addition of MG132 prevented the 26S 
proteasome-dependent depletion of the existing pool of TRIP-Br2-HA in these 
cycloheximide-treated cells (Figure 27A, compare lanes 1 and 6). In the 
absence of de novo synthesis of TRIP-Br2-HA and in the presence of an 
inhibition of the breakdown of the existing pool of TRIP-Br2-HA, a steady-state 
level of TRIP-Br2-HA was achieved. This is comparable to that observed 
under normal physiologic conditions (Figure 27A, compare lanes 1 and 5) in 
which TRIP-Br2-HA is robustly synthesized and, at the same time, actively 
degraded to maintain a physiologic level of TRIP-Br2-HA in these cells.  
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Figure 27A. Inhibition of 26S proteasome activity by MG132 or 
ALLN stabilized TRIP-Br2-HA in transfected COS-7 cells. A two-
hour treatment of TRIP-Br2-HA-transfected COS-7 cells with potent 
proteasome inhibitors, such as MG132 (25 µM) or ALLN (50 µM), led to the 
accumulation of TRIP-Br2-HA. Upon exposure of the transfected cells to CHX 
(20 µg/ml), TRIP-Br2-HA destabilized within two hours. Steady-state levels of 
TRIP-Br2-HA were restored when COS-7 cells were co-incubated with CHX 
(20 µg/ml) and MG132 (25 µM). Treatment of COS-7 cells with DMSO was 
included as a negative control. β–tubulin was used as a loading control. 
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 In addition, we showed that MG132 (25 µM, 2 h) prevented the 
degradation of both TRIP-Br1-HA and TRIP-Br2-HA in NIH3T3 murine 
fibroblasts stably overexpressing these TRIP-Br proteins (Figure 27B). The 
accumulation of TRIP-Br2-HA in these cells was clearly observed within 1 h of 
MG132 treatment (Figure 27C). A similar phenomenon was observed when 
TRIP-Br2-abundant U2OS cells were treated with MG132 or ALLN. Western 
blot analysis of endogenously-expressed TRIP-Br2 in U2OS cells, following a 
MG132 or ALLN treatment time course, revealed a ladder of higher molecular 
weight TRIP-Br2 species, which is a characteristic of polyubiquitinated 
proteins, after prolonged 26S proteasome inhibition (Figure 27D). These data 
suggest that the 26S proteasome regulates the turnover of at least the two 
TRIP-Br family members TRIP-Br1 and TRIP-Br2, though it remains unknown 
if other family members like TRIP-Br3, RBT1 and its Drosophila homolog, 
TARA, are regulated through a similar mechanism. 
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Figure 27B. Inhibition of 26S proteasome activity by MG132 
stabilized TRIP-Br1-HA and TRIP-Br2-HA in NIH3T3 mouse 
fibroblasts stably overexpressing TRIP-Br-HA proteins. Treatment 
of NIH3T3TRIP-Br1-HA and NIH3T3TRIP-Br2-HA fibroblasts with MG132 (25 µM) led 
to the accumulation of TRIP-Br1-HA and TRIP-Br2-HA respectively. β–tubulin 
was used as a loading control. V: Vector-only clones; R1: TRIP-Br1-HA-










Figure 27C. Inhibition of 26S proteasome activity by MG132 
stabilized TRIP-Br2-HA in COS-7 cells over time. Treatment with 
MG132 (25 µM) led to the stabilization of TRIP-Br2-HA in COS-7 cells over 
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Figure 27D. Inhibition of 26S proteasome activity by MG132 
stabilizes TRIP-Br2 in U2OS cells over time. Endogenous TRIP-Br2 
in U2OS cells was stabilized over time by proteasome inhibitors MG132 (25 
µM, up to 6 h) or ALLN (50 µM, up to 6 h, or 10 µM for 16 h). Higher molecular 
weight (MW) isoforms of TRIP-Br2 were observed after six hours of treatment 
with these proteasome inhibitors. β–tubulin was used as a loading control. 
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 As the protein level of TRIP-Br2 has been shown to be higher at the 
G1/S boundary and throughout the S phase, we sought to determine whether 
TRIP-Br2 is more susceptible to the 26S proteasome-dependent proteolysis in 
other phases of the cell cycle, such as the G2/M phase, by treating 
asynchronously-cycling COS-7 cells as well as G1/S phase-synchronized and 
G2/M phase-synchronized COS-7 cells with MG132. The synchronized cell 
populations were derived from treatment of asynchronously-cycling COS-7 
cells with 10 mM HU for 24 hours; the drug effect was reversed to allow 
cycling of the synchronized cell populations. The G1/S phase-synchronized 
cells and G2/M phase-synchronized COS-7 cells were collected 1 hour and 20 
hours post HU block respectively, before being subjected to 2 hours of MG132 
(25µM) treatment. The asynchronously-cycling COS-7 cells that were 
subjected to MG132 treatment were used as a positive control. Western blot 
analysis of endogenously-expressed TRIP-Br2 following MG132 treatment of 
asynchronous or synchronized COS-7 cells showed that MG132 alone was 
sufficient to inhibit the degradation of TRIP-Br2 and to enable its accumulation 
in cells (Figure 27E). The abundance of TRIP-Br2 proteins was markedly 
increased following MG132 treatment of the cells in G2/M phase, while the 
increase in abundance of TRIP-Br2 in the MG132 treated-cells in the G1/S 
phase remained modest. This observation was further validated by 
immunocytochemical and subcellular fractionation analyses (Figures 27F and 
27G).  
 It has been reported that nuclear proteins such as p53 are 
polyubiquitinated in the nucleus and exported to the cytoplasm for degradation 
(Lohrum et al., 2001). To investigate whether TRIP-Br2 follows a similar fate, 
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we treated cells with a nuclear export inhibitor Leptomycin B (LMB). LMB is a 
drug that inhibits the formation of complexes consisting of CRM1, RanGTP 
and NES-containing proteins, thus non-specifically blocking nuclear export 
(Fornerod et al., 1997; Ossareh-Nazari et al., 1997; Ullman et al., 1997; Wolff 
et al., 1997). TRIP-Br2 levels in the G2/M phase were found to accumulate in 
the nucleus upon LMB treatment. This suggests that apart from the 26S 
proteasome complex, nuclear export of TRIP-Br2 might also play a role in 
regulating the turnover of TRIP-Br2. Interestingly, Lai and coworkers have 
recently demonstrated that TRIP-Br2 may be subcellularly localized to the 
cytoplasm as a result of its association with the CRM1-mediated nuclear 
export machinery (Lai et al., 2007).  
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Figure 27E. Inhibition of 26S proteasome activity by MG132 
stabilizes TRIP-Br2 in G2/M phase-COS-7 cells (Western blot). 
Endogenous TRIP-Br2 was stabilized to a greater degree by treatment with 
MG132 (25 µM) in asynchronously growing- and G2/M phase-COS-7 cells than 
in G1/S phase-COS-7 cells. Cell synchronization was achieved by treatment 
with 10 mM HU for 24 h. Flow cytometric DNA analysis validated cell 
synchronization at G1/S phase and G2/M phase for cells harvested 1 h post- 
and 20 h post-removal of HU respectively. β–tubulin was used as a loading 
control. 
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Figure 27F. Inhibition of 26S proteasome by MG132 stabilizes 
TRIP-Br2 in G2/M phase-COS-7 cells (Immunocytochemistry). 
Immunocytochemical analysis revealed that TRIP-Br2 was stabilized to a 
greater degree by treatment with MG132 (25 µM) in asynchronously growing 
and G2/M phase-COS-7 cells than in G1/S phase-COS-7 cells. Cytoplasmic 
TRIP-Br2 in these COS-7 cells was observed following two hours of MG132 
treatment. Cellular DNA was counterstained with DAPI (blue). 
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Figure 27G. TRIP-Br2 in G2/M phase-COS-7 cells was stabilized 
by proteasome inhibitor MG132 and CRM1-mediated nuclear 
export inhibitor LMB. Subcellular fractionation analysis revealed the 
stabilization of endogenous TRIP-Br2 in G2/M phase-COS-7 cells by a two-
hour treatment with either a nuclear export inhibitor Leptomycin B (LMB, 10 
ng/ ml) or a proteasome inhibitor MG132 (25 µM).  LMB treatment restored 
TRIP-Br2 in G2/M phase-COS-7 cells to a level comparable to that of G1/M 
phase-COS-7 cells. Cytoplasmic TRIP-Br2 was observed only in the MG132-
treated COS-7 cells. Lamin B and GAPDH were used as loading controls for 
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4.2.4 TRIP-Br2 is post-translationally modified through its association 
with ubiquitin 
 To directly assess whether the observed ladder of higher molecular 
weight TRIP-Br2 species represents polyubiquitinated forms of TRIP-Br2, we 
cotransfected COS-7 cells with GAL4DBD-hTRIP-Br2 expression vectors or 
GAL4DBD control vectors together with an HA-Ubiquitin (HA-Ub) expression 
vector. These cells were subsequently treated either without or with MG132 
(25 µM, 2 h), and immunoprecipitated with an HA-specific antibody prior to 
GAL4DBD immunoblot analysis.   As shown in Figure 28A (upper panel), the 
GAL4DBD immunoblot analysis revealed a weak ladder of TRIP-Br2-
immunoreactive proteins only in GAL4DBD-hTRIP-Br2/HA-Ub cotransfectant 
lysates that were enriched by HA-antibody immunoprecipitation. Increased 
levels of these polyubiquitinated forms of TRIP-Br2 were observed in lysates 
of GAL4DBD-hTRIP-Br2/HA-Ub cotransfectants that were treated with MG132. 
The levels of GAL4DBD protein, however, did not differ significantly in the 
presence or absence of MG132 (Figure 28A, lower panel). We further 
validated the formation of TRIP-Br2-ubiquitin conjugates when GAL4DBD-
hTRIP-Br2/HA-Ub cotransfectants were subjected to immunoprecipitation with 
a GAL4DBD-specific antibody prior to HA immunoblot analysis. The HA 
immunoblot analysis demonstrated an increase in the polyubiquitinated forms 
of GAL4DBD-hTRIP-Br2 in lysates of GAL4DBD-hTRIP-Br2/HA-Ub 
cotransfectants that were treated with MG132 (Figure 28B). 
 173
Jit Kong, CHEONG  Medicine, NUS 








Figure 28A. HA-Ubiquitin is associated with GAL4DBD-hTRIP-
Br2. COS-7 cells were co-transfected with pBXG1N or pBXG1N-hTRIP-Br2 
and pMT123-HA-Ub for 48 h prior to exposure to MG132 (25 µM) for 2 h. 
Extracts from MG132-treated or -untreated cells were prepared and 
immunoprecipitated with anti-HA antibodies, followed by immunoblotting with 
anti-GAL4DBD antibodies. Immunoprecipitation (IP) analysis revealed 
association of HA-Ub with GAL4DBD-hTRIP-Br2. Polyubiquitinated forms of 
GAL4DBD-hTRIP-Br2 increased following treatment with MG132. No 
polyubiquitinated forms of GAL4DBD were observed in the presence or 
absence of MG132. β–tubulin was used as a loading control in Western blot 
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Figure 28B. GAL4DBD-hTRIP-Br2 is associated with HA-
Ubiquitin. COS-7 cells were co-transfected with pBXG1N or pBXG1N-
hTRIP-Br2 and pMT123-HA-Ub for 48 h prior to exposure to MG132 (25 µM) 
for 2 h. Extracts from MG132-treated or -untreated cells were prepared and 
immunoprecipitated with anti-GAL4DBD antibody-conjugated protein A/G 
beads, followed by immunoblotting with anti-HA antibodies. GAL4DBD-hTRIP-
Br2 co-immunoprecipitated with HA-Ub and polyubiquitinated forms of 
GAL4DBD-hTRIP-Br2 increased following treatment with MG132. β–tubulin 
was used as a loading control in Western blot analyses of the whole cell 
extracts. IP: Immunoprecipitation. 
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4.2.5 Deletion of the TRIP-Br2 C-terminus that includes a putative nuclear 
export signal motif inhibits TRIP-Br2 degradation, independent of its 
ubiquitination status 
 An analysis of GAL4DBD-hTRIP-Br2 truncation mutants revealed that 
the C-terminus of TRIP-Br2, which includes a PHD-Bromo interaction domain 
and a transcriptional activation domain (TAD), is required for its protein 
turnover. As shown in Figure 29A, increased protein stability of GAL4DBD-
hTRIP-Br2 was achieved only when its C-terminus was deleted. In addition, 
fusion of this TRIP-Br2 C-terminus to GAL4DBD resulted in its destabilization 
compared to GAL4DBD alone.   
 Next, we performed cycloheximide chase analysis to examine the half-
lives of GAL4DBD-hTRIP-Br2 truncation mutants in COS-7 cells. GAL4DBD-
hTRIP-Br2 (235-311) exhibited the shortest half-life (<30 minutes), followed by 
the N-terminal truncation mutant, GAL4DBD-hTRIP-Br2 (72-314), and the full 
length GAL4DBD-hTRIP-Br2 (1-314), with half-lives of approximately 30 
minutes and 60 minutes, respectively. On the other hand, the C-terminal 
truncation mutant, GAL4DBD-hTRIP-Br2 (1-179) showed resistance to protein 
degradation and its levels remained constant for over 2 hours after 
cycloheximide treatment (Figure 29B). The level of GAL4DBD-hTRIP-Br2 (1-
314) did not decrease when the transfected cells were treated with DMSO 
control. 
 Earlier we showed that GAL4DBD-hTRIP-Br2 forms ubiquitin 
conjugates and is regulated by the 26S proteasome-dependent proteolytic 
pathway. We next investigated whether the GAL4DBD-hTRIP-Br2 truncation 
mutants differ in their ability to form ubiquitin conjugates that earmark them for 
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recognition by the 26S proteasome complex. COS-7 cells were cotransfected 
with GAL4DBD-hTRIP-Br2 truncation mutant expression vectors and HA-
Ubiquitin (HA-Ub) expression vectors. These cells were subsequently treated 
either without or with MG132 (25 µM, 2 h), followed by immunoprecipitation 
with anti-GAL4DBD antibody-conjugated protein A/G agarose beads prior to 
HA immunoblot analysis. A ladder of polyubiquitinated GAL4DBD-hTRIP-Br2 
(1-179) proteins was observed in GAL4DBD-hTRIP-Br2 (1-179)/HA-Ub 
cotransfectant lysates in the absence of MG132, while the polyubiquitinated 
forms of full-length GAL4DBD-hTRIP-Br2 and all its derivatives were observed 
only upon inhibition of 26S proteasome activity by MG132 treatment (Figure 
29C, upper panel). We confirmed that HA-Ub and full-length GAL4DBD-
hTRIP-Br2 or its truncation mutants were transfected and properly expressed 
in cells used for these immunoprecipitation studies (Figure 29C middle and 
lower panel).  Collectively, these data suggest that ubiquitination most likely 
takes place on multiple sites of TRIP-Br2, as we have demonstrated that full-
length TRIP-Br2 and all its derivatives form ubiquitin conjugates. We have also 
demonstrated that other regulatory mechanisms may be involved in regulating 
the turnover of TRIP-Br2, as deletion of the acidic C-terminal transcriptional 
activation domain (TAD) of TRIP-Br2 resulted in a mutant that was highly 
stable yet heavily ubiquitinated. It remains unknown whether key ubiquitin-
conjugating site(s), which are critical in the regulation of TRIP-Br2 turnover, 
are preferentially localized to the C-terminus over other regions of TRIP-Br2 
and whether the loss of such ubiquitination sites in the C-terminus may result 
in an increase in TRIP-Br2 protein stability. 
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 Given that we have earlier shown that CRM1-mediated nuclear export 
might be involved in maintaining a low steady-state level of TRIP-Br2 in G2/M 
phase cells and that LMB stabilized TRIP-Br2 in these cells, we investigated 
whether the gain in protein stability of TRIP-Br2 (1-179) was due to a loss of 
key nuclear export signal(s). Nuclear export signals (NES) have been shown 
to be important regulators of the subcellular localization of proteins that 
function in diverse cellular processes ranging from cell proliferation to 
programmed cell death. Furthermore, it has been shown that proteins >40 kDa 
must use a nuclear export receptor complex to pass through the nuclear pore 
(Gerace, 1995; Gorlich and Mattaj, 1996). We interrogated the primary amino 
acid sequence of TRIP-Br2, using a web-based nuclear export signal (NES) 
motif predictor, NetNES 1.1 (http://www.cbs.dtu.dk/services/NetNES/), and 
examined this sequence manually to determine whether it contains a leucine-
rich sequence of conserved spacing and hydrophobicity that fits the criteria 
established for an NES (Bogerd et al., 1996; Kim et al., 1996). We observed 
that the C-terminal residues between amino acids (aa) 238 and 243 conform 
to this motif, as indicated by their similarity to other known NES sequences on 
p53, p73 and MDM2 (Stommel et al., 1999). As shown in Figure 29D, this 
putative NES LxxLxL motif overlapped with the PHD-Bromo interaction domain 
(aa242-254) and is highly conserved in widely divergent species, and in the 
other TRIP-Br family members such as TRIP-Br1, RBT1 and TRIP-Br3. 
 178
Jit Kong, CHEONG  Medicine, NUS 






















Figure 29A. Stabilization of TRIP-Br2 by deletion of its C-
terminus. Upper panel: A schematic representation of the GAL4DBD, 
GAL4DBD-hTRIP-Br2 wildtype and its derivatives used. Lower panel: COS-7 
cells were transfected with pBXG1N, pBXG1N-hTRIP-Br2 or its derivatives for 
48 h. Cell lysates were prepared and analyzed by SDS-PAGE/Western blot.  
The C-terminus of TRIP-Br2, which includes a PHD zinc finger- and/or 
bromodomain-interacting domain in an acidic TAD, is required for the 
regulation of protein turnover. Fusion of this TRIP-Br2 C-terminus to the 
heterologous protein tag, GAL4DBD, resulted in the destabilization of 
GAL4DBD. β–tubulin was used as a loading control. 
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Figure 29B. Degradation profile of TRIP-Br2 truncation mutants. 
Degradation of GAL4DBD-hTRIP-Br2 and its derivatives were assayed by 
treatment with CHX (20 µg/ ml) and cell lysates were harvested at the 
indicated time points. CHX chase analysis revealed the stabilization of 
GAL4DBD-hTRIP-Br2 (1-179) as a result of the loss of its C-terminal region. 
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Figure 29C. Deletion of the TRIP-Br2 C-terminus abrogated the 
regulation of its protein turnover independent of its 
ubiquitination status. COS-7 cells were co-transfected with pMT123-HA-
Ub and pBXG1N-hTRIP-Br2 or its derivatives for 48 h, following which they 
were subjected to either no exposure or exposure to MG132 (25 µM) for 2 h. 
Extracts from MG132-treated or -untreated cells were prepared and 
immunoprecipitated with anti-GAL4DBD antibody-conjugated protein A/G 
agarose beads, followed by immunoblotting with anti-HA antibodies. β–tubulin 
was used as a loading control in Western blot analyses of the whole cell 
extracts.  Deletion of the C-terminal region aa180-314 of TRIP-Br2 prevented 
its degradation, independent of its ubiquitination status. IP: 
immunoprecipitation; WCE: whole cell extracts; WB: Western blot (with the 
appropriate antibodies). 
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Figure 29D. A putative nuclear export signal motif is localized 
to the C-terminus of TRIP-Br2. A conserved leucine-rich NES is found in 
the C-terminus of TRIP-Br2. At residues 238-243, the TRIP-Br2 NES 
overlapped with the PHD-Bromo interaction domain (aa242-254) in the C-
terminus. The TRIP-Br2 NES is aligned with homologous sequences of TRIP-
Br family members TRIP-Br1, RBT1 and TRIP-Br3, and the NESs of p53, p73 
and MDM2 (Stommel et al., 1999). The putative NESs of other TRIP-Br family 
members are found to be either localized to the SERTA domain or overlapped 
the PHD-Bromo interaction domain. NetNES1.1 
(http://www.cbs.dtu.dk/services/NetNES/) was used to predict putative NESs 
in TRIP-Br proteins. Hs: Homo sapiens; n: amino-terminus; c: carboxyl-
terminus. 
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4.2.6 The putative C-terminal NES motif of TRIP-Br2 regulates access to 
26S proteasome in G2/M phase 
 To investigate whether the putative C-terminal NES LxxLxL motif of 
TRIP-Br2 was functional, we transiently transfected COS-7 cells with either 
GAL4DBD-hTRIP-Br2 (1-314), GAL4DBD-hTRIP-Br2 (72-314), GAL4DBD-
hTRIP-Br2 (1-179) or GAL4DBD-hTRIP-Br2 (235-311), and analyzed the 
subcellular localization of these TRIP-Br2 wildtype and truncation mutants by 
immunofluorescence and subcellular fractionation. As shown in Figure 30A, 
the exogenously-expressed GAL4DBD-hTRIP-Br2 wildtype and truncation 
mutants were predominantly localized to the nucleus. Partial cytoplasmic 
immunostaining of GAL4DBD-hTRIP-Br2 (1-314) and GAL4DBD-hTRIP-Br2 
(72-314) were observed. Similar findings were demonstrated in the subcellular 
fractionation analysis of TRIP-Br2 wildtype and truncation mutants (Figure 
30B). Although GAL4DBD-hTRIP-Br2 (1-179) and GAL4DBD-hTRIP-Br2 (235-
311) revealed exclusive nuclear localization, their levels appeared to be in 
sharp contrast with each other. GAL4DBD-hTRIP-Br2 (235-311), which 
consisted of only the putative NES LxxLxL motif and the PHD-Bromo 
interaction domain in the acidic C-terminal TAD, was found to be the most 
unstable form of TRIP-Br2. On the other hand, GAL4DBD-hTRIP-Br2 (1-179), 
which lacked the C-terminal region (including NES motif, PHD-Bromo 
interaction domain and the rest of acidic TAD), was found to be the most 
stable form of TRIP-Br2.  
 Among the NES-containing forms of TRIP-Br2, a low level of 
GAL4DBD-hTRIP-Br2 (235-311) expression with exclusive nuclear localization 
was observed. We further scrutinized the role of this putative NES in mediating 
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the nuclear export of TRIP-Br2 for proteolytic degradation. GAL4DBD-hTRIP-
Br2 wildtype- and truncation mutant-transfected COS-7 cells were treated with 
the proteasome inhibitor MG132 (25 µM) and subjected to subcellular 
fractionation analysis. We found that inhibition of the 26S proteasome activity 
led to the accumulation of GAL4DBD-hTRIP-Br2 (1-314), GAL4DBD-hTRIP-
Br2 (72-314) and GAL4DBD-hTRIP-Br2 (235-311) in both the cytosol and 
nucleus (Figure 30C). In contrast, GAL4DBD-hTRIP-Br2 (1-179) remained 
exclusively localized to the nucleus, suggesting that the putative C-terminal 
NES of TRIP-Br2 may play a critical role in mediating TRIP-Br2 nuclear export 
for proteolytic degradation. As the C-terminus-containing forms of TRIP-Br2 
varied in protein stability, we speculate that the N-terminal sequence of TRIP-
Br2 (aa1-234) may be responsible for the negative regulation of TRIP-Br2 
proteolytic degradation.  
 Given that TRIP-Br2 is maintained at its lowest level when cells 
progress through the G2/M phase of cell cycle, we investigated whether the 
loss of acidic C-terminal TAD alone would abrogate TRIP-Br2 proteolysis in 
the G2/M phase. COS-7 cells, which were transiently transfected with 
GAL4DBD-hTRIP-Br2 wildtype and truncation mutants, were arrested by HU 
and subsequently released after 20 h to achieve synchrony at the G2/M phase 
of cell cycle for immunocytochemical analysis. While GAL4DBD-hTRIP-Br2 
wildtype and N-terminal truncation mutants exhibited low steady state levels, 
the C-terminal truncation mutant, GAL4DBD-hTRIP-Br2 (1-179) was found to 
be extremely stable and present in greater amounts in the G2/M phase. When 
these G2/M phase cells were treated with a potent nuclear export inhibitor, 
Leptomycin B, we observed nuclear accumulation of GAL4DBD-hTRIP-Br2 
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wildtype and its derivatives (Figure 30E). These data suggest that deletion of 
the acidic C-terminal TAD, which encodes a putative NES, abrogated TRIP-
Br2 proteolysis and that inhibition of the nuclear export of TRIP-Br2 by LMB 
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Figure 30A. Subcellular localization of wildtype TRIP-Br2 and 
its truncation mutants. Asynchronously growing COS-7 cells were 
transfected with pBXG1N-hTRIP-Br2 or its derivatives for 48 h, followed by 
immunocytochemical analysis.  GAL4DBD-hTRIP-Br2 (1-314) and GAL4DBD-
hTRIP-Br2 (72-314) were found in both cytosol and nucleus, while GAL4DBD-
hTRIP-Br2 (1-179) and GAL4DBD-hTRIP-Br2 (235-311) were localized 
exclusively in the nucleus. Red channel: Cy3-staining; Blue channel: DAPI-
staining.  
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Figure 30B. Subcellular fractionation analysis of wildtype TRIP-
Br2 and its truncation mutants. Similar results were observed when 
asynchronously growing COS-7 cells were transfected with pBXG1N-hTRIP-
Br2 or its derivatives for 48 h and analyzed by subcellular fractionation and 
immunoblotting with anti-GAL4DBD antibodies. Lamin B and GAPDH were 
used as loading controls for nuclear and cytoplasmic fractions respectively.  
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Figure 30C. Deletion of the TRIP-Br2 C-terminus stabilized 
TRIP-Br2 by nuclear entrapment. Asynchronously growing COS-7 cells 
were transfected with pBXG1N-hTRIP-Br2 or its derivatives for 48 h, followed 
by MG132 (25 µM) for 2 h. MG132-treated cells were then analyzed by 
subcellular fractionation and immunoblotting with anti-GAL4DBD antibodies.  
The absence of GAL4DBD-hTRIP-Br2 (1-179) in cytosol, despite inhibition of 
26S proteasome by MG132, is depicted by *. Lamin B and GAPDH were used 
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Figure 30D. Deletion of the C-terminus of TRIP-Br2, which 
includes the putative C-terminal NES of TRIP-Br2, stabilized 
TRIP-Br2 in G2/M phase. COS-7 cells were transfected with pBXG1N-
hTRIP-Br2 or its derivatives for 24 h, followed by 10 mM HU treatment for an 
additional 24 h. 20 h after removal of HU, these G2/M phase cells were 
subjected to immunocytochemical analysis with anti-GAL4DBD antibodies. 
GAL4DBD-hTRIP-Br2 (1-179) evaded proteolysis in the G2/M phase of the cell 
cycle. Red channel: Cy3-staining; Blue channel: DAPI-staining.  
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Figure 30E. Inhibition of nuclear export of TRIP-Br2 by LMB 
restores its stability in G2/M phase. When these transfected cells were 
further treated with LMB (10 ng/ ml) for 2 h, GAL4DBD-hTRIP-Br2 (1-314) and 
all its derivatives evaded proteolysis in the G2/M phase of cell cycle by their 
entrapment in the nucleus. Red channel: Cy3-staining; Blue channel: DAPI-
staining. 
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4.3 Discussion 
 The timely degradation of many transiently induced and/or oscillatory 
cell-cycle regulators is fundamental to the maintenance of proper cell cycle 
progression. Deregulation of such regulatory mechanisms may lead to 
oncogenic transformation or apoptosis. Key cell-cycle regulators such as 
cyclins, CDK inhibitors and E2F transcription factors have been found to be 
short-lived proteins that are degraded through the ubiquitin-proteasome 
pathway (Barinaga, 1995; Campanero and Flemington, 1997; Glotzer et al., 
1991).  In the present study, we provide evidence that TRIP-Br2 is a short-
lived protein like many of these cell-cycle regulators. We further demonstrate 
that the expression of TRIP-Br2 protein is tightly regulated throughout the cell 
cycle by precise spatial and temporal control mechanisms involving the 
ubiquitin-proteasome-dependent proteolytic pathway and the nuclear export 
pathway. This is the first time that a TRIP-Br protein has been shown to be 
differentially modified post-translationally in the regulation of its turnover (and 
function) during cell cycle progression. As truncation mutagenesis of TRIP-Br2 
revealed that TRIP-Br2 is targeted for ubiquitination at multiple sites, we 
postulated that nuclear export of TRIP-Br2 is a rate-limiting step in the 
regulation of TRIP-Br2 turnover.  
 Firstly, we report the presence of a putative NES LxxLxL motif at the C-
terminal region of TRIP-Br2. This leucine-rich NES motif of TRIP-Br2 is highly 
conserved in widely divergent species and in all other TRIP-Br family 
members. Interestingly, this TRIP-Br2 NES motif overlapped with its PHD-
Bromo interaction domain in the acidic TAD, suggesting that the binding of 
TRIP-Br2 to PHD zinc-finger- and/or bromodomain-containing transcription 
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factors during G1/S phase could mask its NES from the recognition of CRM1-
mediated nuclear export machinery and abrogate its proteolysis to maintain 
high steady state levels of TRIP-Br2 for G1/S phase progression. Several 
examples of NES activity being regulated by NES masking have been 
reported (Craig et al., 2002; Heerklotz et al., 2001; Kobayashi et al., 2001; Li 
et al., 1998; Seimiya et al., 2000; Stommel et al., 1999). As highly conserved 
nuclear export signals are also found in TRIP-Br1, RBT-1 and TRIP-Br3 
(Figure 29D), we postulate that the CRM1-mediated nuclear export pathway 
may have evolved to provide a mechanism for regulating the turnover of the 
TRIP-Br family of mammalian transcriptional coregulators. Indeed, nuclear 
export has been shown to be required for the degradation of a number of 
proteins, including p53 (Freedman and Levine, 1998). In addition, 
ubiquitination of the C-terminus of p53, in a region close to both the nuclear 
export and oligomerization sequences, has been shown to unmask the NES 
and allows interaction of p53 with the CRM1-mediated nuclear export 
machinery (Lohrum et al., 2001).  
 Secondly, we have demonstrated that the cell cycle-dependent 
regulation of TRIP-Br2 turnover is mediated by this putative NES motif in an 
LMB-sensitive manner. We propose a regulatory model in which deletion of 
the C-terminal region, aa180-314, of TRIP-Br2 not only results in the loss of 
the key proteolysis-inducing ubiquitination sites that may reside within the 
acidic TAD, but more importantly, leads to the loss of the NES that is required 
for the shuttling of polyubiquitinated TRIP-Br2 to the perinuclear 26S 
proteasome complex for degradation. The failure of TRIP-Br2 proteolysis in 
the G2/M phase of cell cycle as a result of its entrapment in the nucleus was 
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evident in the C-terminal truncation mutant, GAL4DBD-hTRIP-Br2 (1-179). We 
further demonstrated that proteolytic degradation of TRIP-Br2 could be 
abrogated by LMB in the G2/M phase of the cell cycle. Collectively, these data 
suggest that CRM1-mediated nuclear export of TRIP-Br2 may be involved in 
the maintenance of low levels of TRIP-Br2 in the G2/M phase of the cell cycle. 
 In addition, we observed a consistently low protein level of GAL4DBD-
hTRIP-Br2 (235-311) when we exogenously expressed this truncation mutant 
in COS-7 cells. It is unlikely that the GAL4DBD-hTRIP-Br2 wildtype expression 
construct and its derivatives differed in their gene expression levels since they 
were driven by a common SV40 promoter. On the contrary, the destabilization 
of GAL4DBD-hTRIP-Br2 (235-311) is more likely due to the loss of negative 
regulatory elements that are present in TRIP-Br2 protein residues between 
amino acids 1 and 234 or the loss of a native TRIP-Br2 folding scaffold that 
usually masks its NES motif and potential ubiquitination sites in the acidic TAD. 
We envisage that the fusion of an unmasked NES motif and potential 
ubiquitination sites in the acidic TAD to GAL4DBD heterologous protein 
epitope-tag could prime the latter for constitutive and promiscuous degradation 
by multiple proteolytic pathways.  
 As we have previously shown that the highly unstable GAL4DBD-
hTRIP-Br2 (235-311) protein retains transcriptional activity, while highly stable 
C-terminal truncation mutants of GAL4DBD-hTRIP-Br2 are transcriptionally 
inactive (Hsu et al., 2001), we hypothesize that ubiquitination of the acidic C-
terminal TAD of TRIP-Br2 not only serves to activate the TAD for gene 
transactivation, but also that extensive ubiquitination of the same TAD could 
lead to the eventual proteolysis of TRIP-Br2. Indeed, ubiquitination has been 
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recently shown to regulate TAD function of the VP16 transcription factor by 
serving as a dual signal for activation and activator destruction (Salghetti et al., 
2001). Ongoing studies will establish whether unmasking of the TRIP-Br2 NES 
motif is dependent on the extensive ubiquitination of TAD in the G2/M phase of 
cell cycle. As we have recently reported the overexpression of TRIP-Br2 in 
many human cancers, it would be of interest to determine whether point 
mutations of key leucine residues in the NES motif or key lysine residues in 
the TAD may lead to a stable yet functional TRIP-Br2 protein. Establishing the 
role of such mutant forms of TRIP-Br2 in cell cycle progression and cancer 
pathogenesis is an important goal of future investigation. 
 In summary, we propose that a model in which the ubiquitin-
proteasome-dependent degradation pathway and CRM1-mediated nuclear 
export pathway are involved in the regulation of TRIP-Br2 levels during cell 
cycle progression (Figure 31). In response to mitogenic stimulation, TRIP-Br2 
is induced and its translocation to the nucleus may be mediated by a putative 
nuclear localization signal (NLS) motif at its N-terminus (step 1). Upon nuclear 
entry, TRIP-Br2 is recruited to the RB dissociated-E2F1/DP1 transcriptional 
complexes on E2F-responsive promoters through physical association with 
DP1. At the G1/S transition, signals from a variety of PHD zinc-finger- and/or 
bromodomain containing transcription factors and viral oncoproteins could be 
integrated by their interactions with TRIP-Br2 to drive cell cycle progression 
through the induction of E2F-mediated transcription (step 2). Due to the 
binding of these PHD zinc-finger- and/or bromodomain-containing transcription 
factors at the PHD-Bromo interaction domain of TRIP-Br2 at the G1/S phase 
transition, the TRIP-Br2 NES motif is masked, thereby stabilizing TRIP-Br2 for 
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transactivation of E2F-responsive genes that include cyclin A. Cyclin A binds 
to and activates cyclin-dependent kinase 2 (CDK2) from G1 to S phase. The 
cyclin A-CDK2 complex has been shown to phosphorylate the E2F1-DP1 
heterodimer (Dynlacht et al., 1994; Krek et al., 1994; Krek et al., 1995; Xu et 
al., 1994). TRIP-Br2 has been hypothesized to be a substrate of the cyclinA-
CDK2 complex, through its direct interaction with cyclin A (S.I. Hsu, 
unpublished data). Phosphorylation of the E2F1/DP1/TRIP-Br2 transcriptional 
complexes may lead to their release from a subset of E2F-responsive 
promoters that is no longer required in late S phase and further prime them for 
ubiquitin ligase recognition (step 3).  Following the dissociation of TRIP-Br2 
from its interacting PHD zinc-finger- and/or bromodomain-containing 
transcription factors and its subsequent modification by phosphorylation, it 
may be targeted for recognition by a yet-to-be elucidated E3 ubiquitin ligase 
(step 4). Ubiquitination by this E3 ubiquitin ligase near the TRIP-Br2 NES at 
the C-terminus may further unmask its NES for recognition by the CRM1-
mediated nuclear export machinery and thus mediate its eventual nuclear 
export (step 5). As many E3 ubiquitin ligases, such as MDM2, are known to 
possess NESs, the TRIP-Br2-associated E3 ubiquitin ligase may enhance the 
nuclear export of TRIP-Br2. The polyubiquitinated TRIP-Br2 and E3 ubiquitin 
ligase would presumably dissociate in the perinuclear region of the cell (step 6) 
whereupon the polyubiquitinated TRIP-Br2 would be targeted to the 26S 
proteasome complex for proteolysis (step 7). The E3 ubiquitin ligase may be 
recycled back into the nucleus to facilitate further ubiquitination and the 
nuclear export of other TRIP-Br2 protein molecules (step 8).  
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 This model is supported by several lines of new evidence. First, 
treatment of cells with MG132 inhibited the proteolysis of TRIP-Br2 and led to 
its accumulation. Second, a highly conserved leucine-rich putative NES motif 
that overlaps with the PHD-Bromo interaction domain was found in the acidic 
C-terminal TAD of TRIP-Br2. Third, the stabilization of TRIP-Br2 in G2/M 
phase cells was achieved through nuclear entrapment of TRIP-Br2 either by 
deletion of the acidic C-terminal TAD or by inhibition of the CRM1-mediated 
nuclear export machinery by LMB. Deregulation of any of these pathways of 
TRIP-Br2 regulation during cell cycle progression may ultimately lead to 
tumorigenesis. 
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Figure 31. Proposed model of the regulation of TRIP-Br2 during 
cell cycle progression. In response to mitogenic stimulation, TRIP-Br2 is 
induced and its translocation to the nucleus may be mediated by a putative 
nuclear localization signal (NLS) motif at its N-terminus (step 1). Upon nuclear 
entry, TRIP-Br2 is recruited to the RB dissociated-E2F1/DP1 transcriptional 
complexes on E2F-responsive promoters through physical association with 
DP1. At the G1/S transition, signals from a variety of PHD zinc-finger- and/or 
bromodomain containing transcription factors and viral oncoproteins may be 
integrated by their interactions with TRIP-Br2 to drive cell cycle progression 
through the induction of E2F-mediated transcription (step 2). Due to the 
binding of these PHD zinc-finger- and/or bromodomain containing transcription 
factors at the PHD-Bromo interaction domain of TRIP-Br2 at the G1/S phase 
transition, the TRIP-Br2 NES motif is masked and thus TRIP-Br2 is stabilized 
for transactivation of E2F-responsive genes, including cyclin A. Cyclin A binds 
to and activates cyclin-dependent kinase 2 (CDK2) in G1 to S phases. The 
cyclin A/CDK2 complexes phosphorylate E2F1/DP1/TRIP-Br2 transcriptional 
complexes and release them from a subset of E2F-responsive promoters 
whose activities are no longer required in late S phase (step 3). Following the 
dissociation of TRIP-Br2 from its interacting PHD zinc-finger- and/or 
bromodomain-containing transcription factors, it may be targeted for 
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Ubiquitination near the TRIP-Br2 NES at the C-terminus may further unmask 
its NES for recognition by the CRM1-mediated nuclear export machinery and 
thus mediate its eventual nuclear export (step 5). As many E3 ubiquitin ligases, 
such as MDM2, are known to possess NESs, the TRIP-Br2-associated E3 
ubiquitin ligase may enhance the nuclear export of TRIP-Br2. The 
pollyubiquitinated TRIP-Br2 and E3 ubiquitin ligase presumably dissociate in 
the perinuclear region of the cell (step 6) whereupon the polyubiquitinated 
TRIP-Br2 would be targeted to the 26S proteasome for proteolysis (step 7). 
The E3 ubiquitin ligase may be recycled back into the nucleus to facilitate 
further ubiquitination and nuclear export of other TRIP-Br2 protein molecules 
(step 8). Solid line: proposed path of TRIP-Br2 nuclear entry; Dashed line: 
proposed path of TRIP-Br2 nuclear exit/proteolysis. 
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 The TRIP-Br/SERTAD family of mammalian transcriptional regulators 
has recently been identified and shown to be involved in many biological 
processes such as E2F-mediated cell cycle progression, cancer pathogenesis 
and DNA damage response (Abdullah et al., 2001; Bennetts et al., 2006; 
Calgaro et al., 2002; Cho et al., 2000; Darwish et al., 2007; Gupta et al., 2003; 
Hayashi et al., 2006; Hsu et al., 2001; Lai et al., 2007; Li et al., 2004; Li et al., 
2005; Sim et al., 2006; Sim et al., 2004; Sugimoto et al., 1999; Tang et al., 
2005; Tang et al., 2002; Watanabe-Fukunaga et al., 2005). We report, herein, 
further characterization of the least understood member of TRIP-Br/SERTAD 
family, TRIP-Br2. We assessed the role of TRIP-Br2 in development, 
transcriptional regulation and cell cycle progression by inactivating the TRIP-
Br2 locus in mouse through insertional mutagenesis and exon trapping. 
Ablation of TRIP-Br2 did not lead to infertility, embryonic lethality or failure of 
lymphoid system development in mice. As TRIP-Br2 expression was found to 
be significantly higher in bone marrow and highly-proliferative 
lymphohematopoietic cell lineages than in other tissues, we envisage that 
TRIP-Br2 plays more of a tissue-specific role and that a global gene ablation 
approach would be insufficient to reveal these tissue-specific functions of 
TRIP-Br2 on a gross anatomic level. As expected, molecular phenotyping 
demonstrated that ablation of TRIP-Br2 led to a reduced proliferative potential 
in the highly proliferative splenic T cells and PMEFs, as a result of aberrant 
cell cycle reentry and defects in DNA synthesis. These defects in cell cycle 
progression of TRIP-Br2 ablated PMEFs were shown to be associated with the 
downregulation of key cell cycle regulators such as cyclin E, PCNA and CDC2 
(or CDK1). Future efforts should thus be focused on the creation of a 
 200
Jit Kong, CHEONG  Medicine, NUS 
Ph.D Thesis  2003-2007 
_____________________________________________________________________ 
conditional knockout mouse model to serve as a better tool to decipher the 
physiological role of TRIP-Br2 at the organism level.  
 Given that the ablation of TRIP-Br2 negatively regulated growth, we 
postulated that the gain of TRIP-Br2 function could play an important role in 
regulating cell proliferation and tumor progression. We validated the oncogenic 
potential of TRIP-Br2 in cancer pathogenesis by demonstrating that its 
overexpression promoted tumor growth in athymic nude mice and that it was 
overexpressed in many human cancers. Furthermore, we showed that TRIP-
Br2 is a novel prognostic marker as well as a potential transcription-based 
chemotherapeutic drug target to supplement our current regime of therapy for 
human cancers. We have demonstrated the feasibility of a rapid and high 
throughput approach that proceeds rapidly from experimental validation of the 
regulatory function of TRIP-Br2 in promoting cellular proliferation to identifying 
its clinical role as a novel protooncogene in a subset from among a large 
spectrum of tumor types represented on TMAs. This approach presents a 
paradigm for facilitating translational medicine focused on identifying novel 
chemotherapeutic drug targets.  
 As the loss-of- and gain-of-function of TRIP-Br2 lead to cell proliferation 
arrest and tumor progression, respectively, we investigated whether spatial 
and/or temporal regulation of TRIP-Br2 by transcriptional and/or post-
translational mechanisms may serve to regulate the precise execution of its 
function during cell cycle progression. We demonstrated that the oscillatory 
nature of TRIP-Br2 expression in cell cycle progression was tightly regulated 
by multiple mechanisms, including the ubiquitin-proteasome-dependent 
degradation pathway and the CRM1-mediated nuclear export pathway. This is 
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the first time that a TRIP-Br protein has been shown to be differentially 
modified post-translationally in the regulation of its turnover (and function) 
during cell cycle progression. An analysis of TRIP-Br2 truncation mutants 
revealed that the acidic carboxyl-terminal region of TRIP-Br2, which includes a 
putative nuclear export signal (NES) motif, a PHD-Bromo-interacting domain 
and a transcriptional activation domain (TAD), is required for the regulation of 
its protein turnover. These data provide valuable insights into the regulatory 
pathways that may be targeted for the treatment of TRIP-Br2-overexpressing 
tumors. Ongoing efforts are aimed at shedding further light on how the 
interplay between the NES motif, PHD-Bromo-interacting domain and TAD 
regulates the turnover of TRIP-Br2, and whether disease-inducing mutations in 
these key C-terminal regulation sites of TRIP-Br2 may underlie oncogenesis in 
human cancers. 
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Figure 32. H&E staining of liver, heart and kidney of 8-week-old 
129SvEvBrd-TRIP-Br2 wildtype and mutant mice. 10% neutral-
buffered formalin-fixed and paraffin-embedded tissue blocks were sectioned (4 
µM) prior to H&E staining and light microscopy examination of histopathology 
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Figure 33. H&E staining of colon, small intestines and lung of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice. 10% 
neutral-buffered formalin-fixed and paraffin-embedded tissue blocks were 
sectioned (4 µM) prior to H&E staining and light microscopy examination of 
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Figure 34. H&E staining of stomach, pancreas and spleen of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice. 10% 
neutral-buffered formalin-fixed and paraffin-embedded tissue blocks were 
sectioned (4 µM) prior to H&E staining and light microscopy examination of 
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Figure 35. H&E staining of thymus and testis of 8-week-old 
129SvEvBrd-TRIP-Br2 wildtype and mutant mice. 10% neutral-
buffered formalin-fixed and paraffin-embedded tissue blocks were sectioned (4 
µM) prior to H&E staining and light microscopy examination of histopathology 
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Figure 36. H&E staining of liver, heart and kidney of 8-week-old 
C57BL/6J-TRIP-Br2 wildtype and mutant mice. 10% neutral-buffered 
formalin-fixed and paraffin-embedded tissue blocks were sectioned (4 µM) 
prior to H&E staining and light microscopy examination of histopathology at 
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Figure 37. H&E staining of colon, small intestine, lung, stomach 
and testis of 8-week-old C57BL/6J-TRIP-Br2 wildtype and 
mutant mice. 10% neutral-buffered formalin-fixed and paraffin-embedded 
tissue blocks were sectioned (4 µM) prior to H&E staining and light microscopy 
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Figure 38. H&E staining of spleen and thymus of 8-week-old 
C57BL/6J-TRIP-Br2 wildtype and mutant mice. 10% neutral-buffered 
formalin-fixed and paraffin-embedded tissue blocks were sectioned (4 µM) 
prior to H&E staining and light microscopy examination of histopathology at 
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Figure 39. CD8+ cytotoxic T cells and CD4+ helper T cells of 
TRIP-Br2 wildtype and mutant mice (thymus). Cells harvested from 
thymus of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 
each group) were immunostained with anti-CD4-FITC and anti-CD8-PE-Cy5 
antibodies, and analyzed by LSRII flow cytometer. CD8+ cytotoxic T cells and 
CD4+ helper T cells are analyzed in a CD4 gate. Proportion of CD8+ cytotoxic 
T cells and CD4+ helper T cells in thymus of wildtype and mutant mice 
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Figure 40. CD8+ cytotoxic T cells and CD4+ helper T cells of 
TRIP-Br2 wildtype and mutant mice (spleen). Cells harvested from 
spleen of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 
each group) were immunostained with anti-CD4-FITC and anti-CD8-PE-Cy5 
antibodies, and analyzed by LSRII flow cytometer. CD8+ cytotoxic T cells and 
CD4+ helper T cells are analyzed in a CD4 gate. Proportion of CD8+ cytotoxic 
T cells and CD4+ helper T cells in spleen of wildtype and mutant mice 
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Figure 41. Proportion of CD4+ memory T cells of TRIP-Br2 
wildtype and mutant mice (spleen). Cells harvested from spleen of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each group) 
were immunostained with anti-CD62L-PE and anti-CD44-APC antibodies, and 
analyzed by LSRII flow cytometer. CD62L+ cells and CD44+ cells are 
analyzed in a CD4 gate. Proportion of CD4+ memory T cells in spleen of 
wildtype and mutant mice remained constant. Note: Missing data from one 
wildtype mouse due to sample loss. 
 
Jit Kong, CHEONG  Medicine, NUS 



















Figure 42. Proportion of CD8+ memory T cells of TRIP-Br2 
wildtype and mutant mice (spleen). Cells harvested from spleen of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each group) 
were immunostained with anti-CD62L-PE and anti-CD44-APC antibodies, and 
analyzed by LSRII flow cytometer. CD62L+ cells and CD44+ cells are 
analyzed in a CD8 gate. Proportion of CD8+ memory T cells in spleen of 
wildtype and mutant mice remained constant. Note: Missing data from one 
wildtype mouse due to sample loss. 
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Figure 43. CD8+ cytotoxic T cells and CD4+ helper T cells of 
TRIP-Br2 wildtype and mutant mice (lymph nodes). Cells 
harvested from lymph nodes of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype 
and mutant mice (n=3 each group) were immunostained with anti-CD4-FITC 
and anti-CD8-PE-Cy5 antibodies, and analyzed by LSRII flow cytometer. 
CD8+ cytotoxic T cells and CD4+ helper T cells are analyzed in a CD4 gate. 
Proportion of CD8+ cytotoxic T cells and CD4+ helper T cells in lymph nodes 
of wildtype and mutant mice remained constant. Note: Missing data from one 
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Figure 44. CD4+ memory T cells of TRIP-Br2 wildtype and 
mutant mice (lymph nodes). Cells harvested from lymph nodes of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each group) 
were immunostained with anti-CD62L-PE and anti-CD44-APC antibodies, and 
analyzed by LSRII flow cytometer. CD62L+ cells and CD44+ cells are 
analyzed in a CD4 gate. Proportion of CD4+ memory T cells in lymph nodes of 
wildtype and mutant mice remained constant. Note: Missing data from one 
wildtype mouse due to sample loss. 
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Figure 45. CD8+ memory T cells of TRIP-Br2 wildtype and 
mutant mice (lymph nodes). Cells harvested from lymph nodes of 8-
week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each group) 
were immunostained with anti-CD62L-PE and anti-CD44-APC antibodies, and 
analyzed by LSRII flow cytometer. CD62L+ cells and CD44+ cells are 
analyzed in a CD8 gate. Proportion of CD8+ memory T cells in lymph nodes of 
wildtype and mutant mice remained constant. Note: Missing data from one 
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Figure 46. B220+ B cells and CD11c+ dendritic cells of TRIP-
Br2 wildtype and mutant mice (spleen). Cells harvested from spleen 
of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each 
group) were immunostained with anti-CD11c-APC and anti-B220-PE 
antibodies, and analyzed by LSRII flow cytometer. B220+ cells and CD11c+ 
cells are analyzed in a B220 gate. Proportion of B220+ B cells and CD11c+ 
dendritic cells in spleen of wildtype and mutant mice remained constant. Note: 
Missing data from one wildtype mouse due to sample loss. 
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Figure 47. B220+ B cells and CD11c+ dendritic cells of TRIP-
Br2 wildtype and mutant mice (lymph nodes). Cells harvested from 
lymph nodes of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice 
(n=3 each group) were immunostained with anti-CD11c-APC and anti-B220-
PE antibodies, and analyzed by LSRII flow cytometer. B220+ cells and 
CD11c+ cells are analyzed in a B220 gate. Proportion of B220+ B cells and 
CD11c+ dendritic cells in lymph nodes of wildtype and mutant mice remained 
constant. Note: Missing data from one wildtype mouse due to sample loss. 
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Figure 48. CD4+ CD25+ FoxP3+ regulatory T cells of TRIP-Br2 
wildtype and mutant mice (thymus). Cells harvested from thymus of 
8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice (n=3 each group) 
were immunostained with anti-FoxP3-PE and anti-CD25-APC antibodies, and 
analyzed by LSRII flow cytometer. FoxP3+ cells and CD25+ cells are analyzed 
in a CD4 gate. Proportion of CD4+ CD25+ FoxP3+ regulatory T cells in 
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Figure 49. CD4+ CD25+ FoxP3+ regulatory T cells of TRIP-Br2 
wildtype and mutant mice (lymph nodes). Cells harvested from 
lymph nodes of 8-week-old 129SvEvBrd-TRIP-Br2 wildtype and mutant mice 
(n=3 each group) were immunostained with anti-FoxP3-PE and anti-CD25-
APC antibodies, and analyzed by LSRII flow cytometer. FoxP3+ cells and 
CD25+ cells are analyzed in a CD4 gate. Proportion of CD4+ CD25+ FoxP3+ 
regulatory T cells in lymph nodes of wildtype and mutant mice remained 
constant. Note: Missing data from one wildtype mouse due to sample loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
